var title_f37_39_38512="Cysteamine: Patient drug information";
var content_f37_39_38512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cysteamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F15516478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F15516479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/40/8836?source=see_link\">",
"       Cysteamine (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/49/16148?source=see_link\">",
"       Cysteamine (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11332 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-90A40F4040-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38512=[""].join("\n");
var outline_f37_39_38512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?8/40/8836?source=related_link\">",
"      Cysteamine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?15/49/16148?source=related_link\">",
"      Cysteamine (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_39_38513="Bone scan in calciphylaxis";
var content_f37_39_38513=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    3 phase bone scan (Technetium 99m methylene diphosphate bone scintography)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Bone scan showing no activity in the lungs and musculature of lower extremities 5 months prior to diagnosis of calciphylaxis. B) Extensive increase activity throughout both lungs and lower extremities suggestive of metastatic calcification in a patient with a diagnosis of calciphylaxis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter W. Santos, DO and L. Darryl Quarles, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38513=[""].join("\n");
var outline_f37_39_38513=null;
var title_f37_39_38514="Neomycin, colistin, hydrocortisone, and thonzonium: Drug information";
var content_f37_39_38514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Neomycin, colistin, hydrocortisone, and thonzonium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/44/34499?source=see_link\">",
"    see \"Neomycin, colistin, hydrocortisone, and thonzonium: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coly-Mycin&reg; S;",
"     </li>",
"     <li>",
"      Cortisporin&reg;-TC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Otic;",
"     </li>",
"     <li>",
"      Antibiotic/Corticosteroid, Otic;",
"     </li>",
"     <li>",
"      Corticosteroid, Otic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F200613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Ear inflammation/infection:",
"     </b>",
"     Otic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calibrated dropper: 5 drops in affected ear 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dropper bottle: 4 drops in affected ear 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Alternatively, a cotton wick may be inserted in the ear canal and saturated with suspension every 4 hours; wick should be replaced at least every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F200619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Ear inflammation/infection:",
"     </b>",
"     Otic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Calibrated dropper:",
"     </i>",
"     4 drops in affected ear 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Dropper bottle:",
"     </i>",
"     3 drops in affected ear 3-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Alternatively, a cotton wick may be inserted in the ear canal and saturated with suspension every 4 hours; wick should be replaced at least every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, otic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Coly-Mycin&reg; S: Neomycin 0.33%, colistin 0.3%, hydrocortisone acetate 1%, and thonzonium bromide 0.05% (5 mL) [contains thimerosal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cortisporin&reg;-TC: Neomycin 0.33%, colistin 0.3%, hydrocortisone acetate 1%, and thonzonium bromide 0.05% (10 mL) [contains thimerosal]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of superficial and susceptible bacterial infections of the external auditory canal; for treatment of susceptible bacterial infections of mastoidectomy and fenestration cavities",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Hypersensitivity reaction, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ototoxicity (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation and/or aminoglycosides; herpes simplex, vaccinia, varicella",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neomycin sensitization: May cause cutaneous sensitization, including itching, reddening, edema, and failure to heal. Neomycin may also cause sensorineural hearing loss (due to cochlear damage); risk is greater with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ototoxicity: Risk of ototoxicity is increased in patients with longstanding otitis media or tympanic perforation; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For otic use only; avoid contact with eyes. Avoid contaminating dropper.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Do not use for longer than 10 days; prolonged treatment may result in overgrowth of nonsusceptible organisms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F200620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14287256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to the neomycin and hydrocortisone monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14287259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F200610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Coly-Mycin S Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.3-3-10-0.5 mg/mL (5 mL): $45.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Cortisporin-TC Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.3-3-10-0.5 mg/mL (10 mL): $82.98",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10168 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-DBEF2E8A07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38514=[""].join("\n");
var outline_f37_39_38514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200612\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200624\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200613\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200619\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200614\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200606\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200598\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200607\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200622\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200609\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200600\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200620\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200603\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287256\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287257\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287259\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200610\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10168\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10168|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?33/44/34499?source=related_link\">",
"      Neomycin, colistin, hydrocortisone, and thonzonium: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_39_38515="Needle advancement into liver";
var content_f37_39_38515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transjugular liver biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 503px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopic image of the right upper quadrant of the abdomen showing the biopsy needle (arrow) advanced into the liver parenchyma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38515=[""].join("\n");
var outline_f37_39_38515=null;
var title_f37_39_38516="Continuous renal replacement therapies: Overview";
var content_f37_39_38516=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Continuous renal replacement therapies: Overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38516/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38516/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38516/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38516/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38516/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38516/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/39/38516/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous renal replacement therapies (CRRTs) involve either dialysis (diffusion-based solute removal) or filtration (convection-based solute and water removal) treatments that operate in a continuous mode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38516/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Variations of CRRT might run 12 to 14 hours, especially during daytime periods of full staffing. This regimen has become more prevalent in Europe and has been called \"go slow dialysis.\" Other variations of this technique are discussed below and probably should be called hybrid therapies because they are a merging of intermittent and continuous duration. The longer duration of CRRT makes it quite different from conventional intermittent hemodialysis in which each treatment lasts four to six hours or less.",
"   </p>",
"   <p>",
"    The major advantage of continuous therapy is the slower rate of solute or fluid removal per unit of time. Thus, CRRT is generally better tolerated than conventional therapy, since many of the complications of intermittent hemodialysis are related to the rapid rate of solute and fluid loss. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33174?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many variations of CRRT and the remainder of this topic will provide a general overview of the nomenclature that has been developed. The different modalities are categorized according to the access characteristics &mdash; blood or peritoneal, venovenous or arteriovenous (",
"    <a class=\"graphic graphic_table graphicRef81183 \" href=\"mobipreview.htm?26/12/26827\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Arteriovenous or venovenous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriovenous (AV) refers to the use of an arterial catheter that allows blood to flow into the extracorporeal circuit by virtue of the systemic blood pressure. A venous catheter is placed for return. Venovenous (VV) is an alternative modality in which both catheters or one dual lumen catheter are placed in veins. An extracorporeal blood pump is required to circulate blood through the extracorporeal circuit.",
"   </p>",
"   <p>",
"    The advantage of arteriovenous access is that it is simple to set up and does not require an extracorporeal blood pump. It does, however, require arterial puncture with an attendant risk of arterial embolization. Blood flow may also be unreliable in patients who are hypotensive or have severe peripheral vascular disease.",
"   </p>",
"   <p>",
"    Venovenous access, on the other hand, does not require arterial access, involves less systemic anticoagulation, uses only one dual lumen catheter, and has faster and more reliable blood flow than with arterial access. The only disadvantage is the requirement for an extracorporeal blood pump.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis (HD) refers to the transport process by which a solute",
"    <strong>",
"     passively diffuses down its concentration gradient",
"    </strong>",
"    from one fluid compartment (either blood or dialysate) into the other. During HD, urea, creatinine, and potassium move from blood to dialysate, while other solutes, such as calcium and bicarbonate, move from dialysate to blood. The dialysate flows countercurrent to blood flow through the dialyzer to maximize the concentration gradient between the compartments and therefore to maximize the rate of solute removal. The net effect is the production of desired changes in the plasma concentrations of these solutes: a reduction in the blood urea nitrogen and plasma creatinine concentration; and an elevation in the plasma calcium and bicarbonate concentrations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hemofiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemofiltration (HF) refers to the use of a hydrostatic pressure gradient to induce the filtration (or",
"    <strong>",
"     convection",
"    </strong>",
"    ) of plasma water across the membrane of the hemofilter. The frictional forces between water and solutes (called",
"    <strong>",
"     solvent drag",
"    </strong>",
"    ) results in the convective transport of small and middle molecular weight solutes (less than 5000 Daltons) in the same direction as water. Substitution fluid is usually required to prevent excessive fluid removal.",
"   </p>",
"   <p>",
"    The process of HF itself removes smaller solutes (such as urea and electrolytes) in roughly the",
"    <strong>",
"     same concentration as the plasma",
"    </strong>",
"    . There is therefore no change in the plasma concentrations of these solutes by HF, in contrast to those achieved by HD. However, the administration of substitution fluid will lower by dilution the plasma concentrations of those solutes (such as urea and creatinine) not present in the substitution fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemodiafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodiafiltration (HDF) refers to a combination of dialysis and filtration. Solute loss primarily occurs by diffusion dialysis but 25 percent or more may occur by hemofiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONTINUOUS REPLACEMENT THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acronyms that have derived from the above concepts describe continuous therapies with the following general characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Continuous arteriovenous hemofiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous arteriovenous hemofiltration or CAVH uses AV access to remove fluid and solutes by convection. Its per hour efficiency of solute removal is generally quite low, since no diffusion occurs. Thus, 24",
"    <span class=\"nowrap\">",
"     hour/day",
"    </span>",
"    operation or the addition of enhancing techniques is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Continuous venovenous hemofiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous venovenous hemofiltration or CVVH is similar to CAVH except that the venovenous access mandates use of a blood pump.",
"   </p>",
"   <p>",
"    Chronic hemofiltration, although not commonly used in North America as a chronic renal replacement therapy, offers some advantages compared with conventional hemodialysis, including a more physiologic process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38516/abstract/5\">",
"     5",
"    </a>",
"    ]. High volume hemofiltration is a variant of CVVH with very high (threefold) ultrafiltration rate and substitution fluid administration rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38516/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Slow continuous ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slow continuous ultrafiltration or SCUF is strictly a dehydrating procedure with no intent to substantially remove solute. Access can be arteriovenous or venovenous. SCUF is similar to CAVH or CVVH except that the ultrafiltration rate is held at a lower rate; thus, SCUF is primarily used when the fluid removal goals are modest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Continuous arteriovenous hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous arteriovenous hemodialysis (CAVHD or CAVD) is similar to CAVH with two exceptions: dialysate is run at a low flow rate countercurrent to the direction of blood flow; and the ultrafiltration rate is not maximized to protect against the development of hypotension. Fluid removal is slower than with CAVH alone, but a greater reduction in solute concentration is achieved. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=see_link\">",
"     \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Continuous venovenous hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous venovenous hemodialysis (CVVHD or CVVD) utilizes venovenous access and a blood pump, but is otherwise similar to CAVHD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Continuous arteriovenous hemodiafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous arteriovenous hemodiafiltration is similar to CAVHD except that ultrafiltration is allowed at a rate beyond that necessary to reestablish euvolemia. From the viewpoint of solute removal, CAVHDF combines diffusion to aggressively removal small solutes with convection to remove large solutes. Because the volume of fluid ultrafiltered is so large, replacement fluid must be given to maintain euvolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Continuous venovenous hemodiafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous venovenous hemodiafiltration or CVVHDF is similar to CAVHDF, except that venovenous access is utilized and a blood pump is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Continuous equilibrium peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous equilibrium peritoneal dialysis (CEPD) is a long-dwell procedure similar to CAPD. A semipermanent peritoneal dialysis catheter is placed. Rapid exchanges are used initially to attain fluid and solute balance (as in acute PD). This is followed by longer dwell times to maintain this balance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Continuous flow peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In this variant of peritoneal dialysis, there are two points of access into the peritoneal cavity, one for continuous inflow of fresh dialysate, the other for efflux of used dialysate. Clearances still primarily depend upon the flow rate of dialysate up to a point in PD, because peritoneal blood flow is limited. However, continuous flow PD clearances exceed those of CEPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Sustained low efficiency or extended daily dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialytic regimens have been developed which, although not necessarily continuous, have therapeutic aims in common with other CRRTs; these include lower solute clearances that are maintained for longer periods of time. Such regimens are collectively referred to as \"sustained low efficiency dialysis\" (SLED), but terms used in the literature include \"extended daily dialysis\" (EDD) and \"slow continuous dialysis\" (SCD). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33530?source=see_link\">",
"     \"Sustained low efficiency or extended daily dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CHOICE OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of modality is dependent upon several factors including availability, the expertise of the clinician, hemodynamic stability, vascular access, and whether the primary need is for fluid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    solute removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38516/abstract/7\">",
"     7",
"    </a>",
"    ]. The last factor is often an important determinant, since each of these procedures is associated with a different rate of solute and water removal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=see_link\">",
"     \"Continuous renal replacement therapy in acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SCUF, CVVH, or CAVH can be used if fluid removal is the primary goal. We generally prefer venovenous access because of its more predictable blood flow rate. However, arteriovenous access can be used if blood pumps are not available.",
"     </li>",
"     <li>",
"      CAVHD will probably be more effective than CAVH in the highly catabolic patient with a large small solute load. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=see_link\">",
"       \"Continuous arteriovenous hemodialysis: Technical considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One of the forms of HDF, with its convective removal of larger solutes, may be desirable in the patient with sepsis in whom an ancillary goal is the removal of inflammatory mediators.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous renal replacement therapies (CRRTs) involve either dialysis (diffusion-based solute removal) or filtration (convection-based solute and water removal) treatments that operate in a continuous mode. The major advantage of continuous therapy is the slower rate of solute or fluid removal per unit of time. Thus, CRRT is generally better tolerated than conventional therapy, since many of the complications of intermittent hemodialysis are related to the rapid rate of solute and fluid loss. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are many variations of CRRT. The different modalities are categorized according to the access characteristics &mdash; blood or peritoneal, venovenous or arteriovenous. A large number of acronyms have been derived that describe the different continuous therapies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Continuous replacement therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of modality is dependent upon several factors including availability, the expertise of the clinician, hemodynamic stability, vascular access, and whether the primary need is for fluid",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      solute removal. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38516/abstract/1\">",
"      Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 32:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38516/abstract/2\">",
"      Kanagasundaram NS, Paganini EP. Critical care dialysis--a Gordian knot (but is untying the right approach?). Nephrol Dial Transplant 1999; 14:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38516/abstract/3\">",
"      Ronco C, Bellomo R, Kellum JA. Continuous renal replacement therapy: opinions and evidence. Adv Ren Replace Ther 2002; 9:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38516/abstract/4\">",
"      Mehta RL. Continuous renal replacement therapy in the critically ill patient. Kidney Int 2005; 67:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38516/abstract/5\">",
"      McCarthy JT, Moran J, Posen G, et al. A time for rediscovery: chronic hemofiltration for end-stage renal disease. Semin Dial 2003; 16:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38516/abstract/6\">",
"      Honore PM, Jamez J, Wauthier M, et al. Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000; 28:3581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38516/abstract/7\">",
"      Palevsky PM. Dialysis modality and dosing strategy in acute renal failure. Semin Dial 2006; 19:165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1849 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38516=[""].join("\n");
var outline_f37_39_38516=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Arteriovenous or venovenous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hemofiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemodiafiltration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONTINUOUS REPLACEMENT THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Continuous arteriovenous hemofiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Continuous venovenous hemofiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Slow continuous ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Continuous arteriovenous hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Continuous venovenous hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Continuous arteriovenous hemodiafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Continuous venovenous hemodiafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Continuous equilibrium peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Continuous flow peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Sustained low efficiency or extended daily dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CHOICE OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1849\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1849|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/12/26827\" title=\"table 1\">",
"      CRRT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37303?source=related_link\">",
"      Continuous arteriovenous hemodialysis: Technical considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28295?source=related_link\">",
"      Continuous renal replacement therapy in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33174?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Metabolic and hemodynamic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/47/33530?source=related_link\">",
"      Sustained low efficiency or extended daily dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_39_38517="Type 1 breast lobule";
var content_f37_39_38517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F52636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F52636&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Type 1 breast lobule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 359px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whole mount preparation of breast tissue of an 18-year-old nulliparous woman showing&nbsp;histology of type 1 breast&nbsp;lobules as viewed by light microscopy.",
"    <br>",
"     <br>",
"      Left panel: tissue section stained with toluidine blue. x 2.5. Right panels: histological section of lobule type 1 stained with hematoxylin and eosin (H &amp; E). Photographs at 10x and 40x respectively.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Russo, J, Hu, Y-F, Silva, IDCG, and Russo, IH. Cancer risk related to mammary gland structure and development. Microscopy Research and Technique 2001; 52:204. Copyright &copy; 2001 American Cancer Society.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38517=[""].join("\n");
var outline_f37_39_38517=null;
var title_f37_39_38518="Sleep related breathing disorders and stroke";
var content_f37_39_38518=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sleep related breathing disorders and stroke",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38518/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38518/contributors\">",
"     Antonio Culebras, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38518/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38518/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38518/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38518/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38518/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/39/38518/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep related breathing disorders (SRBDs), including obstructive sleep apnea (OSA), central sleep apnea syndrome (CSAS), and Cheyne-Stokes breathing (CSB), may be related to stroke:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      OSA appears to be a risk factor for stroke",
"     </li>",
"     <li>",
"      OSA, CSAS, and CSB are frequently detected following a stroke",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OSA is characterized by the intermittent cessation or reduction of airflow during sleep due to complete or partial upper airway obstruction, while CSAS is characterized by the intermittent absence of airflow and ventilatory effort. CSB refers to cyclic crescendo-decrescendo airflow and respiratory effort during wakefulness or sleep, without upper airway obstruction. CSB is considered a type of CSAS when the decrescendo effort is accompanied by apnea during sleep. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationships between SRBDs and stroke are discussed here. Other respiratory abnormalities that can occur after a stroke are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/54/10087?source=see_link&amp;anchor=H8#H8\">",
"     \"Stroke-related pulmonary complications and abnormal respiratory patterns\", section on 'Abnormal respiratory patterns'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SLEEP RELATED BREATHING DISORDERS AND STROKE RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with obstructive sleep apnea (OSA) appear to be at increased risk of having a stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/1\">",
"     1",
"    </a>",
"    ]. It is unknown whether patients with central sleep apnea syndrome, including Cheyne-Stokes breathing, also have an increased risk. This section focuses on the relationship between OSA and the risk of stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical evidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is accumulating evidence from prospective cohort studies that suggests that OSA increases the risk for stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Our confidence in the evidence is increased by the findings of a large effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/3\">",
"     3",
"    </a>",
"    ] and a dose response gradient (ie, correlation between the severity of the OSA and the risk for stroke) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest study was a prospective cohort study that followed 5422 individuals without a history of stroke for a median of 8.7 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/5\">",
"     5",
"    </a>",
"    ]. Men whose obstructive apnea-hypopnea index (AHI) was in the highest quartile were more likely to have an ischemic stroke than men whose AHI was in the lowest quartile, even after adjustment for potential confounders (adjusted HR 2.86, 95% CI 1.10-7.39). The highest AHI quartile included patients who had &gt;19.1 respiratory events per hour of sleep, whereas the lowest AHI quartile included patients who had &lt;4.1 respiratory events per hour of sleep. A similar effect was not found among women in the study. This may have been due to limitations of the study (eg, few strokes among the women, potential misclassification of OSA severity, and competing confounders masking the effect of OSA), but the possibility that the effect is real cannot be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Impact of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since elevated blood pressure is a known risk factor for stroke and the treatment of OSA has been associated with decreased blood pressure, it is reasonable to expect that the treatment of OSA may reduce the incidence of stroke among patients who have OSA. However, there are insufficient data to support this expectation. Controlled trials evaluating the impact of treating OSA on the incidence of stroke have not been performed and the prospective cohort studies described above were not designed to evaluate treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link&amp;anchor=H2#H2\">",
"     \"Cardiovascular effects of obstructive sleep apnea\", section on 'Systemic hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which OSA may increase the risk of stroke is probably multifactorial.",
"   </p>",
"   <p>",
"    One proposal is that the negative intrathoracic pressure that is typically generated during an obstructive apnea (in an effort to overcome the upper airway obstruction) decreases cerebral blood flow velocity. Recurrent reductions of cerebral blood flow velocity then precipitate ischemic changes in patients with poor hemodynamic reserve (eg, intracranial arterial stenosis), particularly in border zone areas and terminal artery territories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/7\">",
"     7",
"    </a>",
"    ]. Permanent structural changes in the white matter of the hemispheres result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/8\">",
"     8",
"    </a>",
"    ]. Supporting this mechanism, middle cerebral artery blood flow velocity has been shown to decrease during an obstructive apnea and correlates with the duration of the apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative proposal is that OSA may exacerbate cerebrovascular abnormalities or other risk factors for stroke. Supporting this hypothesis, patients with OSA have an increased prevalence of systemic hypertension, heart disease, impaired vascular endothelial function, accelerated atherogenesis, diabetes, atrial fibrillation, prothrombotic coagulation shifts, proinflammatory states, and increased platelet aggregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential role of vibratory trauma due to snoring is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22022?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of snoring in adults\", section on 'Potential consequences'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SLEEP RELATED BREATHING DISORDERS FOLLOWING A STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies performed in patients following a stroke recorded all sleep-related respiratory events (eg, apneas, hypopneas), without distinguishing central from obstructive respiratory events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The studies applied the terminology sleep disordered breathing (SDB) or sleep related breathing disorder (SRBD) when sleep-related respiratory events occurred frequently, since they did not distinguish obstructive sleep apnea (OSA), central sleep apnea syndrome (CSAS), or Cheyne-Stokes breathing (CSB). SDB and SRBD are umbrella terms that encompass OSA, CSAS, and CSB, although SRBD has replaced SDB [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a systematic review of 29 studies that included 2342 patients who had a stroke or transient ischemic attack, a SRBD was subsequently identified in 70, 60, and 40 percent of patients when defined as an apnea hypopnea index (AHI) of &gt;5, &gt;10, and &gt;20 respiratory events per hour of analysis time, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/14\">",
"     14",
"    </a>",
"    ]. Among the 17 studies that distinguished central from obstructive respiratory events, OSA was the most common type of SRBD. Only 7 percent of patients had CSAS or CSB as their predominant respiratory abnormality.",
"   </p>",
"   <p>",
"    SRBDs are often detectable within 24 hours after the stroke and tend to be more severe if the stroke began while the patient was asleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/11,15,16\">",
"     11,15,16",
"    </a>",
"    ]. They are particularly prominent among elderly male patients whose stroke was caused by diabetes and macroangiopathy, and whose stroke began at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with an acute stroke frequently have inversion of their sleep-wake rhythm, particularly after a large hemispheric stroke. They may appear agitated during the night and lethargic during the day. This may be misinterpreted as neurologic deterioration or may precipitate the administration of sedatives or tranquilizers, thereby interfering with the neurologic examination and aggravating any existing SRBD. Early normal sleep cycles and early rapid eye movement (REM) sleep indicate a favorable prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the patient has OSA or CSAS is not helpful for localizing the stroke because a wide variety of central nervous system locations can manifest OSA",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CSAS. As examples, a vascular injury to the respiratory centers in the medulla (eg, lateral medullary syndrome) can cause OSA, CSAS, or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/19\">",
"     19",
"    </a>",
"    ], infratentorial lesions can cause OSA, CSAS, or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/20\">",
"     20",
"    </a>",
"    ], and bilateral hemispheric lesions typically cause CSB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Early neurologic deterioration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 30 percent of patients have early neurologic deterioration after a stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/11\">",
"     11",
"    </a>",
"    ]. Well known causes of increased ischemic injury and neurologic worsening include reocclusion of the affected vessel, brain edema, and cardiovascular instability. SRBDs should also be considered potential causes of early neurologic deterioration in patients with a stroke, since SRBDs following a stroke have been associated with an increased likelihood of early deterioration and an increased severity of the neurologic worsening.",
"   </p>",
"   <p>",
"    A usual mechanism by which SRBDs may contribute to early neurologic worsening is called reversed Robin Hood syndrome (RRHS). Carbon dioxide-related vasodilation during intermittent exposure to hypercapnia increases blood flow velocity in unaffected vessels. This creates an intracranial steal phenomenon that decreases the blood flow velocity in the vessels that supply ischemic areas of the brain. The name, RRHS, refers to the observation that blood flow is being robbed from the poor (affected vessels) and given to the rich (unaffected vessels).",
"   </p>",
"   <p>",
"    In a prospective cohort study of 153 patients with acute ischemic stroke, 15 percent of patients had transcranial Doppler ultrasound abnormalities consistent with intracranial steal and 7 percent also had neurologic worsening consistent with RRHS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/21\">",
"     21",
"    </a>",
"    ]. The magnitude of the intracranial steal was directly related to the severity of neurologic worsening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a SRBD following a stroke (particularly a moderate or severe SRBD) may be a marker of a poorer long-term outcome, as suggested by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective cohort study evaluated 47 patients via overnight oximetry approximately 13 days after an ischemic stroke [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/22\">",
"       22",
"      </a>",
"      ]. More frequent arterial oxyhemoglobin desaturation episodes and increased time spent with an arterial oxyhemoglobin saturation less than 90 percent were associated with both increased mortality at one year and a decreased Barthel index at discharge, three months, and 12 months. A low Barthel index indicates functional impairment and predicts increased length of stay and mortality. Polysomnography was performed on 19 of the patients, which demonstrated that more frequent arterial oxyhemoglobin desaturation episodes were associated with a higher AHI. Episodes of oxyhemoglobin desaturation were largely due to obstructive apneas.",
"     </li>",
"     <li>",
"      In a prospective cohort study of 223 patients who were consecutively admitted for stroke, 166 survivors underwent polysomnography approximately two months after the stroke and were followed for seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/23\">",
"       23",
"      </a>",
"      ]. Ninety six patients had an apnea hypopnea index of &ge;20 events per hour and were offered autotitrated CPAP therapy. Patients who did not use CPAP for &gt;4 hours on 70 percent of days had an increased risk for new ischemic stroke (27.9 percent) when compared with patients who had the same apnea hypopnea index but tolerated CPAP (14.3 percent), patients with an apnea hypopnea index of 10 to 19 events per hour (7.7 percent), and patients with an apnea hypopnea index of &le;9 events per hour (12.9 percent). This study had several limitations, including that it did not control for several potentially important confounders (eg, changes in cardiovascular risk factors and medication usage during the study).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Diagnosis and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial treatment for all patients whose stroke is complicated by a SRBD should be directed at the stroke itself because such treatment may be lifesaving (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    ). However, as soon as possible, all patients with clinical features of a SRBD should undergo a diagnostic evaluation. The clinical features and diagnostic evaluation of SRBDs are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44502?source=see_link\">",
"     \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence, frequency, and severity of respiratory events, as well as the symptoms and other sequelae of the SRBD determine whether treatment is indicated. Treatment typically involves avoiding factors that may exacerbate the SRBD (eg, certain medications) and positive airway pressure therapy, with the type of positive airway therapy determined by the predominant type of SRBD. The use of other therapies (eg, oral appliances) in patients who have a SRBD following a stroke have not been studied. The treatment of SRBDs is reviewed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39239?source=see_link\">",
"     \"Central sleep apnea: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who receive therapy for their SRBD should be frequently reassessed for its ongoing need. SRBDs can improve as the stroke improves and therapy may not be required indefinitely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/24\">",
"     24",
"    </a>",
"    ], although it is generally required into the rehabilitative phase of the stroke.",
"   </p>",
"   <p>",
"    This approach to patients with a SRBD due to a stroke is extrapolated from patients with SRBDs that are unrelated to a stroke. In such patients, treatment improves sleepiness, quality of life, cognitive function, and hypertension, while decreasing health care utilization and, possibly, mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/25-31\">",
"     25-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of obstructive sleep apnea in adults\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a paucity of direct evidence regarding the treatment of SRBDs following a stroke and the evidence that exists is inconsistent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suggesting that treatment is not beneficial, a randomized trial with 30 patients who had been identified as having a SRBD following a stroke found that patients who received continuous positive airway pressure (CPAP) therapy had no improvement in clinical outcomes compared to those who did not receive such therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/32\">",
"       32",
"      </a>",
"      ]. However, adherence was poor and the trial had significant methodological flaws.",
"     </li>",
"     <li>",
"      Suggesting that treatment may be beneficial, observational studies of 96 patients with an ischemic stroke and an AHI of &ge;20 events per hour found lower mortality at five years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/33\">",
"       33",
"      </a>",
"      ] and fewer nonfatal cardiovascular events at seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/23\">",
"       23",
"      </a>",
"      ] among patients who tolerated CPAP therapy than among those who did not. In addition, a trial that randomly assigned 140 older adults with an ischemic stroke and an AHI of &ge;20 events per hour (primarily obstructive events) to either autotitrated CPAP or no CPAP three to six days after the stroke, found that CPAP increased the proportion of patients with neurological improvement after one month, although the improvements were no longer statistically significant after three months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Until the impact of therapy on clinical outcomes is better understood, a trial of positive airway pressure therapy seems reasonable for most patients (especially those who seem likely to adhere to therapy) given the potential benefits and presumed low risk of therapy. Poor adherence with positive airway therapy among patients who have had a stroke has been attributed to difficulty tolerating the positive airway pressure, poor motivation, cognitive deficits, age, and neglect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/32,35,36\">",
"     32,35,36",
"    </a>",
"    ]. Frequent reassessment is necessary for patients who receive a trial of positive airway pressure therapy, due to the theoretical potential for a reduction in blood pressure induced by positive airway pressure to impair cerebral perfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/37\">",
"     37",
"    </a>",
"    ] and worsen physical function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38518/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep related breathing disorders (SRBDs) include obstructive sleep apnea (OSA), central sleep apnea syndrome (CSAS), and Cheyne-Stokes breathing (CSB). OSA appears to be a risk factor for stroke, while SRBDs are frequently detected following a stroke. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With respect to the relationship between SRBDs and the risk of stroke:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with OSA appear to be at increased risk of having a stroke. It is unknown whether CSAS and CSB are also risk factors for stroke. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sleep related breathing disorders and stroke risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that SRBDs not be treated for the sole purpose of reducing the stroke risk (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Therapy may be warranted to improve other outcomes, such as daytime sleepiness and hypertension. The management of SRBDs is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"       \"Management of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39239?source=see_link\">",
"       \"Central sleep apnea: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With respect to SRBDs that are detected following a stroke:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      SRBDs are commonly found after a stroke. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Sleep related breathing disorders following a stroke'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SRBDs are associated with early neurologic worsening and may also be associated with a poorer long-term outcome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Early neurologic deterioration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial treatment should be directed at the stroke but, as soon as feasible, all patients with clinical features of a SRBD should undergo diagnostic evaluation. The presence and severity of respiratory events, symptoms, and other sequelae caused by the SRBD determine whether treatment is indicated. Treatment involves positive airway pressure therapy, with the type of positive airway therapy determined by the predominant type of SRBD. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis and treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/1\">",
"      Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/2\">",
"      Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005; 353:2034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/3\">",
"      Valham F, Mooe T, Rabben T, et al. Increased risk of stroke in patients with coronary artery disease and sleep apnea: a 10-year follow-up. Circulation 2008; 118:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/4\">",
"      Arzt M, Young T, Finn L, et al. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 2005; 172:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/5\">",
"      Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med 2010; 182:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/6\">",
"      Loke YK, Brown JW, Kwok CS, et al. Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2012; 5:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/7\">",
"      Behrens S, Spengos K, Hennerici M. Acceleration of cerebral blood flow velocity in a patient with sleep apnea and intracranial arterial stenosis. Sleep Breath 2002; 6:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/8\">",
"      Neau, JP, Paquereau, J, Meurice, JC, et al. Auditory event-related potentials before and after treatment with nasal continuous positive airway pressure in sleep apnea syndrome. Eur J Neurol 1996; 3:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/9\">",
"      Netzer N, Werner P, Jochums I, et al. Blood flow of the middle cerebral artery with sleep-disordered breathing: correlation with obstructive hypopneas. Stroke 1998; 29:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/10\">",
"      Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/11\">",
"      Iranzo A, Santamar&iacute;a J, Berenguer J, et al. Prevalence and clinical importance of sleep apnea in the first night after cerebral infarction. Neurology 2002; 58:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/12\">",
"      Culebras, A. Balancing sleep and breathing. Stroke 2001; 32:1277.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Sleep Medicine. International classification of sleep disorders, 2nd ed: Diagnostic and coding manual, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/14\">",
"      Johnson KG, Johnson DC. Frequency of sleep apnea in stroke and TIA patients: a meta-analysis. J Clin Sleep Med 2010; 6:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/15\">",
"      Bassetti C, Aldrich MS. Sleep apnea in acute cerebrovascular diseases: final report on 128 patients. Sleep 1999; 22:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/16\">",
"      Bassetti C, Aldrich MS, Quint D. Sleep-disordered breathing in patients with acute supra- and infratentorial strokes. A prospective study of 39 patients. Stroke 1997; 28:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/17\">",
"      Bassetti CL, Milanova M, Gugger M. Sleep-disordered breathing and acute ischemic stroke: diagnosis, risk factors, treatment, evolution, and long-term clinical outcome. Stroke 2006; 37:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/18\">",
"      Giubilei F, Iannilli M, Vitale A, et al. Sleep patterns in acute ischemic stroke. Acta Neurol Scand 1992; 86:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/19\">",
"      Askenasy JJ, Goldhammer I. Sleep apnea as a feature of bulbar stroke. Stroke 1988; 19:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/20\">",
"      Vingerhoets F, Bogousslavsky J. Respiratory dysfunction in stroke. Clin Chest Med 1994; 15:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/21\">",
"      Alexandrov AV, Nguyen HT, Rubiera M, et al. Prevalence and risk factors associated with reversed Robin Hood syndrome in acute ischemic stroke. Stroke 2009; 40:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/22\">",
"      Good DC, Henkle JQ, Gelber D, et al. Sleep-disordered breathing and poor functional outcome after stroke. Stroke 1996; 27:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/23\">",
"      Mart&iacute;nez-Garc&iacute;a MA, Campos-Rodr&iacute;guez F, Soler-Catalu&ntilde;a JJ, et al. Increased incidence of nonfatal cardiovascular events in stroke patients with sleep apnoea: effect of CPAP treatment. Eur Respir J 2012; 39:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/24\">",
"      Parra O, Arboix A, Bechich S, et al. Time course of sleep-related breathing disorders in first-ever stroke or transient ischemic attack. Am J Respir Crit Care Med 2000; 161:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/25\">",
"      Campos-Rodriguez F, Pe&ntilde;a-Gri&ntilde;an N, Reyes-Nu&ntilde;ez N, et al. Mortality in obstructive sleep apnea-hypopnea patients treated with positive airway pressure. Chest 2005; 128:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/26\">",
"      Bahammam A, Delaive K, Ronald J, et al. Health care utilization in males with obstructive sleep apnea syndrome two years after diagnosis and treatment. Sleep 1999; 22:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/27\">",
"      Kapur V, Blough DK, Sandblom RE, et al. The medical cost of undiagnosed sleep apnea. Sleep 1999; 22:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/28\">",
"      He J, Kryger MH, Zorick FJ, et al. Mortality and apnea index in obstructive sleep apnea. Experience in 385 male patients. Chest 1988; 94:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/29\">",
"      Giles TL, Lasserson TJ, Smith BJ, et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006; :CD001106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/30\">",
"      Patel SR, White DP, Malhotra A, et al. Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. Arch Intern Med 2003; 163:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/31\">",
"      Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003; 107:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/32\">",
"      Hsu CY, Vennelle M, Li HY, et al. Sleep-disordered breathing after stroke: a randomised controlled trial of continuous positive airway pressure. J Neurol Neurosurg Psychiatry 2006; 77:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/33\">",
"      Mart&iacute;nez-Garc&iacute;a MA, Soler-Catalu&ntilde;a JJ, Ejarque-Mart&iacute;nez L, et al. Continuous positive airway pressure treatment reduces mortality in patients with ischemic stroke and obstructive sleep apnea: a 5-year follow-up study. Am J Respir Crit Care Med 2009; 180:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/34\">",
"      Parra O, S&aacute;nchez-Armengol A, Bonnin M, et al. Early treatment of obstructive apnoea and stroke outcome: a randomised controlled trial. Eur Respir J 2011; 37:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/35\">",
"      Palombini L, Guilleminault C. Stroke and treatment with nasal CPAP. Eur J Neurol 2006; 13:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/36\">",
"      Minnerup J, Ritter MA, Wersching H, et al. Continuous positive airway pressure ventilation for acute ischemic stroke: a randomized feasibility study. Stroke 2012; 43:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38518/abstract/37\">",
"      Watson NF. Stroke and sleep specialists: an opportunity to intervene? J Clin Sleep Med 2010; 6:138.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7716 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38518=[""].join("\n");
var outline_f37_39_38518=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SLEEP RELATED BREATHING DISORDERS AND STROKE RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical evidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Impact of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SLEEP RELATED BREATHING DISORDERS FOLLOWING A STROKE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Early neurologic deterioration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Diagnosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39239?source=related_link\">",
"      Central sleep apnea: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/32/22022?source=related_link\">",
"      Overview of snoring in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/54/10087?source=related_link\">",
"      Stroke-related pulmonary complications and abnormal respiratory patterns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_39_38519="Cephalosporins";
var content_f37_39_38519=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cephalosporins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38519/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38519/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38519/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38519/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38519/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38519/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/39/38519/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta-lactam antibiotics are among the most commonly prescribed drugs, grouped together based upon a shared structural feature, the beta-lactam ring. Cephalosporins cover a broad range of organisms, are generally well-tolerated, and are easy to administer; thus, these agents are frequently used beta-lactam drugs.",
"   </p>",
"   <p>",
"    The classification, spectrum of activity, and pharmacology of the cephalosporins will be reviewed here. The mechanisms of action and resistance and major adverse reactions of the beta-lactam antibiotics, and the penicillins and other beta-lactam drugs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=see_link\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/5/1110?source=see_link\">",
"     \"Penicillins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF CEPHALOSPORINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalosporins include the closely related cephamycin compounds. The parenteral agents are commonly classified into the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First generation (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Second generation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; A. &nbsp;Subgroup with activity against Haemophilus influenzae (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; B. &nbsp;Cephamycin subgroup with activity against Bacteroides spp (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Third generation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; A. &nbsp;Subgroup with poor activity against Pseudomonas aeruginosa (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , and ceftizoxime)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; B. &nbsp;Subgroup with good activity against Pseudomonas aeruginosa (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fourth generation (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fifth generation (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"       ceftaroline",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY AND CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the available cephalosporins are semi-synthetic derivatives of cephalosporin C, a compound with antibacterial activity produced by the fungus Cephalosporium. The closely related cephamycin compounds (derived from Streptomyces spp) are regarded as members of the cephalosporin class. In clinical practice, these antibiotics have frequently been grouped into five \"generations\" based upon their spectrum of activity against aerobic and facultative gram-negative bacilli and gram-positive bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2999651\">",
"    <span class=\"h2\">",
"     Parenteral agents",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     First generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalothin is the oldest of the first generation cephalosporins and was previously used as the prototype of this group. Cephalothin is active against most gram-positive cocci (including penicillinase-producing staphylococci), but does not have clinically useful activity against enterococci, Listeria, oxacillin-resistant staphylococci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/1\">",
"     1",
"    </a>",
"    ], or penicillin-resistant pneumococci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cephalothin is active against most strains of Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae, but has little activity against indole-positive Proteus, Enterobacter, Serratia, and the non-enteric gram-negative bacilli such as Acinetobacter spp and Pseudomonas aeruginosa. Gram-negative cocci (such as the gonococcus and meningococcus) and H. influenzae are generally resistant. Cephalothin is active against most of the common anaerobic pathogens, with certain exceptions such as Bacteroides species, particularly B. fragilis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     Cefazolin",
"    </a>",
"    has a similar spectrum of activity to cephalothin, is available worldwide, and is now the only parenteral first generation cephalosporin available in the United States. Cefazolin achieves substantially higher serum levels than cephalothin, and has a longer half-life of elimination. Cefazolin is less stable than cephalothin in vitro to the type A penicillinase of staphylococci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/5\">",
"     5",
"    </a>",
"    ]; the relevance of this for clinical therapy, however, is not certain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Second generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second generation cephalosporins are somewhat less active against gram-positive cocci than the first generation agents but are more active against certain gram-negative bacilli. This generation of compounds can be divided into two subgroups, one with activity against H. influenzae and the other, the cephamycins, with activity against Bacteroides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Activity against Haemophilus influenzae",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first subgroup,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    is available parenterally and is more active than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    in vitro against strains of Enterobacter and indole-positive Proteus. However, this agent induces the chromosomal beta-lactamases of these organisms, leading to resistance and failures of clinical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=see_link&amp;anchor=H3#H3\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Mechanisms of bacterial resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     Cefuroxime",
"    </a>",
"    is also more active than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    against H. influenzae, and cefuroxime is quite stable to the TEM beta-lactamase in ampicillin-resistant strains. Although cefuroxime is approved for the therapy of H. influenzae meningitis, delayed responses and treatment failures have occurred, and a third generation cephalosporin is now preferred for therapy of meningitis due to ampicillin-resistant strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/7\">",
"     7",
"    </a>",
"    ]. Cefuroxime is also highly active against beta-lactamase producing Moraxella catarrhalis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Cephamycin subgroup (active against Bacteroides)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cephamycin subgroup of the second generation cephalosporins includes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    . This subgroup is active against most strains of E. coli, P. mirabilis and Klebsiella like the first generation cephalosporins. The cephamycins are quite stable to many plasmid-mediated beta-lactamases, but the activity of this group against Enterobacter and indole-positive Proteus is limited by induction of chromosomal cephalosporinases of these species and selection of stably derepressed mutants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike the first generation cephalosporins, the cephamycins are active against many strains of Bacteroides. The combination of activity against common aerobic and facultative gram-negative bacilli plus Bacteroides has led to the use of the cephamycins in the prophylaxis and therapy of infections in the abdominal and pelvic cavities (where these organisms predominate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/8\">",
"     8",
"    </a>",
"    ]. The cephamycins have no clear advantages over the first generation cephalosporins for infections outside of the abdominal and pelvic areas.",
"   </p>",
"   <p>",
"    Overall resistance rates to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    agents range from 10 to 80 percent for different members of the Bacteroides fragilis group, compared with 15 to 30 percent for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , and essentially no resistance for the carbapenems,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Third generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third generation cephalosporin class [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/10\">",
"     10",
"    </a>",
"    ] is marked by stability to the common beta-lactamases of gram-negative bacilli, and these compounds are highly active against Enterobacteriaceae (E. coli, Proteus mirabilis, indole-positive Proteus, Klebsiella, Enterobacter, Serratia, Citrobacter), Neisseria, and H. influenzae. They are the therapy of choice for gram-negative meningitis due to Enterobacteriaceae. Third generation cephalosporins may also be useful alternatives to the aminoglycosides in treating gram-negative infections resistant to other beta-lactams, particularly in the patient with renal dysfunction. However, mutants of Enterobacter, indole-positive Proteus, Serratia, and Citrobacter, with stable derepression of the chromosomal beta-lactamase, are resistant to these antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Even if these organisms (Enterobacter, indole-positive Proteus, Serratia, and Citrobacter) test susceptible to cephalosporins, use of a third generation cephalosporin as a single agent for treatment of serious infections due to these bacteria can lead to the emergence of resistance during therapy.",
"   </p>",
"   <p>",
"    The third generation cephalosporins are less active against most gram-positive organisms than the first generation cephalosporins and are inactive against enterococci, Listeria, oxacillin-resistant staphylococci, and Acinetobacter.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     Cefotaxime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    are usually active against pneumococci with intermediate susceptibility to penicillin, but strains fully resistant to penicillin are often resistant to the third generation cephalosporins as well. In 1998, for example, 25 percent of strains of S. pneumoniae in the United States were intermediately or fully resistant to penicillin, and 14 percent were resistant to third generation cephalosporins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/2-4,12-14\">",
"     2-4,12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/81?source=see_link\">",
"     \"Resistance of Streptococcus pneumoniae to beta-lactam antibiotics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with third generation cephalosporins may be complicated by superinfection (particularly with enterococci or Candida) or by the emergence of resistance on therapy (particularly when used as single agents for Enterobacter, indole-positive Proteus, or P. aeruginosa infections) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Third generation cephalosporins are not currently recommended for prophylactic use in surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Poor activity against Pseudomonas",
"    </span>",
"    &nbsp;&mdash;&nbsp;One subgroup of the third generation cephalosporins, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , and ceftizoxime, has poor activity against P. aeruginosa. Within this subgroup, cefotaxime has the shortest serum half-life (1 hour) because of partial metabolism in the liver to desacetyl-cefotaxime. However, this metabolite also has antibacterial activity and a longer half-life in serum (1.7 hours), allowing dosing every six hours.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     Ceftriaxone",
"    </a>",
"    has the longest serum half-life of this group (6.4 hours) and can be administered once or twice a day. Ceftriaxone has been particularly recommended for the therapy of penicillin-resistant gonorrhea, Lyme disease involving the central nervous system or joints, meningitis due to ampicillin-resistant H. influenza, and meningitis in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/7,16\">",
"     7,16",
"    </a>",
"    ]. One of the complications of ceftriaxone therapy, however, has been the formation in the biliary tract of \"sludge\" composed of ceftriaxone crystals, causing the syndrome of biliary pseudolithiasis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Activity against Pseudomonas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The other subgroup of the third generation cephalosporins, including cefoperazone and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    , has activity against P. aeruginosa. Cefoperazone was the first available drug in this subgroup, but is currently not used as often due to decreased stability to the plasmid-mediated beta-lactamases of gram-negative bacilli that make it less active against Enterobacteriaceae than the other third generation cephalosporins. The newer member of the subgroup, ceftazidime, is quite stable to the common plasmid-mediated beta-lactamases and is highly active against Enterobacteriaceae, Neisseria, and H. influenzae. Ceftazidime is also particularly active against P. aeruginosa and is an effective therapy for serious infections due to P. aeruginosa when the organism is resistant to the anti-pseudomonal penicillins or the patient is penicillin allergic. In addition, it is effective therapy for meningitis caused by P. aeruginosa. As with the anti-pseudomonal penicillins, however, ceftazidime should generally be given in combination with an aminoglycoside for treatment of serious P. aeruginosa infection. Ceftazidime has poor activity against gram-positive organisms and should be reserved for use in infections proven or highly suspected to be due to P. aeruginosa.",
"   </p>",
"   <p>",
"    Cefoperazone contains an N-methylthiotetrazole (NMTT) side chain. This NMTT group can dissociate from the parent antibiotic in solution or in vivo and competitively inhibit vitamin K action, leading to prolongation of the prothrombin time and bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/18\">",
"     18",
"    </a>",
"    ]. This side chain is also associated with a disulfiram-like reaction to alcohol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Fourth generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     Cefepime",
"    </a>",
"    is the fourth generation cephalosporin currently available. It has a positively charged quaternary ammonium attached to the dihydrothiazone ring, which results in better penetration through the outer membrane of gram-negative bacteria and a lower affinity than the third generation cephalosporins for certain chromosomal beta-lactamases of gram-negative bacilli.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     Cefepime",
"    </a>",
"    has similar activity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    against pneumococci (including penicillin-intermediate strains) and oxacillin-sensitive S. aureus. Like the earlier third generation agents, it is active against the Enterobacteriaceae, Neisseria, and H. influenzae but has greater activity against the gram-negative enterics that have a broad-spectrum, inducible, chromosomal beta-lactamase (Enterobacter, indole-positive Proteus, Citrobacter, and Serratia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/19\">",
"     19",
"    </a>",
"    ]. The role of cefepime in therapy of infections due to stably-derepressed mutants of these organisms, however, has not yet been fully defined. Cefepime is not active against Acinetobacter. Cefepime is as active as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    for Pseudomonas aeruginosa, and is active against some ceftazidime-resistant isolates. As with the anti-pseudomonal penicillins, cefepime should generally be given in combination with an aminoglycoside for treatment of serious P. aeruginosa infection. There has not been enough clinical experience with cefepime in meningitis to recommend its routine use for this purpose. It is also not currently recommended for prophylactic use in surgery.",
"   </p>",
"   <p>",
"    Despite these potential advantages over third generation cephalosporins, especially against organisms with inducible, chromosomal resistance, comparative trials of third and fourth generation cephalosporins have not yet been performed.",
"   </p>",
"   <p>",
"    A review by the United States Food and Drug Administration (FDA) of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    safety data was initiated in 2007 following findings of a meta-analysis that raised concern regarding increased all-cause mortality associated with cefepime use (risk ratio 1.26, 95% CI 1.08-1.49) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/20\">",
"     20",
"    </a>",
"    ]. The FDA reviewed these study data, conducted additional analyses based on other data, and determined that the data do not indicate a higher rate of death in cefepime-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/21\">",
"     21",
"    </a>",
"    ]. Cefepime remains an appropriate therapy for its approved indications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    may be complicated by superinfection (particularly with enterococci or Candida) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/15\">",
"     15",
"    </a>",
"    ]. Cefepime use also carries a risk of seizures (specifically nonconvulsive status epilepticus), particularly in patients with renal failure for whom the dose is not appropriately adjusted downwards [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=see_link&amp;anchor=H13#H13\">",
"     \"Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects\", section on 'Neurologic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fifth generation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"     Ceftaroline",
"    </a>",
"    is a fifth generation cephalosporin whose active metabolite has a spectrum of in vitro activity similar to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    but with improved gram-positive activity. In particular, ceftaroline has higher affinity for PBP2a in oxacillin-resistant staphylococci, and has activity against MRSA, as well as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -intermediate Staphylococcus aureus (VISA) and hetero-VISA. In addition, ceftaroline has activity for Streptococcus pneumoniae that is intermediate or resistant to penicillin or ceftriaxone. Ceftaroline is not active for enterococci nor against AmpC-overproducing or ESBL-producing Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter baumanii, or Bacteroides fragilis. Several randomized, double-blind controlled clinical trials have suggested that ceftaroline is noninferior to vancomycin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    for treatment of complicated skin and soft tissue infections including those due to MRSA, and to ceftriaxone for therapy of community-acquired pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The efficacy of this anti-MRSA cephalosporin is not yet known for hospital-acquired MRSA pneumonia or for bacteremia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=see_link&amp;anchor=H38757748#H38757748\">",
"     \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Ceftaroline versus ceftriaxone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28298?source=see_link&amp;anchor=H13032953#H13032953\">",
"     \"Pharmacology of antimicrobial agents for treatment of methicillin-resistant Staphylococcus aureus and vancomycin resistant enterococcus\", section on 'Ceftaroline'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ceftobiprole is an investigational cephalosporin also capable of binding to penicillin binding protein 2a, the protein conferring S. aureus resistance to beta-lactam antibiotics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/27\">",
"     27",
"    </a>",
"    ]. It can also bind penicillin binding protein 2x in penicillin-resistant S. pneumoniae. It has in vitro activity similar to that of ceftazidime or cefepime against Enterobacteriaceae; it also has activity against enterococci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In addition, ceftobiprole appears to have a low potential for selection of resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical trial data on these agents for use in MRSA infections are detailed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=see_link&amp;anchor=H16779285#H16779285\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\", section on 'Cephalosporins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Oral agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cephalosporins available for oral use include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/7/10357?source=see_link\">",
"     cefadroxil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/22/14693?source=see_link\">",
"     cefprozil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    proxetil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/58/8101?source=see_link\">",
"     ceftibuten",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/21/5461?source=see_link\">",
"     cefdinir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/19/38196?source=see_link\">",
"     cefditoren",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/7/10357?source=see_link\">",
"     Cefadroxil",
"    </a>",
"    has a longer serum half-life than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    and is generally given in a dose of 500 to 1000 mg every 12 hours. The oral cephalosporins are poorly active against penicillin-resistant pneumococci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oral second generation cephalosporins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/11/27829?source=see_link\">",
"     cefaclor",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/22/14693?source=see_link\">",
"     cefprozil",
"    </a>",
"    , have improved activity against H. influenzae compared with the first generation oral cephalosporins and may be useful in treating otitis, sinusitis, and respiratory tract infections.",
"   </p>",
"   <p>",
"    The oral third generation cephalosporins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    proxetil,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/58/8101?source=see_link\">",
"     ceftibuten",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/21/5461?source=see_link\">",
"     cefdinir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/19/38196?source=see_link\">",
"     cefditoren",
"    </a>",
"    , are active against streptococci, H. influenzae (including beta-lactamase producing strains), and M. catarrhalis. They are more active than the other oral cephalosporins against enteric gram-negative bacilli, including E. coli, P. mirabilis, and Klebsiella. However, they have poor activity against most strains of Enterobacter, Acinetobacter, P. aeruginosa, and the anaerobes. Cefixime and ceftibuten have little activity against staphylococci, but cefpodoxime proxetil and cefdinir have more activity. Ceftibuten is also only weakly active against pneumococci. Its spectrum of activity is similar to cefdinir and cefpodoxime.",
"   </p>",
"   <p>",
"    These antibiotics are relatively stable to many plasmid-mediated beta-lactamases but are much less stable to common chromosomally-mediated cephalosporinases. Although these antibiotics are promoted as oral third generation cephalosporins, they are",
"    <strong>",
"     less",
"    </strong>",
"    active against the enteric gram-negative bacilli than the parenteral third or fourth generation cephalosporins. These antibiotics are recommended as therapy for otitis media, upper and lower respiratory tract infections, and urinary tract infections (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/44/16070?source=see_link\">",
"     cefixime",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/44/27333?source=see_link\">",
"     cefpodoxime",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/21/5461?source=see_link\">",
"     cefdinir",
"    </a>",
"    ). These indications are shared with the oral second generation cephalosporins,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , all of which are less costly. In addition, cefixime and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/58/8101?source=see_link\">",
"     ceftibuten",
"    </a>",
"    have little or no activity against staphylococci in contrast to some of these other agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2999961\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the available parenteral cephalosporins have short serum half-lives (generally one hour or less) and should be administered on an every four hour basis when treating serious systemic infections in patients with normal renal function (",
"    <a class=\"graphic graphic_table graphicRef58411 \" href=\"mobipreview.htm?40/10/41132\">",
"     table 1",
"    </a>",
"    ). Certain cephalosporins have longer serum half-lives and may be dosed less frequently (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    Q8h and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    Q24h). All of the cephalosporins except cefoperazone and ceftriaxone require dose modification in the presence of severe renal failure (",
"    <a class=\"graphic graphic_table graphicRef58411 \" href=\"mobipreview.htm?40/10/41132\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    All of the cephalosporins achieve therapeutic levels in pleural, pericardial, peritoneal, and synovial fluids, and urine. Biliary concentrations exceed serum levels (in the absence of obstruction) and are particularly high for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    , cefoperazone, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    First and second generation cephalosporins (except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    ) penetrate the cerebrospinal fluid (CSF) barrier poorly and should not be used to treat infections of the central nervous system. The third generation cephalosporins achieve much more reliable CSF levels in patients with meningeal irritation. Peak CSF concentrations of several cephalosporins given at meningeal doses are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef62934 \" href=\"mobipreview.htm?7/25/7579\">",
"     table 2",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     Cefotaxime",
"    </a>",
"    , ceftizoxime,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    are approved for the treatment of bacterial meningitis.",
"   </p>",
"   <p>",
"    Fatal reactions due to calcium-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    precipitates in the lungs and kidneys of neonates have been reported. Ceftriaxone should still not be reconstituted or mixed with a calcium-containing product (eg, Ringer's or Hartmann's solution or parenteral nutrition). In addition, ceftriaxone should be avoided in infants aged &le;28 days if they are receiving or expected to receive intravenous calcium-containing products. However, ceftriaxone and calcium-containing products may be used concomitantly in patients aged &gt;28 days, provided that the infusion lines are thoroughly flushed between infusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38519/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19315799\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First generation cephalosporins, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/2/4136?source=see_link\">",
"       cefazolin",
"      </a>",
"      , are active against most gram-positive cocci except for enterococci, oxacillin-resistant staphylococci, and penicillin-resistant pneumococci. They are also active against most strains of E. coli, P. mirabilis, and K. pneumoniae. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'First generation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The second generation cephalosporins include two subgroups. One subgroup has activity against H. influenzae and M. catarrhalis. The other subgroup consists of the cephamycins, which are active against many strains of Bacteroides. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Second generation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Third generation cephalosporins have less activity against most gram-positive organisms than first generation agents but are highly active against Enterobacteriaceae, Neisseria, and H. influenzae.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"       Ceftazidime",
"      </a>",
"      and cefoperazone are also active against P. aeruginosa. The fourth generation",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      has similar activity as the third generation cephalosporins, including against P. aeruginosa, with the addition of greater activity against enteric gram-negative rods that have an inducible chromosomal beta-lactamase. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Third generation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Fourth generation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The fifth generation cephalosporins have activity against oxacillin-resistant staphylococci, penicillin-resistant pneumococci and enteric gram-negative rods. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Fifth generation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral cephalosporins are also divided into different generations and their spectra of activity generally mirror those parenteral agents of the corresponding generation. However, oral third generation drugs are less active against enteric gram-negative bacteria than the parenteral third generation cephalosporins. Second and third generation oral cephalosporins have similar indications, namely otitis media, respiratory tract infections, and urinary tract infections. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Oral agents'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Most of the available parenteral cephalosporins have short serum half-lives and require frequent administration. All of the cephalosporins except cefoperazone and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      require dose modification in the presence of severe renal failure (",
"      <a class=\"graphic graphic_table graphicRef58411 \" href=\"mobipreview.htm?40/10/41132\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2999961\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All of the cephalosporins achieve therapeutic levels in pleural, pericardial, peritoneal, and synovial fluids, and urine. First and second generation cephalosporins enter into cerebrospinal fluid poorly. Third generation cephalosporins achieve more reliable cerebrospinal fluid levels in patients with meningeal irritation. (See",
"      <a class=\"local\" href=\"#H2999961\">",
"       'Pharmacology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/1\">",
"      Mulligan ME, Murray-Leisure KA, Ribner BS, et al. Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/2\">",
"      Tomasz A. Antibiotic resistance in Streptococcus pneumoniae. Clin Infect Dis 1997; 24 Suppl 1:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/3\">",
"      Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med 1994; 331:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/4\">",
"      Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/5\">",
"      Sabath LD. Reappraisal of the antistaphylococcal activities of first-generation (narrow-spectrum) and second-generation (expanded-spectrum) cephalosporins. Antimicrob Agents Chemother 1989; 33:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/6\">",
"      Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997; 103:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/7\">",
"      Schaad UB, Suter S, Gianella-Borradori A, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/8\">",
"      Bohnen JM, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992; 127:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/9\">",
"      Snydman DR, McDermott L, Cuchural GJ Jr, et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994. Clin Infect Dis 1996; 23 Suppl 1:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/10\">",
"      Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am 1995; 79:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/11\">",
"      Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I beta-lactamase-producing organisms. Clin Infect Dis 1995; 21:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/12\">",
"      Pallares R, Li&ntilde;ares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/13\">",
"      Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med 1997; 336:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/14\">",
"      Reichmann P, K&ouml;nig A, Li&ntilde;ares J, et al. A global gene pool for high-level cephalosporin resistance in commensal Streptococcus species and Streptococcus pneumoniae. J Infect Dis 1997; 176:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/15\">",
"      Lynch JP 3rd. Combination antibiotic therapy is appropriate for nosocomial pneumonia in the intensive care unit. Semin Respir Infect 1993; 8:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/16\">",
"      Steere AC. Lyme disease. N Engl J Med 1989; 321:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/17\">",
"      Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/18\">",
"      Sattler FR, Weitekamp MR, Ballard JO. Potential for bleeding with the new beta-lactam antibiotics. Ann Intern Med 1986; 105:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/19\">",
"      Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996; 23:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/20\">",
"      Yahav D, Paul M, Fraser A, et al. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/21\">",
"      Kim PW, Wu YT, Cooper C, et al. Meta-analysis of a possible signal of increased mortality associated with cefepime use. Clin Infect Dis 2010; 51:381.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm167427.htm (Accessed on June 18, 2009).",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment, June 26, 2012. file://www.fda.gov/Drugs/DrugSafety/ucm309661.htm (Accessed on June 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/24\">",
"      Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/25\">",
"      File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/26\">",
"      File TM Jr, Wilcox MH, Stein GE. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 2012; 55 Suppl 3:S173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/27\">",
"      Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin Microbiol Infect 2007; 13 Suppl 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/28\">",
"      Bush K, Heep M, Macielag MJ, Noel GJ. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy. Expert Opin Investig Drugs 2007; 16:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/29\">",
"      Willems RJ, Top J, van Santen M, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38519/abstract/30\">",
"      Bogdanovich T, Ednie LM, Shapiro S, Appelbaum PC. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm084263.htm (Accessed on June 08, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 480 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.96.59.103-4655A9FD26-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38519=[""].join("\n");
var outline_f37_39_38519=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19315799\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF CEPHALOSPORINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SPECTRUM OF ACTIVITY AND CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2999651\">",
"      Parenteral agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - First generation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Second generation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Activity against Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cephamycin subgroup (active against Bacteroides)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Third generation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Poor activity against Pseudomonas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Activity against Pseudomonas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Fourth generation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fifth generation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Oral agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2999961\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19315799\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/480\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/480|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/10/41132\" title=\"table 1\">",
"      Renal dosing of cephalosporins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/25/7579\" title=\"table 2\">",
"      CSF drug conc with inflammation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/2/26663?source=related_link\">",
"      Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/5/1110?source=related_link\">",
"      Penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/40/28298?source=related_link\">",
"      Pharmacology of antimicrobial agents for treatment of methicillin-resistant Staphylococcus aureus and vancomycin resistant enterococcus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/81?source=related_link\">",
"      Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_39_38520="Secondary endocrine therapies for castration resistant prostate cancer";
var content_f37_39_38520=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary endocrine therapies for castration resistant prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38520/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38520/contributors\">",
"     Nancy A Dawson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38520/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38520/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38520/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38520/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38520/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38520/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/39/38520/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen deprivation therapy (ADT) is generally the initial treatment for men with advanced prostate cancer. Standard approaches include orchiectomy, a gonadotropin releasing hormone (GnRH) agonist, or a combination of a GnRH agonist plus an antiandrogen (combined androgen blockade). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/20/1353?source=see_link\">",
"     \"Initial hormone therapy for metastatic prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite initial response rates of 80 to 90 percent, nearly all men eventually develop castration resistant, progressive disease. Clinical trials have shown that a number of contemporary approaches can significantly increase overall survival in this setting (",
"    <a class=\"graphic graphic_table graphicRef85716 \" href=\"mobipreview.htm?17/56/18317\">",
"     table 1",
"    </a>",
"    ). In addition, several older endocrine therapies may induce biochemical or clinical responses, even though no overall survival benefit has been demonstrated in randomized trials.",
"   </p>",
"   <p>",
"    The role of continuing ADT in men with castration resistant prostate cancer and options for secondary endocrine therapy are reviewed here. An overview of the management of advanced prostate cancer is presented separately, as is a detailed discussion of newer treatment modalities interfering with the androgen stimulation pathway. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16503?source=see_link\">",
"     \"Castrate resistant prostate cancer: Treatments targeting the androgen pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CONTINUATION OF ADT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgenic steroids are growth factors for prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/1\">",
"     1",
"    </a>",
"    ]. When disease progresses, discontinuation of GnRH agonist therapy can result in an increase in serum testosterone and thus contribute to progressive disease.",
"   </p>",
"   <p>",
"    There are no trials that directly address the utility of continued ADT in men with castrate-resistant prostate cancer. However, a multivariate analysis of 341 patients with castrate-resistant prostate cancer who were treated in four clinical trials found observational evidence that continued testicular androgen suppression was associated with a median survival benefit of two to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Cancer Care Ontario Practice guidelines, which have been endorsed by the American Society of Clinical Oncology (ASCO), recommend that maintenance gonadal androgen suppression be continued during chemotherapy, while antiandrogens should be discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/3\">",
"     3",
"    </a>",
"    ]. Similarly, guidelines from the Prostate Specific Antigen Working Group recommended that all patients who have not undergone surgical castration should be continued on testicular androgen suppression as a protocol eligibility criterion in phase II studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2165877156\">",
"    <span class=\"h1\">",
"     SECONDARY ENDOCRINE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several alternative endocrine therapies (antiandrogens, antiandrogen withdrawal,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    , estrogens) have not been demonstrated to improve survival. However, these approaches may induce clinical responses or stable disease. Secondary endocrine therapies are often used sequentially and may be useful in postponing interventions such as chemotherapy with more severe toxicity or when no other effective options are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antiandrogen withdrawal",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients receiving an antiandrogen as part of a combined androgen blockade regimen with either medical or surgical orchiectomy, the discontinuation of the antiandrogen may result in a clinical or biochemical (PSA) response. Similarly, a response may be seen when antiandrogen therapy that is being used as therapy for castration resistant disease is discontinued. The mechanism of the antiandrogen withdrawal response is not known.",
"   </p>",
"   <p>",
"    Antiandrogen withdrawal responses have been observed following discontinuation of all of the antiandrogens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. With",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    , which has a half-life of five hours, withdrawal responses develop in one to two weeks. In contrast, PSA decline may not occur for three to six weeks with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33204?source=see_link\">",
"     nilutamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    , which have half-lives of approximately 56 hours and one week, respectively.",
"   </p>",
"   <p>",
"    The role of antiandrogen withdrawal was studied in men with castrate-resistant prostate cancer in a phase III trial conducted by the Cancer and Leukemia Group B (CALGB 9583) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/5\">",
"     5",
"    </a>",
"    ]. In this trial, 260 patients who had progressed on ADT were randomly assigned to antiandrogen withdrawal plus simultaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    or antiandrogen withdrawal alone, with ketoconazole reserved for subsequent use upon progression. More patients had a PSA response or an objective tumor response when ketoconazole was initiated immediately rather than waiting to see if an antiandrogen withdrawal response occurred (27 versus 11 percent and 20 versus 2 percent, respectively). However, there was no statistically significant difference in overall survival with the two treatment strategies (15.3 versus 16.7 months, p = 0.94).",
"   </p>",
"   <p>",
"    Two other observational series that each included over 200 patients observed antiandrogen withdrawal PSA response rates of 15 and 21 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these observations, the first therapeutic maneuver in a man with progression following hormone ablation is generally the discontinuation of his current antiandrogen or other endocrine therapy. Alternative therapy should not be initiated until adequate time has elapsed to rule out a withdrawal response. The time interval is based upon the half-life of the drug administered. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Antiandrogens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antiandrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiandrogens act by blocking the binding of dihydrotestosterone to the androgen receptor. These agents are useful both as therapy for castrate resistant prostate cancer and in combination with medical or surgical orchiectomy as part of a combined androgen blockade for the initial treatment of men with advanced prostate cancer. Generally, antiandrogens are given in the context of continued GnRH agonist therapy or in men who have undergone orchiectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/20/1353?source=see_link&amp;anchor=H261287030#H261287030\">",
"     \"Initial hormone therapy for metastatic prostate cancer\", section on 'Combined androgen blockade'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials that directly compare the different antiandrogen compounds. Decisions on choice of agent are generally based upon side effect profiles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Flutamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     Flutamide",
"    </a>",
"    has a half-life of about five hours and is almost completely secreted in the urine. The standard dose is 250 mg orally three times per day. Common side effects include diarrhea, breast tenderness, and nipple tenderness. Less commonly, diarrhea, nausea and vomiting occur. Hepatotoxicity is uncommon (3 per 10,000 patients) but can be fatal, and therefore serum aminotransferases should be closely monitored during therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    was illustrated by a series of 209 men treated after failing initial endocrine therapy with either orchiectomy, diethylstilbestrol, or a GnRH agonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/11\">",
"     11",
"    </a>",
"    ]. The overall response rate was 35 percent, and the mean duration of response was 24 months. Smaller studies have yielded similar results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No trial has established the superiority of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    compared with other treatments of metastatic castration resistant prostate cancer. One trial sponsored by the European Organization for Research and Treatment of Cancer (EORTC) randomly assigned 201 men who were progressing after initial androgen ablation therapy to either flutamide (250 mg three times daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (5 mg four times daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/13\">",
"     13",
"    </a>",
"    ]. There were no significant differences between the groups in time to progression, overall survival, subjective response rate, biochemical response rate, or duration of response. However, patients receiving prednisone had less pain, fatigue, anorexia, gastrointestinal distress, and a better quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Bicalutamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     Bicalutamide",
"    </a>",
"    has a half-life of about five to six days. Bicalutamide (50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is administered orally once a day in conjunction with a GnRH.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     Bicalutamide",
"    </a>",
"    is considered to be as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    in terms of PSA response, objective response, and quality of life (QOL), but diarrhea and hepatotoxicity are less frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/14\">",
"     14",
"    </a>",
"    ]. Adverse effects include loss of libido, impotence, hot flashes, and breast tenderness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gynecomastia. Less common side effects include transient liver function abnormalities in less than 5 percent and diarrhea in 10 percent.",
"   </p>",
"   <p>",
"    Several clinical studies have evaluated the use of high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    as monotherapy in men with castrate-resistant prostate cancer. In one study of 51 such men receiving bicalutamide (200 mg per day), PSA declines of 50 percent or greater were documented in 12 (24 percent), although there are no data that high dose bicalutamide is better than standard dose bicalutamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/15\">",
"     15",
"    </a>",
"    ]. Similar results were noted in two other series using high-dose bicalutamide (150 mg per day) in men with castrate-resistant prostate cancer progressing after initial treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Differences between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    may account for the responses observed to bicalutamide in some patients who had progressed while on treatment with flutamide. Bicalutamide has a significantly increased affinity for the androgen receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/18\">",
"     18",
"    </a>",
"    ]. Furthermore, bicalutamide retains its antagonistic properties for the mutated or supersensitive androgen receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/19\">",
"     19",
"    </a>",
"    ]. In men treated with flutamide as part of a complete androgen blockade regimen, flutamide may exert selection pressure for AR mutations, thereby enhancing the subsequent inhibitory effect of bicalutamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H261302558\">",
"     'Switching antiandrogens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Nilutamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33204?source=see_link\">",
"     Nilutamide",
"    </a>",
"    has a half-life of approximately two days. In addition to the side effects caused by its antiandrogenic properties, toxicities include delayed adaptation to darkness in 25 percent of patients, nausea in 10 percent, reversible increases in hepatic transaminases in up to 8 percent, and alcohol intolerance in 5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/21\">",
"     21",
"    </a>",
"    ]. There are rare reports of interstitial lung disease caused by nilutamide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biochemical responses to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33204?source=see_link\">",
"     nilutamide",
"    </a>",
"    have been observed after both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In the largest series, 8 of 28 men treated with nilutamide who had failed prior flutamide or bicalutamide had a PSA response for longer than three months with nilutamide (200 to 300 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/24\">",
"     24",
"    </a>",
"    ]. Men with a prior antiandrogen withdrawal response were significantly more likely to have a response to nilutamide than those without such a response. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Antiandrogen withdrawal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33204?source=see_link\">",
"     Nilutamide",
"    </a>",
"    appears to offer no benefit compared to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    , and has the least favorable toxicity profile in this class [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Cyproterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steroidal antiandrogen",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    (CPA) is considered to be as effective as estrogens or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    , with better tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/26\">",
"     26",
"    </a>",
"    ]. However, liver toxicity can complicate long-term use.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"     Cyproterone",
"    </a>",
"    acetate is not approved in the United States for the treatment of men with prostate cancer.",
"   </p>",
"   <p>",
"    The most extensive data on the activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"     cyproterone acetate",
"    </a>",
"    come from a randomized trial in which 310 men with treatment na&iuml;ve metastatic prostate cancer were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/2/14374?source=see_link\">",
"     cyproterone",
"    </a>",
"    acetate or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/27\">",
"     27",
"    </a>",
"    ]. At a median follow-up of over eight years, there was no difference in overall survival, disease-specific survival, or time to progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H261302558\">",
"    <span class=\"h3\">",
"     Switching antiandrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for switching to another antiandrogen in patients who have progressed on an antiandrogen or complete androgen blockade is based upon the assumption that the specific antiandrogens interact differently with the androgen receptor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/9/30874?source=see_link&amp;anchor=H29#H29\">",
"     \"Molecular biology of prostate cancer\", section on 'Acquired androgen resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential utility of using an alternative nonsteroidal antiandrogen was illustrated by a retrospective series of 232 patients who progressed after initial treatment with combined androgen blockade [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/7\">",
"     7",
"    </a>",
"    ]. After observation for an antiandrogen response, patients were treated with an alternative nonsteroidal antiandrogen. Overall, a PSA decrease of &ge;50 percent was observed in 36 percent of patients and a lesser PSA decrease (&lt;50 percent) was seen in another 25 percent. There was no significant difference in those who switched from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/23/4470?source=see_link\">",
"     flutamide",
"    </a>",
"    compared to those who changed from flutamide to bicalutamide. Multivariate analysis found that any response to second-line antiandrogen therapy was significantly associated with an improved cause-specific survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ketoconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cytochrome P450 enzyme inhibitors block the synthesis of androgens by the adrenal gland through inhibition of the enzyme 17,20-lyase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/28\">",
"     28",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    is an imidazole antifungal agent that inhibits adrenal androgen synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/28,29\">",
"     28,29",
"    </a>",
"    ] and has a direct cytotoxic effect on prostatic cancer cells in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The usual dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    is 200 to 400 mg three times per day. Ketoconazole requires a low gastric pH for maximum absorption and thus should be taken on an empty stomach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, antacids, proton pump inhibitors, and histamine H2-receptor antagonists should be avoided if possible.",
"   </p>",
"   <p>",
"    Adverse effects including nausea and vomiting in up to one-half of patients, skin rash in 10 percent, fatigue, nail dystrophy, asthenia, and gynecomastia. High doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    can cause adrenal insufficiency. Thus, ketoconazole is usually administered with concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , which complicates the interpretation of therapeutic results of this agent in castrate-resistant prostate cancer.",
"   </p>",
"   <p>",
"    Treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    is generally initiated after allowing for a potential response from the withdrawal of an antiandrogen. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Antiandrogen withdrawal'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a phase III trial conducted by the Cancer and Leukemia Group B (CALGB 9583), 260 patients who had progressed on ADT were randomly assigned to antiandrogen withdrawal plus simultaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    or antiandrogen withdrawal alone, with ketoconazole reserved for subsequent use upon progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 128 patients assigned to antiandrogen withdrawal plus immediate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      , a PSA decline &ge;50 percent was observed in 27 percent, and an objective tumor response was observed in 10 of 50 patients (20 percent) with measurable disease.",
"     </li>",
"     <li>",
"      In the group of 132 patients assigned to antiandrogen withdrawal alone, 108 were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      when PSA progression was documented. In these men, 35 of 108 (32 percent) had a PSA response, and 3 of 41 (7 percent) with measurable disease had an objective response.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    is a less specific inhibitor of CYP17 than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/29/44503?source=see_link\">",
"     abiraterone",
"    </a>",
"    . However, it may retain a role in some patients given ketoconazole&rsquo;s much costs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374890087\">",
"    <span class=\"h2\">",
"     Megestrol acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     Megestrol acetate",
"    </a>",
"    is a synthetic progestin that may act through several mechanisms. These include blockade of the androgen receptor, inhibition of luteinizing hormone release, inhibition of the conversion of testosterone to dihydrotestosterone, and adrenal suppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In addition, megestrol is directly cytotoxic to prostate cancer cells in vitro at high doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most extensive data using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    come from a multicenter trial, in which 149 men with advanced prostate cancer were randomly assigned to either low-dose (160",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or high-dose (640",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    megestrol acetate. A greater than 50 percent decrease in serum PSA was observed in 14 and 9 percent of low dose and high treatment groups. Median survival was the same in both groups (11 and 12 months, respectively)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ) reduce the pituitary production of ACTH, resulting in suppression of adrenal steroidogenesis including adrenal androgens. Other possible mechanisms of glucocorticoid action include direct inhibition of tumor growth by disruption of intracellular signaling pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    suppression of tumor lymphangiogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Several studies have shown significant subjective and objective improvement in men with castrate-resistant prostate cancer who receive glucocorticoids.",
"   </p>",
"   <p>",
"    Data on the activity of glucocorticoids come from trials in which steroids served as a control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/13,39,40\">",
"     13,39,40",
"    </a>",
"    ]. As an example, in one trial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (40 mg per day) was compared to hydrocortisone plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"     suramin",
"    </a>",
"    in men with castrate-resistant prostate cancer; 16 percent of those given cortisone alone had a decline in serum PSA of greater than 50 percent, while 28 percent had improved bone pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/39\">",
"     39",
"    </a>",
"    ]. Similarly, in another trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    plus hydrocortisone to hydrocortisone alone, 22 percent of men receiving hydrocortisone alone had a greater than 50 percent decline in serum PSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;DES at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and other estrogen preparations are a useful alternative in some patients.",
"   </p>",
"   <p>",
"    High doses of estrogens compete with androgens for the androgen receptor (AR), and have a cytotoxic effect on human androgen-sensitive and androgen-insensitive prostate cancer cells in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/41\">",
"     41",
"    </a>",
"    ]. Diethylstilbestrol (DES) formerly was widely used in the treatment of metastatic prostate cancer and is the estrogen that has been most extensively studied, primarily in the setting of initial hormone therapy for advanced disease.",
"   </p>",
"   <p>",
"    The potential role of DES (1 mg daily) as a second-line agent was evaluated in a trial in which 58 men who had progressed on GnRH agonist therapy were randomly assigned to either DES or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/2/30758?source=see_link\">",
"     bicalutamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38520/abstract/42\">",
"     42",
"    </a>",
"    ]. Both the PSA response rate and median response durations were similar in the two groups (23 versus 31 percent and 9 versus 12 months, respectively). Bicalutamide was better tolerated. Despite the prophylactic use of 75 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    daily in the DES group, three of seven patients with adverse effects had cardiovascular toxicity (congestive heart failure, pulmonary embolism, stroke). &nbsp;",
"   </p>",
"   <p>",
"    Various herbal supplements, such as PC-SPES, have been touted for their activity in patients with prostate cancer. These preparations contain inconsistent amounts of estrogen that appear to be responsible for the activity that has been observed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=see_link&amp;anchor=H13#H13\">",
"     \"Complementary and alternative therapies for cancer\", section on 'PC-SPES'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2165877131\">",
"    <span class=\"h1\">",
"     TREATMENTS TARGETING THE ANDROGEN PATHWAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research has led to the development of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/29/44503?source=see_link\">",
"     abiraterone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16103?source=see_link\">",
"     enzalutamide",
"    </a>",
"    , both of which have been demonstrated to improve overall survival in phase III trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347803880\">",
"    <span class=\"h2\">",
"     Abiraterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/29/44503?source=see_link\">",
"     Abiraterone",
"    </a>",
"    is an orally administered agent that blocks the synthesis of androgens in the tumor as well as in the testes and adrenal glands. Abiraterone has been shown to increase overall survival in men with castrate resistant prostate cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16503?source=see_link&amp;anchor=H1409980#H1409980\">",
"     \"Castrate resistant prostate cancer: Treatments targeting the androgen pathway\", section on 'Abiraterone'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H347803888\">",
"    <span class=\"h2\">",
"     Enzalutamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16103?source=see_link\">",
"     Enzalutamide",
"    </a>",
"    is an oral agent that acts at multiple sites in the androgen receptor signaling pathway. Enzalutamide has been shown to increase overall survival in castrate resistant men who have progressed during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16503?source=see_link&amp;anchor=H1385299855#H1385299855\">",
"     \"Castrate resistant prostate cancer: Treatments targeting the androgen pathway\", section on 'Enzalutamide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4110854\">",
"    <span class=\"h1\">",
"     SURVEILLANCE DURING TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveillance strategies during treatment for disseminated prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10055?source=see_link&amp;anchor=H11088148#H11088148\">",
"     \"Follow-up surveillance during and after treatment for prostate cancer\", section on 'Metastatic prostate cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=see_link\">",
"       \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/51/21300?source=see_link\">",
"       \"Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Androgen deprivation therapy (ADT) is generally the initial treatment for men with advanced prostate cancer. Despite high response rates to the initial hormone therapy, nearly all men eventually develop progressive, castrate-resistant, disease. Subsequent management utilizes sequential application of various treatments. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=see_link&amp;anchor=H25221296#H25221296\">",
"       \"Overview of the treatment of disseminated prostate cancer\", section on 'Androgen deprivation therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A number of newer approaches have demonstrated improved overall survival in this setting, but these have not been compared with each other in randomized clinical trials (",
"      <a class=\"graphic graphic_table graphicRef85716 \" href=\"mobipreview.htm?17/56/18317\">",
"       table 1",
"      </a>",
"      ). The optimal sequence of these therapies and their timing relative to older endocrine approaches remains uncertain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=see_link&amp;anchor=H261299183#H261299183\">",
"       \"Overview of the treatment of disseminated prostate cancer\", section on 'Sequence of systemic therapies'",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      For patients with advanced prostate cancer whose initial hormonal therapy included a GnRH agonist, we recommend that the GnRH agonist be continued so as to maintain suppression of testicular androgen production (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Continuation of ADT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with advanced prostate cancer whose initial hormonal therapy included both an GnRH agonist and an antiandrogen, we suggest withdrawing the antiandrogen and observing for evidence of response before initiating an alternative systemic therapy treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Antiandrogen withdrawal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several alternative endocrine therapies (antiandrogens, antiandrogen withdrawal,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      , glucocorticoids,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      , estrogens) have not been demonstrated to improve survival. However, these approaches may induce clinical responses or stable disease. Secondary endocrine therapies are often used sequentially and may be useful in postponing interventions such as chemotherapy with more severe toxicity or when no other effective options are available. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antiandrogens'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Antiandrogen withdrawal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Ketoconazole'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H374890087\">",
"       'Megestrol acetate'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Glucocorticoids'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Estrogens'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/1\">",
"      Fowler JE Jr, Whitmore WF Jr. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol 1981; 126:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/2\">",
"      Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol 1993; 11:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/3\">",
"      Basch EM, Somerfield MR, Beer TM, et al. American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol 2007; 25:5313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/4\">",
"      Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17:3461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/5\">",
"      Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/6\">",
"      Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008; 112:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/7\">",
"      Suzuki H, Okihara K, Miyake H, et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J Urol 2008; 180:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/8\">",
"      Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/9\">",
"      Wysowski DK, Fourcroy JL. Flutamide hepatotoxicity. J Urol 1996; 155:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/10\">",
"      Wysowski DK, Freiman JP, Tourtelot JB, Horton ML 3rd. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann Intern Med 1993; 118:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/11\">",
"      Labrie F, Dupont A, Giguere M, et al. Benefits of combination therapy with flutamide in patients relapsing after castration. Br J Urol 1988; 61:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/12\">",
"      Fowler JE Jr, Pandey P, Seaver LE, Feliz TP. Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 1995; 154:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/13\">",
"      Foss&aring; SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001; 19:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/14\">",
"      Schellhammer PF. Combined androgen blockade for the treatment of metastatic cancer of the prostate. Urology 1996; 47:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/15\">",
"      Scher HI, Liebertz C, Kelly WK, et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 1997; 15:2928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/16\">",
"      Joyce R, Fenton MA, Rode P, et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998; 159:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/17\">",
"      Kucuk O, Fisher E, Moinpour CM, et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/18\">",
"      Kolvenbag GJ, Furr BJ, Blackledge GR. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis 1998; 1:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/19\">",
"      Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/20\">",
"      Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 1999; 59:2511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/21\">",
"      Decensi AU, Boccardo F, Guarneri D, et al. Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol 1991; 146:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/22\">",
"      Pfitzenmeyer P, Foucher P, Piard F, et al. Nilutamide pneumonitis: a report on eight patients. Thorax 1992; 47:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/23\">",
"      Davis NB, Ryan CW, Stadler WM, Vogelzang NJ. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int 2005; 96:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/24\">",
"      Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J Urol 2003; 169:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/25\">",
"      Dole EJ, Holdsworth MT. Nilutamide: an antiandrogen for the treatment of prostate cancer. Ann Pharmacother 1997; 31:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/26\">",
"      Schr&ouml;der FH, Collette L, de Reijke TM, Whelan P. Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer. Br J Cancer 2000; 82:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/27\">",
"      Schr&ouml;der FH, Whelan P, de Reijke TM, et al. Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the \"European Organization for Research and Treatment of Cancer\" (EORTC) Protocol 30892. Eur Urol 2004; 45:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/28\">",
"      De Coster R, Caers I, Coene MC, et al. Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin Endocrinol (Oxf) 1986; 24:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/29\">",
"      Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982; 142:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/30\">",
"      Eichenberger T, Trachtenberg J, Toor P, Keating A. Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J Urol 1989; 141:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/31\">",
"      Blum RA, D'Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/32\">",
"      Geller J, Albert J, Geller S, et al. Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate. J Clin Endocrinol Metab 1976; 43:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/33\">",
"      Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995; 122:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/34\">",
"      Anderson DG. The possible mechanisms of action of progestins on endometrial adenocarcinoma. Am J Obstet Gynecol 1972; 113:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/35\">",
"      Nishimura K, Nonomura N, Satoh E, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001; 93:1739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/36\">",
"      Fakih M, Johnson CS, Trump DL. Glucocorticoids and treatment of prostate cancer: a preclinical and clinical review. Urology 2002; 60:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/37\">",
"      Yano A, Fujii Y, Iwai A, et al. Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 2006; 12:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/38\">",
"      Yano A, Fujii Y, Iwai A, et al. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res 2006; 12:6012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/39\">",
"      Small EJ, Meyer M, Marshall ME, et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000; 18:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/40\">",
"      Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/41\">",
"      Landstr&ouml;m M, Damber JE, Bergh A. Estrogen treatment postpones the castration-induced dedifferentiation of Dunning R3327-PAP prostatic adenocarcinoma. Prostate 1994; 25:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38520/abstract/42\">",
"      Manikandan R, Srirangam SJ, Pearson E, et al. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Urol Int 2005; 75:217.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6942 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38520=[""].join("\n");
var outline_f37_39_38520=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CONTINUATION OF ADT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2165877156\">",
"      SECONDARY ENDOCRINE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antiandrogen withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antiandrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Flutamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Bicalutamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Nilutamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Cyproterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H261302558\">",
"      - Switching antiandrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ketoconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H374890087\">",
"      Megestrol acetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Estrogens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2165877131\">",
"      TREATMENTS TARGETING THE ANDROGEN PATHWAY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H347803880\">",
"      Abiraterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H347803888\">",
"      Enzalutamide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4110854\">",
"      SURVEILLANCE DURING TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/6942\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/6942|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/56/18317\" title=\"table 1\">",
"      Therapies for castrate resistant prostate cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/7/16503?source=related_link\">",
"      Castrate resistant prostate cancer: Treatments targeting the androgen pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40154?source=related_link\">",
"      Complementary and alternative therapies for cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/52/10055?source=related_link\">",
"      Follow-up surveillance during and after treatment for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/20/1353?source=related_link\">",
"      Initial hormone therapy for metastatic prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/9/30874?source=related_link\">",
"      Molecular biology of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/51/21300?source=related_link\">",
"      Patient information: Complementary and alternative medicine treatments (CAM) for cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?41/41/42643?source=related_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_39_38521="Use of iron preparations in hemodialysis patients";
var content_f37_39_38521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of iron preparations in hemodialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38521/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38521/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38521/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38521/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38521/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38521/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/39/38521/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic kidney disease are commonly iron deficient. Adequate iron stores are essential for achieving maximum benefit from erythropoietic agents (ESAs). Decreased iron stores or decreased availability of iron are the most common reasons for resistance to the effect of these agents.",
"   </p>",
"   <p>",
"    Dialysis patients commonly suffer iron loss from gastrointestinal bleeding, blood drawing,",
"    <span class=\"nowrap\">",
"     and/or,",
"    </span>",
"    most important with hemodialysis, the dialysis treatment itself. Hemodialysis patients lose an average of 1 to 2 g of iron per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, iron deficiency will tend to develop in virtually all dialysis patients unless supplemental iron therapy is given.",
"   </p>",
"   <p>",
"    An overview of the use of iron in patients undergoing maintenance hemodialysis is presented in this topic review. Discussions related to the use of iron in predialysis, peritoneal dialysis, and home hemodialysis patients as well as the diagnosis of iron deficiency in patients with chronic kidney disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37752?source=see_link\">",
"     \"Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28005?source=see_link\">",
"     \"Diagnosis of iron deficiency in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF IRON DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiating therapy, iron stores must be assessed and non-renal causes of anemia excluded. As discussed in detail separately, the evaluation of patients with kidney disease and anemia must therefore include red blood cell indices, reticulocyte count, serum iron, total iron binding capacity, percent transferrin saturation, serum ferritin, and testing for occult blood in stool. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"     \"Approach to the adult patient with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Absolute and functional iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although none of the routinely available tests for iron status are entirely satisfactory, among hemodialysis patients, absolute iron deficiency is likely to be present when [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The percent transferrin saturation (TSAT) (plasma iron divided by total iron binding capacity x 100) falls &le;20 percent",
"     </li>",
"     <li>",
"      The serum ferritin concentration is less than 200",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even with TSAT and ferritin above these levels, at least up to a TSAT of about 30 percent and ferritin level of about 500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    many dialysis patients will respond to supplemental intravenous iron with an increase in Hb level",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction in erythropoietin stimulating agents (ESA) dose.",
"   </p>",
"   <p>",
"    In addition to absolute iron deficiency, it is now recognized that dialysis patients may have functional iron deficiency. This is characterized by the presence of adequate iron stores as defined by conventional criteria but an inability to sufficiently mobilize this iron when erythropoiesis is stimulated by an erythropoietic-stimulating agent (ESA). Functional deficiency is associated with transferrin saturation &le;20 percent and elevated ferritin level (typically between 100 to 800",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or even higher).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     OVERVIEW OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously discussed, prior to initiating therapy, iron stores must be assessed and non-renal causes of anemia excluded prior to initiating therapy. Among in-center hemodialysis patients, loading therapy is used to correct and treat existing iron deficiency and maintenance therapy is often used for those receiving an erythropoietin stimulating agent (ESA) who are already iron-replete although data in favor of maintenance rather than intermittent iron dosing is limited. Due to enhanced efficacy, intravenous iron rather than oral iron therapy should be used in these patients. In all patients the risks of iron administration must be weighed against any potential clinical benefits that are expected.",
"   </p>",
"   <p>",
"    We recommend the administration of iron therapy among all hemodialysis patients who have absolute iron deficiency (transferrin saturation (TSAT) &le;20 percent and ferritin &le;200",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    In addition, prior to the administration of treatment with an ESA, among patients who have TSAT &le;30 percent and ferritin &le;500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    we suggest the administration of iron therapy if an increase in the hemoglobin concentration is desired, providing an underlying infection has been excluded.",
"   </p>",
"   <p>",
"    This is principally because ESA therapy requires significant amounts of supplemental iron for effective erythropoiesis. Although normal body stores of iron are 800 to 1000 mg, approximately 1000 mg is required among hemodialysis patients to raise hemoglobin levels from approximately 8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    to 11 to 12",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    with the initiation of ESA therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/3\">",
"     3",
"    </a>",
"    ]. After target hemoglobin levels are achieved, approximately 250 to 500 mg of iron may be required every three months to maintain adequate iron stores to support erythropoiesis with ESA therapy.",
"   </p>",
"   <p>",
"    The most common cause of resistance to ESA is iron deficiency, which can be present at the time of initiation of ESA treatment or can develop as the result of exhaustion of iron stores due to the increase in erythropoiesis caused by ESA treatment. As shown in numerous observational and prospective studies, the administration of iron to obtain adequate iron stores increases hemoglobin levels in patients who are not on ESA treatment, as well as those who are, and lowers ESA doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/4-13\">",
"     4-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In order to achieve and maintain target hemoglobin levels of 10 to 11.5",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    most hemodialysis patients will need treatment with both an ESA and supplemental iron although some can be maintained in this range with adequate iron alone.",
"   </p>",
"   <p>",
"    The 2012 KDIGO guidelines suggest intravenous iron therapy for dialysis patients with a transferrin saturation &le;30 percent and ferritin &le;500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and anemia in whom an increase in Hgb is desired and the risks and benefits have been considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not routinely administer intravenous iron with ferritin levels above 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and anemia, although each patient should be individually assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Iron loading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, based upon a large number of prospective and observational studies, it was thought that iron supplementation should be given only to raise the serum ferritin level greater than 100",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and the percent TSAT level greater than 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. These levels appeared to adequately support erythropoiesis in hemodialysis patients receiving ESA for the anemia of CKD. However, subsequent well-designed prospective studies suggest that a ferritin level greater than 200",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is better able to support effective erythropoiesis with ESA. These studies are discussed in the next section.",
"   </p>",
"   <p>",
"    Thus, if iron indices indicate absolute iron deficiency (TSAT &le;20 percent and serum ferritin &lt;200",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    a sufficient amount of iron to correct the iron deficiency should be administered.",
"   </p>",
"   <p>",
"    In addition, among patients in whom an increase in hemoglobin concentration is desired, a sufficient amount of iron should be administered to achieve a TSAT near 30 percent, providing the serum ferritin remains &le;500",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    There are various loading regimens based in part on the different parenteral iron preparations. Our goals with any loading regimen are to increase hemoglobin levels and increase the TSAT to approximately 30 percent while not increasing the serum ferritin level above 500",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Overview of dosing regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    At this time, we do not routinely recommend administration of intravenous iron to patients with ferritin levels above 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and anemia. However, there is some evidence that additional intravenous iron, in association with an increase in ESA dose, can be effective in increasing hemoglobin levels over the short-term. This was best shown in the DRIVE study, in which 134 patients with anemia (hemoglobin levels less than 11",
"    <span class=\"nowrap\">",
"     g/dL),",
"    </span>",
"    elevated ferritin levels (500 to 1200",
"    <span class=\"nowrap\">",
"     ng/mL),",
"    </span>",
"    low TSAT levels (&le;25 percent), and high ESA requirements (&ge;225 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per week or &ge;22,500 international units per week) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    (125 mg with eight consecutive dialysis sessions) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/19\">",
"     19",
"    </a>",
"    ]. ESA doses were increased in all patients by 25 percent at the beginning of the study. At six weeks, hemoglobin levels had increased significantly more in the active therapy group (1.6 versus 1.1",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"   </p>",
"   <p>",
"    Although the DRIVE study shows that the combination of a 25 percent increase in ESA dose and supplemental intravenous iron was associated with a greater erythropoietic response compared with an increase in ESA dose alone over six weeks, the differences in response are of unclear clinical significance. There is concern that some patients who received both intravenous iron and the increase in ESA dose were more likely to have larger, more rapid increases in Hgb level, possibly resulting in adverse effects. Clinical outcomes beyond an increase in Hgb level were not assessed.",
"   </p>",
"   <p>",
"    Thus, each patient should be individually assessed, and some patients with ferritin levels above 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    will respond with an increase in hemoglobin level if administered supplemental iron. Repletion of iron stores alone without an ESA will raise the hemoglobin level to the target level in a significant proportion of patients. In addition, ESA administration in the presence of uncorrected iron deficiency will be relatively ineffective and is economically unsound. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=see_link\">",
"     \"Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Maintenance iron therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following goals of iron therapy during administration of ESAs among patients undergoing hemodialysis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      TSAT up to 30 percent",
"     </li>",
"     <li>",
"      Serum ferritin concentration up to &le;500",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To ensure an adequate response with ESAs, most dialysis patients will require supplemental iron on a continuing basis. Oral iron is often effective in predialysis patients; by comparison, most hemodialysis patients require intravenous iron and have improved erythropoiesis with intravenous compared to oral iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2012 KDIGO guidelines suggest intravenous iron therapy for dialysis patients with a transferrin saturation &le;30 percent and ferritin &le;500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    if an increase in Hgb is desired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some recommend caution in administering iron among patients with possibly excessive iron stores, which are suggested by a serum ferritin concentration above 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a TSAT above 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. It is very important that trends in Hb, TSAT, ferritin, and ESA dose be assessed over time when decisions about iron supplementation are made, rather than considering single isolated values.",
"   </p>",
"   <p>",
"    As previously noted, the DRIVE study reported that additional intravenous iron (in association with an increase in ESA dose) increased hemoglobin levels over the short-term in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/19\">",
"     19",
"    </a>",
"    ]. Nevertheless, the response is of unclear clinical significance, and some patients who received both intravenous iron and the increase in ESA dose may be more likely to have larger, more rapid increases in Hgb level, possibly resulting in adverse effects. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Iron loading'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We do not currently routinely recommend administration of intravenous iron to patients with ferritin levels above 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    and anemia, although each patient should be individually assessed. An initial trial of increased ESA dose alone, without intravenous iron, may also be reasonable if the Hgb level is persistently below 11.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    with an ESA dose that is not particularly high. The long-term clinical benefit and safety of providing additional supplemental iron in the setting of anemia with persistently elevated ferritin levels remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ORAL VERSUS PARENTERAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend the use of parenteral iron in hemodialysis patients rather than oral iron therapy. Among maintenance hemodialysis patients, intravenous iron is more effective than oral iron in increasing hemoglobin concentrations and iron stores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/11,23-25\">",
"     11,23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best data are from a Cochrane meta-analysis, which showed an increase in hemoglobin concentration (13 studies, 828 patients), ferritin concentration (16 studies, 960 patients), and transferrin saturation (11 studies, 709 patients) associated with intravenous compared with oral iron among dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/25\">",
"     25",
"    </a>",
"    ]. Among 9 studies (487 patients), there was a reduction in the dose of erythropoietin stimulating agents in patients treated with IV compared with oral iron.",
"   </p>",
"   <p>",
"    The 2012 KDIGO guidelines suggest intravenous rather than oral iron among hemodialysis patients who require iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PARENTERAL IRON PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different parenteral preparations of iron available in the United States are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       Iron dextran",
"      </a>",
"     </li>",
"     <li>",
"      Sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex in sucrose",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       Iron sucrose",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"       Ferumoxytol",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon the 2005 USRDS Annual Report, approximately 70 percent of hemodialysis patients in the United States received parenteral iron [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the different parenteral preparations of iron that are currently available in the United States, we recommend either intravenous sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex in sucrose or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    for hemodialysis patients because of their apparently equivalent efficacy but greater relative safety compared to iron",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    . Unfortunately, there have been no studies that have compared the safety and efficacy of sodium ferric gluconate complex in sucrose with iron sucrose.",
"   </p>",
"   <p>",
"    Despite their relative safety, it is important to be aware that all intravenous iron preparations have the potential to be associated with acute reactions, including abdominal pain, nausea, chest pain, shortness of breath, flushing, pruritus, rash, hypotension, and anaphylactic-like reactions.",
"   </p>",
"   <p>",
"    An initial test dose is not necessary with either sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex in sucrose or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    . Although not highly predictive of serious reactions, an initial test dose is recommended with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex in sucrose and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    appear to be safe among patients who are allergic to or intolerant of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. In such patients, although some may recommend an initial test dose, it is not specifically required or indicated in the package inserts of these drugs; it appears safe to administer these other agents for iron support in patients who have been previously intolerant of iron",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Iron dextran",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     Iron dextran",
"    </a>",
"    , which is composed of a mixture of synthetic polymers of glucose, is highly effective when given for loading or maintenance therapy. A discussion of some of the studies evaluating the efficacy of this agent for maintenance therapy can be found elsewhere. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Overview of dosing regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    when given for loading therapy in patients with iron deficiency has been reported in a number of studies. The following is a survey of some of these trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/16,31\">",
"     16,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study, 23 patients with serum ferritin levels less than 100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      were administered 100 mg of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      for 10 consecutive hemodialysis sessions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/16\">",
"       16",
"      </a>",
"      ]. At 10 weeks, therapy significantly increased the mean hematocrit level (29 to 34) and mean serum ferritin level (38 to 87",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"     </li>",
"     <li>",
"      In an open study of iron deficient hemodialysis patients, 30 individuals were first administered an intravenous loading dose of 1000 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      administered in five divided doses, which was followed by monthly maintenance doses of 100 mg for a four-month study period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/31\">",
"       31",
"      </a>",
"      ]. At study end, significant increases were noted in the mean serum ferritin (49 to 225",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      and transferrin saturation (27 to 33 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     Iron dextran",
"    </a>",
"    is associated with significant safety issues that are of much less concern with the other intravenous iron preparations. Anaphylaxis to intravenous iron",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    therapy may occur in both nonuremic and uremic patients, occasionally resulting in death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. It is thought to be due to the high-molecular weight dextran moiety, which may share carbohydrate antigens with gastrointestinal organisms.",
"   </p>",
"   <p>",
"    The incidence of anaphylaxis to and safety of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    was examined in a review of 573 hemodialysis patients treated with intravenous iron",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/32\">",
"     32",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-seven patients (4.7 percent) had an adverse reaction. The most common were itching (1.5 percent) and dyspnea or wheezing (1.5 percent).",
"     </li>",
"     <li>",
"      Ten patients (1.7 percent) had reactions classified as anaphylactoid. Serious reactions included cardiac arrest (0.2 percent), chest pain (1.0 percent), and hypotension (0.5 percent). No patient died.",
"     </li>",
"     <li>",
"      Among the 10 anaphylactoid reactions, six occurred with doses other than the test dose. Thus, the absence of a reaction to a test dose does not preclude one with later doses.",
"     </li>",
"     <li>",
"      Less severe reactions, which were frequently delayed, included arthralgias, myalgias, fever, headache, and lymphadenopathy.",
"     </li>",
"     <li>",
"      Although only five reactions occurred with the test dose, four were classified as anaphylactoid.",
"     </li>",
"     <li>",
"      A history of single or, particularly, multiple drug allergies was a strong predictor of a reaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Others have also reported that serious adverse reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    , including anaphylactic-like reactions, while rare, can occur with other than the first or test dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/33\">",
"     33",
"    </a>",
"    ]. In addition, the risk of adverse reactions may vary among different iron",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/33,38,39\">",
"     33,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    is to be administered, an initial test dose must be given prior to the initiation of intravenous iron",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    therapy, given the possibility of anaphylaxis. One protocol with iron dextran consists of the administration (over five minutes) of 25 mg of iron dextran mixed in 50 mL of normal saline as a test dose, with appropriate precautions for treatment of an anaphylactic reaction. If tolerated, larger doses of iron dextran (up to 500 to 1000 mg) may subsequently be given as a slow intravenous infusion. It is not necessary to premedicate patients prior to the test dose, but emergency medications (eg, epinephrine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , and corticosteroids) must be readily available. As previously mentioned, it should be remembered that serious reactions may occur with doses subsequent to the test or first full dose. Some side effects, such as arthralgias and myalgias, appear to be dose related.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intravenous sodium ferric gluconate complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex in sucrose (Ferrlecit) has been used for decades, mostly in Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/40\">",
"     40",
"    </a>",
"    ]. Sodium ferric gluconate complex in sucrose has fewer life-threatening and fatal adverse reactions than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    . In addition, its relative efficacy and adverse reaction profile are as good or better than iron",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. Ferric gluconate may also be safe among patients who are allergic to or intolerant of iron dextran [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/27,30\">",
"     27,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex in sucrose (Ferrlecit) is an effective parenteral preparation when given for loading or maintenance therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one randomized study of 83 iron-deficient dialysis patients, sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex administered over eight consecutive dialysis days in equally divided doses for a total amount of 1.0 gram significantly increased hemoglobin levels (mean 1.3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      at 30 days), serum ferritin, and iron saturation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a three year prospective maintenance study, 30 hemodialysis patients received intravenous iron gluconate at 31.25",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      for 12 months, which was followed by a six-month withdrawal or stop phase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/45\">",
"       45",
"      </a>",
"      ]. Patients subsequently received another 9 months of intravenous iron gluconate at 31.25",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"      Serum hemoglobin levels and ESA doses were similar over the study period (10.4 and 10.8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      at baseline and study end, respectively, and 3300 and 3545",
"      <span class=\"nowrap\">",
"       units/week,",
"      </span>",
"      respectively). However, serum ferritin markedly increased (123 and 317",
"      <span class=\"nowrap\">",
"       ng/mL).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since it does not contain",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    , sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex is less immunogenic than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. In a crossover, prospective phase four intravenous single-dose study, the incidence and types of adverse reactions were evaluated among 2534 hemodialysis patients administered sodium ferric gluconate complex (125 mg over 10 minutes) and placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/46\">",
"     46",
"    </a>",
"    ]. All patients were naive to the complex, and were not concurrently using antihistamines or corticosteroids. Outcomes were also compared to historic controls given iron dextran.",
"   </p>",
"   <p>",
"    The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A similar number of serious adverse events were observed with both sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex and placebo (14 and 12, respectively).",
"     </li>",
"     <li>",
"      There was a single life-threatening event observed with the sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex.",
"     </li>",
"     <li>",
"      Adverse events were significantly less common with sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex than with historic controls given",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      (0.4 and 2.5 percent, respectively, for drug intolerance and 0.04 and 0.61 percent for life-threatening events).",
"     </li>",
"     <li>",
"      Based upon logistic regression analysis, there did not appear to be a correlation between prior sensitivity to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      and an adverse reaction to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This study was further extended to evaluate the adverse reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex among patients tolerant of or sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/30\">",
"     30",
"    </a>",
"    ]. Among 143 iron-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    sensitive patients, 140 tolerated ferric gluconate without incident; in addition, 91 of 92 such patients tolerated repeated doses of ferric gluconate with no serious adverse events. However, the incidence of an adverse reaction to ferric gluconate was seven-fold higher among those sensitive to iron dextran (2.1 versus 0.3 percent for those tolerant of iron dextran [7 of 2194 patients]); these patients also had an increased reaction rate to placebo (0.7 versus 0.09 percent).",
"   </p>",
"   <p>",
"    Sodium",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"     ferric gluconate",
"    </a>",
"    complex is also safe when given repeatedly over prolonged periods. As an example, no life-threatening events were reported among 1321 hemodialysis patients who received over 13,000 infusions of sodium ferric gluconate complex during a nine month evaluation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/47\">",
"     47",
"    </a>",
"    ]. An adverse event was observed in 51 patients (3.9 percent), with one experiencing hypotension. Five patients (0.5 percent) also had a clinical event (pruritus, vasodilatation, or loss of taste) that prevented subsequent administration of the agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Intravenous iron sucrose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravenous iron formulation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     iron sucrose",
"    </a>",
"    (iron saccharate, Venofer), has been used extensively outside the United States for many years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/27,48,49\">",
"     27,48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Efficacy and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;This formulation is effective and well-tolerated for either loading or maintenance therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/28,34,36,50-53\">",
"     28,34,36,50-53",
"    </a>",
"    ]. The following is a survey of the some of the studies that have examined this issue:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 10 doses of 100 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      , each given intravenously over five minutes without a prior test dose, was both effective and safe among 77 iron deficient hemodialysis patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/51\">",
"       51",
"      </a>",
"      ]. There was a significant increase in Hgb level that was first evident after three doses of iron sucrose and persisted at least five weeks after the 10th dose. Among enrolled patients, serious adverse drug reactions were not noted.",
"     </li>",
"     <li>",
"      A randomized trial of 38 hemodialysis patients that compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      and sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex for six months found that these agents were equally effective and safe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"     Iron sucrose",
"    </a>",
"    also appears to be safe among those with a prior history of sensitivity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"     iron dextran",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest reported study, the safety of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      when administered as replacement or maintenance therapy was assessed among 665 hemodialysis patients, including 80 with previous intolerance to other parenteral iron preparations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/28\">",
"       28",
"      </a>",
"      ]. No serious drug-related adverse events or anaphylactic reactions were reported with iron sucrose.",
"     </li>",
"     <li>",
"      In another report, 100 mg of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      was administered in each of 10 consecutive dialysis sessions (total of 1000 mg) to 16 patients with mild (group A) and seven with severe (group B) sensitivity to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/29\">",
"       29",
"      </a>",
"      ]. Patients in group A received the formulation by intravenous (IV) push over five minutes, while those in group B were administered the agent by IV push over five minutes or by IV infusion over 15 to 30 minutes; a test dose was not given. No serious adverse reactions were reported after a total of 184 and 39 doses by IV push or infusion, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ferumoxytol",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new parenteral iron preparation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    (Feraheme), has been approved by the FDA in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Efficacy and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     Ferumoxytol",
"    </a>",
"    appears to be safe and effective when given as a rapid infusion of up to 510 mg in patients with CKD and patients on dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. Among 230 hemodialysis patients, for example, one randomized study evaluated the increase in hemoglobin and safety among those who received either two injections of 510 mg of ferumoxytol administered within seven days of each other or oral iron (200 mg per day) administered for a total of 21 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/57\">",
"     57",
"    </a>",
"    ]. An increase in hemoglobin levels was significantly more common with ferumoxytol (1 versus 0.46",
"    <span class=\"nowrap\">",
"     g/dL).",
"    </span>",
"    Both arms had similar adverse event rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the prescribing information monograph, 510 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    can be administered intravenously at a rapid rate (up to 30",
"    <span class=\"nowrap\">",
"     mg/sec)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/58\">",
"     58",
"    </a>",
"    ]. For the treatment of iron deficiency in those with CKD, the manufacturer recommends an initial 510 mg dose to be followed by a second 510 mg injection three to eight days after the first dose. A decision to administer a second or subsequent dose should be made after consideration of the severity of iron deficiency (ferritin and TSAT levels), hemoglobin level, and ESA responsiveness.",
"   </p>",
"   <p>",
"    In the absence of direct comparisons of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"     ferumoxytol",
"    </a>",
"    and other intravenous iron preparations, the assessment of relative safety and efficacy is not possible. The ability to provide large iron doses with short administration times is potentially attractive for hemodialysis patients as well as patients on peritoneal dialysis and CKD patients being administered ESA therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link\">",
"     \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Adverse effects other than anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to anaphylaxis, some experimental evidence suggests that parenteral iron therapy may be associated with the following adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased mortality from sepsis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased toxicity from free iron [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Renal tubular injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/61,62\">",
"       61,62",
"      </a>",
"      ], with limited data suggesting that the various preparations have different degrees of renal toxicity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/61,63\">",
"       61,63",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To clarify these issues, studies examining the issue of both acute and long-term iron toxicity with the different parenteral iron preparations are required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/59\">",
"     59",
"    </a>",
"    ]. Although earlier results were conflicting, subsequent studies have found that intravenous iron administration is not associated with increased risk of bacterial infection or mortality in hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/64-66\">",
"     64-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OVERVIEW OF DOSING REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Iron deficient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among iron-deficient hemodialysis patients, the administration of intensive iron regimens is effective in replenishing iron stores and markedly improving the efficacy of ESA therapy, as previously described. If iron therapy is indicated, we suggest administering one of the following regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      125 mg of sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex in sucrose can be given at each consecutive hemodialysis treatment for a total of eight doses (1000 mg in total).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      100 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      can be given at each consecutive hemodialysis treatment for a total of 10 doses (1000 mg in total).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"       Ferumoxytol",
"      </a>",
"      510 mg given one to four weeks apart.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We repeat the initial loading regimen if the TSAT remains below 30 percent and the hemoglobin is below target",
"   </p>",
"   <p>",
"    Our goal with any loading regimen is to increase hemoglobin levels and raise the TSAT to approximately above 30 percent, while not exceeding a serum ferritin level of 500",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"   </p>",
"   <p>",
"    While previous",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommended that intravenous iron should not be administered when ferritin levels exceeded 800",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    the 2006 guidelines indicate that there is insufficient evidence of efficacy to recommend routine administration of intravenous iron when the ferritin level exceeds 500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/3\">",
"     3",
"    </a>",
"    ]. However, in individual patients, continued iron administration might be appropriate depending upon clinical circumstances, even when the ferritin level exceeds 500",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    In this setting, additional intravenous iron administration may reduce ESA requirements; direct clinical benefits have not been demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Iron replete",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron replete patients are characterized by TSAT levels approaching 30 percent and serum ferritin levels under 500",
"    <span class=\"nowrap\">",
"     ng/L.",
"    </span>",
"    Among such patients receiving erythropoietin stimulating agents, a dosing issue with intravenous iron preparations is whether to administer iron intermittently or consistently for maintenance therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With intermittent regimens, intravenous iron is principally given in larger doses when iron indices fall below target levels, indicating the development of iron deficiency. Intravenous iron can be given in doses of 50 to 125 mg (depending on the specific iron preparation being used) with each dialysis treatment for a total of 8 to 20 injections. This provides a total dose of 1000 mg whenever iron indices fall below the target levels of a transferrin saturation of 30 percent providing the serum ferritin concentration is &le;500",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"     </li>",
"     <li>",
"      A continuous dosing regimen consists of the regular administration of low doses of parenteral iron, which is designed to prevent the development of iron deficiency once adequate iron stores have been established.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With intermittent therapy, iron is only given when iron indices are clearly inadequate; such regimens are likely to result in less than ideal delivery of iron to the marrow, which then results in an inadequate amount of iron available for continued effective erythropoiesis. Thus, intermittent maintenance therapy dosing regimens may result in the ineffective use of erythropoietin, less effective erythropoiesis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marked changes in serum iron parameters.",
"   </p>",
"   <p>",
"    Continuous regimens have therefore been evaluated and compared to the intermittent administration approach. Significant benefits have been observed with low dose continuous therapy in well-designed randomized trials.",
"   </p>",
"   <p>",
"    The following is a survey of some of these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 24 patients were randomly assigned to either a regimen in which an initial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      dose of 300 to 500 mg was followed by 25 to 100 mg every one to two weeks (to maintain a transferrin saturation between 30 and 50 percent) or an intermittent dosing regimen (to maintain a transferrin saturation &le;20 percent or a ferritin level &gt;200",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/62\">",
"       62",
"      </a>",
"      ]. All patients remained on oral iron therapy. A hemoglobin level of 10 to 11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      was achieved in both groups. However, the amount of ESA required in the maintenance group was significantly less than that utilized in the intermittent group (1569 versus 3527 units).",
"     </li>",
"     <li>",
"      In a prospective study, 26 hemodialysis patients with adequate iron indices (serum ferritin level &gt;100",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and transferrin saturation &le;20 percent) were randomly assigned to receive intravenous sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      either in a continuous (6.25 to 21.3 mg in every hemodialysis session) or an intermittent regimen (62.5 mg every 1 to 4 weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/64\">",
"       64",
"      </a>",
"      ]. At 16 weeks, the continuous group had a significant increase in serum hemoglobin level versus baseline values (11.8 versus 11.0",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      respectively), whereas no differences were obtained in intermittent group (baseline and 16 weeks and baseline were 11.2 and 11.1",
"      <span class=\"nowrap\">",
"       g/dL,",
"      </span>",
"      respectively).",
"     </li>",
"     <li>",
"      In a three-year prospective study, 30 hemodialysis patients received intravenous iron gluconate at 31.25",
"      <span class=\"nowrap\">",
"       mg/week",
"      </span>",
"      for 12 months, which was followed by a six-month withdrawal or stop phase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38521/abstract/65\">",
"       65",
"      </a>",
"      ]. Patients subsequently received another nine months of intravenous iron gluconate at 31.25",
"      <span class=\"nowrap\">",
"       mg/week.",
"      </span>",
"      Serum hemoglobin levels and ESA doses were similar over the study period (10.4 and 10.8",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      at baseline and study end, respectively, and 3300 and 3545",
"      <span class=\"nowrap\">",
"       units/week,",
"      </span>",
"      respectively). However, the study was not powered to detect a change in ESA dose.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We therefore recommend the administration of weekly continuous maintenance therapy rather than intermittent therapy to the iron-replete dialysis patient who is receiving erythropoietin-stimulating therapy. Prior to initiation of treatment with an ESA, we recommend the administration of iron therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with chronic kidney disease are commonly iron deficient. Prior to initiating therapy, iron stores must be assessed. The evaluation of patients with kidney disease and anemia must include red blood cell indices, reticulocyte count, serum iron, total iron binding capacity, percent transferrin saturation (TSAT), serum ferritin, and testing for occult blood in stool. Non-renal causes of anemia must be excluded. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=see_link\">",
"       \"Approach to the adult patient with anemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Iron therapy with or without erythropoietic stimulating agents (ESAs) are administered as needed to achieve and maintain target hemoglobin levels between 10 and 11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      among hemodialysis patients. Both iron therapy and an ESA are indicated in most hemodialysis patients with anemia due to CKD and hemoglobin levels less than 10",
"      <span class=\"nowrap\">",
"       g/dL.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=see_link\">",
"       \"Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among hemodialysis patients with anemia due to CKD and absolute iron deficiency (TSAT &le;20 percent and ferritin &le;200",
"      <span class=\"nowrap\">",
"       ng/mL),",
"      </span>",
"      we administer iron therapy for the treatment of anemia. Among hemodialysis patients who have TSAT &le;30 percent and ferritin &le;500",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and in whom an increase in hemoglobin concentration is desired, we also administer iron therapy prior to the use of ESAs, providing an underlying infection has been excluded. We do not routinely administer intravenous iron to patients with ferritin levels above 500",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and anemia, although each patient should be individually assessed. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among hemodialysis patients, we use parenteral iron rather than oral iron therapy. The different parenteral preparations of iron available in the United States are",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      , sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex in sucrose,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"       ferumoxytol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      . These preparations are largely equivalent in efficacy. However, sodium ferric gluconate complex in sucrose and iron sucrose appear to be safer than iron",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      , which is associated with a significant risk of anaphylaxis. Experience with ferumoxytol remains limited. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Oral versus parenteral therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Parenteral iron preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients in who parenteral iron therapy is indicated, we use either intravenous sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex in sucrose,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"       ferumoxytol",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      &nbsp;. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Parenteral iron preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among hemodialysis patients who require iron therapy we use iron loading therapy, providing an underlying infection has been excluded. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Iron deficient'",
"      </a>",
"      above.) For loading therapy, the optimal regimens with either sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex in sucrose or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      are unclear. We administer one of the following regimens:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      125 mg of sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex in sucrose can be given at each consecutive hemodialysis treatment for a total of eight doses (1000 mg in total).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      100 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      can be given at each consecutive hemodialysis treatment for a total of 10 doses (1000 mg in total).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     OR",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      510 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/46/27364?source=see_link\">",
"       ferumoxytol",
"      </a>",
"      as a rapid intravenous infusion, with a second dose given one to four weeks later if needed.",
"      <br/>",
"      <br/>",
"      We repeat either of these loading regimens if the TSAT remains below 30 percent. We aim to raise the transferrin saturation above 30 percent, and increase hemoglobin levels, while not exceeding the serum ferritin level of 500",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      in most patients. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For maintenance iron therapy, we use weekly continuous therapy rather than intermittent therapy. Among iron replete patients receiving ESA, the optimal iron regimen for maintenance therapy is unclear. Typical regimens include sodium",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/53/31573?source=see_link\">",
"       ferric gluconate",
"      </a>",
"      complex in sucrose at a dose of 31.25 to 125 mg or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/31/41461?source=see_link\">",
"       iron sucrose",
"      </a>",
"      at a dose of 25 to 100 mg administered once weekly or every other week. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Iron replete'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For maintenance iron therapy, we generally maintain the TSAT up to 30 percent, providing the ferritin is &le;500",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      We do not routinely administer intravenous iron to patients with ferritin levels above 500",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and anemia, although each patient should be individually assessed. Among such patients, an initial trial of increased erythropoietin dose alone, without intravenous iron, may be considered if the hemoglobin level is persistently below 11.5",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      with an erythropoietin dose that is not particularly high. If this is not successful in raising the hemoglobin level or a further increase is desired, we try supplemental iron with or without a further increase in erythropoietin dose. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Iron replete'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Overview of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/46/21222?source=see_link\">",
"       iron dextran",
"      </a>",
"      is administered, an initial test dose must be given prior to the initiation of intravenous iron",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"       dextran",
"      </a>",
"      therapy given the possibility of anaphylaxis. It is not necessary to premedicate patients prior to the test dose, but emergency medications (eg, epinephrine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      , and corticosteroids) must be readily available. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/1\">",
"      Eschbach JW, Cook JD, Scribner BH, Finch CA. Iron balance in hemodialysis patients. Ann Intern Med 1977; 87:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/2\">",
"      KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/3\">",
"      K/DOQI Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/4\">",
"      Macdougall IC, Hutton RD, Cavill I, et al. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ 1989; 299:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/5\">",
"      Van Wyck DB, Stivelman JC, Ruiz J, et al. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989; 35:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/6\">",
"      Hotta T, Ogawa H, Saito A, Ito A. Iron balance following recombinant human erythropoietin therapy for anemia associated with chronic renal failure. Int J Hematol 1991; 54:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/7\">",
"      Kooistra MP, van Es A, Struyvenberg A, Marx JJ. Iron metabolism in patients with the anaemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 1991; 79:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/8\">",
"      Macdougall IC. How to get the best out of r-HuEPO. Nephrol Dial Transplant 1995; 10 Suppl 2:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/9\">",
"      Tarng DC, Chen TW, Huang TP. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am J Nephrol 1995; 15:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/10\">",
"      Tarng DC, Huang TP, Chen TW. Mathematical approach for estimating iron needs in hemodialysis patients on erythropoietin therapy. Am J Nephrol 1997; 17:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/11\">",
"      Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/12\">",
"      Silverberg DS, Blum M, Agbaria Z, et al. Intravenous iron for the treatment of predialysis anemia. Kidney Int Suppl 1999; 69:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/13\">",
"      Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/14\">",
"      Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/15\">",
"      Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/16\">",
"      Fishbane S, Lynn RI. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients. Clin Nephrol 1995; 44:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/17\">",
"      Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol 1996; 7:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/18\">",
"      Rosenl&ouml;f K, Kivivuori SM, Gr&ouml;nhagen-Riska C, et al. Iron availability is transiently improved by intravenous iron medication in patients on chronic hemodialysis. Clin Nephrol 1995; 43:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/19\">",
"      Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007; 18:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/20\">",
"      Dr&uuml;eke TB, B&aacute;r&aacute;ny P, Cazzola M, et al. Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clin Nephrol 1997; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/21\">",
"      NKF-DOQI Clinical Practice Guidelines for the Treatment of Anemia of Chronic Renal Failure. III. Iron support. Am J Kidney Dis 2001; 37(Suppl 1):S194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/22\">",
"      Besarab A, Amin N, Ahsan M, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/23\">",
"      Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/24\">",
"      Fudin R, Jaichenko J, Shostak A, et al. Correction of uremic iron deficiency anemia in hemodialyzed patients: a prospective study. Nephron 1998; 79:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/25\">",
"      Albaramki J, Hodson EM, Craig JC, Webster AC. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012; 1:CD007857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/26\">",
"      Centers for Medicare and Medicaid Services, Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006; 48:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/27\">",
"      Bailie GR, Johnson CA, Mason NA. Parenteral iron use in the management of anemia in end-stage renal disease patients. Am J Kidney Dis 2000; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/28\">",
"      Aronoff GR, Bennett WM, Blumenthal S, et al. Iron sucrose in hemodialysis patients: safety of replacement and maintenance regimens. Kidney Int 2004; 66:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/29\">",
"      Van Wyck DB, Cavallo G, Spinowitz BS, et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000; 36:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/30\">",
"      Coyne DW, Adkinson NF, Nissenson AR, et al. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney Int 2003; 63:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/31\">",
"      Park L, Uhthoff T, Tierney M, Nadler S. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients. Am J Kidney Dis 1998; 31:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/32\">",
"      Fishbane S, Ungureanu VD, Maesaka JK, et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/33\">",
"      Fletes R, Lazarus JM, Gage J, Chertow GM. Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001; 37:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/34\">",
"      Fishbane S. Safety in iron management. Am J Kidney Dis 2003; 41:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/35\">",
"      Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/36\">",
"      Bailie GR, Clark JA, Lane CE, Lane PL. Hypersensitivity reactions and deaths associated with intravenous iron preparations. Nephrol Dial Transplant 2005; 20:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/37\">",
"      Walters BA, Van Wyck DB. Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients. Nephrol Dial Transplant 2005; 20:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/38\">",
"      Chertow GM, Mason PD, Vaage-Nilsen O, Ahlm&eacute;n J. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004; 19:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/39\">",
"      Chertow GM, Mason PD, Vaage-Nilsen O, Ahlm&eacute;n J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006; 21:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/40\">",
"      Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/41\">",
"      Nissenson AR, Lindsay RM, Swan S, et al. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 1999; 33:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/42\">",
"      Matzke GR. Intravenous iron supplementation in end-stage renal disease patients. Am J Kidney Dis 1999; 33:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/43\">",
"      Fishbane S, Wagner J. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis. Am J Kidney Dis 2001; 37:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/44\">",
"      Folkert VW, Michael B, Agarwal R, et al. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (&gt; or =250 mg) administration. Am J Kidney Dis 2003; 41:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/45\">",
"      Canavese C, Bergamo D, Ciccone G, et al. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients. Nephrol Dial Transplant 2004; 19:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/46\">",
"      Michael B, Coyne DW, Fishbane S, et al. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran. Kidney Int 2002; 61:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/47\">",
"      Michael B, Coyne DW, Folkert VW, et al. Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety. Nephrol Dial Transplant 2004; 19:1576.",
"     </a>",
"    </li>",
"    <li>",
"     American Regent Venofer approved without test dose requirement. The Pink Sheet 2000; 62:30. (November 13, 2000).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/49\">",
"      Yee J, Besarab A. Iron sucrose: the oldest iron therapy becomes new. Am J Kidney Dis 2002; 40:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/50\">",
"      Silverberg DS, Blum M, Peer G, et al. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996; 72:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/51\">",
"      Charytan C, Levin N, Al-Saloum M, et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial. Am J Kidney Dis 2001; 37:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/52\">",
"      Sheashaa H, El-Husseini A, Sabry A, et al. Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate. Nephron Clin Pract 2005; 99:c97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/53\">",
"      Schiesser D, Binet I, Tsinalis D, et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Nephrol Dial Transplant 2006; 21:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/54\">",
"      Landry R, Jacobs PM, Davis R, et al. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol 2005; 25:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/55\">",
"      Spinowitz BS, Schwenk MH, Jacobs PM, et al. The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients. Kidney Int 2005; 68:1801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/56\">",
"      Spinowitz BS, Kausz AT, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008; 19:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/57\">",
"      Provenzano R, Schiller B, Rao M, et al. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009; 4:386.",
"     </a>",
"    </li>",
"    <li>",
"     Feraheme prescribing information, June 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/59\">",
"      Alam MG, Krause MW, Shah SV. Parenteral iron therapy: beyond anaphylaxis. Kidney Int 2004; 66:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/60\">",
"      Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 2004; 65:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/61\">",
"      Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004; 66:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/62\">",
"      Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/63\">",
"      Agarwal R, Rizkala AR, Kaskas MO, et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 2007; 72:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/64\">",
"      Hoen B, Paul-Dauphin A, Kessler M. Intravenous iron administration does not significantly increase the risk of bacteremia in chronic hemodialysis patients. Clin Nephrol 2002; 57:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/65\">",
"      Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38521/abstract/66\">",
"      Kalantar-Zadeh K, Regidor DL, McAllister CJ, et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:3070.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1953 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38521=[""].join("\n");
var outline_f37_39_38521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSIS OF IRON DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Absolute and functional iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      OVERVIEW OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Iron loading",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Maintenance iron therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ORAL VERSUS PARENTERAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PARENTERAL IRON PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Iron dextran",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intravenous sodium ferric gluconate complex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Intravenous iron sucrose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Efficacy and safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ferumoxytol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Efficacy and safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Adverse effects other than anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OVERVIEW OF DOSING REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Iron deficient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Iron replete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/18/41257?source=related_link\">",
"      Anemia of chronic kidney disease: Target hemoglobin/hematocrit for patients treated with erythropoietic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/22/28005?source=related_link\">",
"      Diagnosis of iron deficiency in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/45/33496?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5626?source=related_link\">",
"      Erythropoietin for the anemia of chronic kidney disease in hemodialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/55/37752?source=related_link\">",
"      Iron balance in non-dialysis, peritoneal dialysis, and home hemodialysis patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_39_38522="Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage";
var content_f37_39_38522=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38522/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38522/contributors\">",
"     Robert J Singer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38522/contributors\">",
"     Christopher S Ogilvy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38522/contributors\">",
"     Guy Rordorf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38522/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38522/contributors\">",
"     Jose Biller, MD, FACP, FAAN, FAHA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/39/38522/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/39/38522/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/39/38522/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty percent of strokes are hemorrhagic, with subarachnoid hemorrhage (SAH) and intracerebral hemorrhage each accounting for 10 percent. The epidemiology, etiology, clinical manifestations, and diagnosis of aneurysmal SAH are reviewed here. The treatment of this disorder and the epidemiology and pathogenesis of intracranial aneurysms and management of unruptured aneurysms are discussed separately. Mycotic aneurysms and nonaneurysmal subarachnoid hemorrhage are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=see_link\">",
"     \"Overview of infected (mycotic) arterial aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38696?source=see_link\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6441?source=see_link\">",
"     \"Perimesencephalic nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most SAHs are caused by ruptured saccular aneurysms. Other causes include trauma, arteriovenous",
"    <span class=\"nowrap\">",
"     malformations/fistulae,",
"    </span>",
"    vasculitides, intracranial arterial dissections, amyloid angiopathy, bleeding diatheses, and illicit drug use (especially cocaine and amphetamines).",
"   </p>",
"   <p>",
"    The prevalence of intracranial saccular aneurysms by radiographic and autopsy series is 5 percent, or 10 to 15 million people in the United States. Approximately 20 to 30 percent of patients have multiple aneurysms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/1\">",
"     1",
"    </a>",
"    ]. Aneurysmal SAH occurs at an estimated rate of 3 to 25 per 100,000 population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The mean age at onset is 55 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/5\">",
"     5",
"    </a>",
"    ]. In North America, this translates into approximately 30,000 affected persons per year. Thus, most aneurysms do not rupture. The risk of rupture of intracranial aneurysms is related in part to aneurysm size and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=see_link&amp;anchor=H13#H13\">",
"     \"Unruptured intracranial aneurysms\", section on 'Natural history of unruptured aneurysms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most aneurysmal SAH occur between 40 and 60 years of age; however young children and the elderly can be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. African Americans appear to be at higher risk than Caucasian Americans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/8\">",
"     8",
"    </a>",
"    ]. There is a slightly higher incidence of aneurysmal SAH in women, which may relate to hormonal status (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Estrogen deficiency'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/6,9\">",
"     6,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most SAHs are due to the rupture of intracranial aneurysms. Because of this, risk factors for aneurysm formation overlap with risk factors for SAH. Risk factors that are primarily associated with formation of intracranial aneurysms are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stressful life events have not been convincingly shown to be a risk factor for SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking appears to be the most important preventable risk factor for SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/12-16\">",
"     12-16",
"    </a>",
"    ]. The importance of cigarette smoking is illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A case-control study of 432 adults with SAH found that current cigarette smokers had a significantly increased risk of SAH compared with nonsmokers not exposed to secondhand smoke (odds ratio 5.0) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/13\">",
"       13",
"      </a>",
"      ]. Current and lifetime exposures showed a clear dose-dependent effect, and the risks appeared to be more prominent in women and in aneurysmal SAH. The risk attributable to cigarette smoking declined rapidly and largely disappeared within a few years of quitting. There was no significant effect of secondhand smoke.",
"     </li>",
"     <li>",
"      In a systematic review of 14 longitudinal and 23 case-control studies that included 3936 patients with SAH, current smoking was a significant risk factor for SAH in both the longitudinal (relative risk [RR] 2.2, 95% CI 1.3-3.6) and case-control studies (odds ratio [OR] 3.1, 95% CI 2.7-3.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of data from the Asia Pacific Cohort Studies Collaboration (APCSC) involving 26 cohorts with 306,620 participants and 236 SAH events found that the risk for SAH was significantly associated with current smoking (hazard ratio [HR] 2.4, 95% CI 1.8-3.4) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension is a major risk factor for SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/12,14-18\">",
"     12,14-18",
"    </a>",
"    ]. The best data come from the systematic review cited above that included 3936 patients with SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/14\">",
"     14",
"    </a>",
"    ]. Hypertension was significantly associated with SAH risk in both the longitudinal (RR 2.5, 95% CI 2.0-3.1) and case-control studies (OR 2.6, 95% CI 2.0-3.1).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Alcohol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate to heavy alcohol consumption appears to increase the risk of SAH (",
"    <a class=\"graphic graphic_figure graphicRef56342 \" href=\"mobipreview.htm?40/41/41630\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/14,19\">",
"     14,19",
"    </a>",
"    ]. In the systematic review cited above, excessive alcohol intake was a significant risk factor for SAH in both the longitudinal (RR 2.1, 95% CI 1.5-2.8) and case-control studies (OR 1.5, 95% CI 1.3-1.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most aneurysmal SAHs are of nongenetic origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/20\">",
"     20",
"    </a>",
"    ]. However, a number of relatively rare inherited conditions are associated with increased risk of cerebral aneurysm and SAH. These include autosomal dominant polycystic kidney disease, glucocorticoid-remediable aldosteronism, and Ehler Danlos syndrome. The risk of aneurysmal SAH associated with these conditions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3767?source=see_link&amp;anchor=H6#H6\">",
"     \"Screening for intracranial aneurysm\", section on 'Hereditary syndromes associated with aneurysm formation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A family history of SAH also increases the risk of SAH in individuals without one of these conditions. As an example, one case-control study found that patients with a family history of SAH had an odds ratio of 4.0 (95% CI 2.0-8.0) for SAH compared with controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/21\">",
"     21",
"    </a>",
"    ]. Similarly, another study found that first-degree relatives of patients with SAH have a three to five-fold increased risk of SAH compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/22\">",
"     22",
"    </a>",
"    ]. It may be reasonable to screen some family members for the presence of cerebral aneurysm. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3767?source=see_link&amp;anchor=H3#H3\">",
"     \"Screening for intracranial aneurysm\", section on 'Relatives of patients with cerebral aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genetic susceptibility to SAH appears to be heterogeneous. Some familial SAH pedigrees are most consistent with autosomal dominant inheritance, while others are more consistent with autosomal recessive or multifactorial transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. One study found evidence of anticipation in two successive generations of familial SAH, with affected parents significantly older than affected children (55.2 versus 35.4 years, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/25\">",
"     25",
"    </a>",
"    ]. Some evidence points to the elastin gene on chromosome 7q as a candidate gene related to the development of familial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/26,27\">",
"     26,27",
"    </a>",
"    ] and sporadic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/28\">",
"     28",
"    </a>",
"    ] SAH. Other evidence supports linkage of familial SAH to chromosomes 1p [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/29\">",
"     29",
"    </a>",
"    ], 2p [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/30\">",
"     30",
"    </a>",
"    ], 9p [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/31\">",
"     31",
"    </a>",
"    ], 11q, 14q [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/32\">",
"     32",
"    </a>",
"    ], 19q [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/33-35\">",
"     33-35",
"    </a>",
"    ], and Xp22 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. A polymorphism affecting the platelet adhesive glycoprotein GPIIIa HPA-1 (HPA comes from human platelet alloantigen; GPIIIa HPA-1 is also called PIA) is associated with increased risk of thrombosis and a decreased risk of SAH (odds ratio 0.48; 95% CI 0.24-0.96) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Familial susceptibility to SAH may be nongenetic and attributed to environmental and other shared risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sympathomimetic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case-control studies, phenylpropanolamine in appetite suppressants, and possibly cold remedies, appeared to be an independent risk factor for hemorrhagic stroke (including intracerebral hemorrhage and subarachnoid hemorrhage) in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cocaine abuse has been associated with both aneurysmal and nonaneurysmal SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38696?source=see_link&amp;anchor=H9#H9\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\", section on 'Other causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Estrogen deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a female preponderance for aneurysms ranging from 54 to 61 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/9\">",
"     9",
"    </a>",
"    ]. In one case-control study, premenopausal women without a history of smoking or hypertension were at reduced risk of SAH compared with age-matched postmenopausal women (odds ratio 0.24) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/42\">",
"     42",
"    </a>",
"    ]. Furthermore, the use of estrogen replacement therapy was associated with a reduced risk of SAH in postmenopausal women (odds ratio 0.47). Risk reduction with the use of estrogen replacement therapy has been seen in other studies as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/14,43\">",
"     14,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hormonal effects may also explain the association between risk of SAH and repeated childbirth that was observed in one case-control study; each additional parity increased the risk with an OR = 1.34 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/44\">",
"     44",
"    </a>",
"    ]. However, physical and environmental factors during pregnancy and delivery are also likely factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antithrombotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sufficient data are not available to determine whether anticoagulant (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) or antiplatelet therapy increase the risk of aneurysm rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/45\">",
"     45",
"    </a>",
"    ]. However, anticoagulation therapy does appear to increase the severity of a SAH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33348?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between cholesterol status, statin use, and the risk of ischemic versus hemorrhagic cerebrovascular events is complex. Statin use is associated with an overall lower risk of total and ischemic cerebrovascular events, but there is some concern that low cholesterol levels and statin use may increase the risk of intracerebral hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=see_link\">",
"     \"Secondary prevention of stroke: Risk factor reduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One case control study found that current statin use was not significantly associated with a lower SAH risk, and that recent statin drug withdrawal increased the risk of SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/46\">",
"     46",
"    </a>",
"    ]. However, the effect of statin withdrawal was highest in patients who had also stopped taking antihypertensive drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of an aneurysm releases blood directly into the cerebrospinal fluid (CSF) under arterial pressure. The blood spreads quickly within the CSF, rapidly increasing intracranial pressure. The bleeding usually lasts only a few seconds, but rebleeding is common and occurs more often within the first day.",
"   </p>",
"   <p>",
"    Consistent with the rapid spread of blood, the symptoms of SAH typically begin abruptly, occurring at night in 30 percent of cases. The premier symptom is a sudden, severe headache (97 percent of cases) classically described as the \"worst headache of my life.\" The headache is lateralized in 30 percent of patients, predominantly to the side of the aneurysm. The onset of the headache may or may not be associated with a brief loss of consciousness, seizure, nausea or vomiting, and meningismus (",
"    <a class=\"graphic graphic_figure graphicRef60831 \" href=\"mobipreview.htm?0/5/88\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/47\">",
"     47",
"    </a>",
"    ]. In one series, these occurred in 53, 77, and 35 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/48\">",
"     48",
"    </a>",
"    ]. Meningismus and often lower back pain may not develop until several hours after the bleed since it is caused by the breakdown of blood products within the CSF, which lead to an aseptic meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 30 to 50 percent of patients have a minor hemorrhage or \"warning leak,\" manifested only by a sudden and severe headache (the sentinel headache) that precedes a major SAH by 6 to 20 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/47\">",
"     47",
"    </a>",
"    ]. A systematic literature review through September 2002 found that the incidence of sentinel headaches in aneurysmal SAH ranged from 10 to 43 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The complaint of the sudden onset of severe headache is sufficiently characteristic that a minor SAH should always be considered. In a prospective study of 148 patients presenting with sudden and severe headache, for example, SAH was present in 25 percent overall and in 12 percent of those in whom headache was the only symptom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/51\">",
"     51",
"    </a>",
"    ]. Similar findings were noted in another report in which 20 of 107 patients with the \"worst headache of my life\" had an SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical exertion may be an acute trigger for SAH. A case-crossover study in 338 patients with SAH found that patients were more likely to have engaged in moderate or greater exertion in the two hours prior to SAH than in the same two-hour period on the previous day (odds ratio 2.7, 95% CI 1.6-4.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/53\">",
"     53",
"    </a>",
"    ]. Acute elevation in blood pressure is believed to be the mechanism by which physical exertion acts as a trigger for SAH and may also play a role in the observed associations between caffeine consumption, acute anger or startling, and sexual exertion as triggers for SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/54\">",
"     54",
"    </a>",
"    ]. A trigger event preceding SAH is not invariable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subarachnoid hemorrhage (SAH) is associated with a high mortality rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/55\">",
"     55",
"    </a>",
"    ]. A systematic review found that the average case fatality rate for SAH was 51 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/56\">",
"     56",
"    </a>",
"    ]. Approximately 10 percent of patients with aneurysmal SAH die prior to reaching the hospital, 25 percent die within 24 hours of SAH onset, and about 45 percent die within 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality rates due to SAH appear to be decreasing over time in Western populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Improvements in rates of smoking, treatment of hypertension, and management of SAH are plausible but unproven reasons for the reduction in mortality. Improved diagnostic accuracy over time, including exclusion of SAH mimics, may also be playing a role.",
"   </p>",
"   <p>",
"    A number of additional complications commonly occur in patients who have suffered a SAH:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rebleeding",
"     </li>",
"     <li>",
"      Vasospasm and delayed cerebral ischemia",
"     </li>",
"     <li>",
"      Hydrocephalus",
"     </li>",
"     <li>",
"      Increased intracranial pressure",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Hyponatremia",
"     </li>",
"     <li>",
"      Cardiac abnormalities",
"     </li>",
"     <li>",
"      Hypothalamic dysfunction and pituitary insufficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/61\">",
"       61",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rebleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have found that the risk of rebleeding is highest in the first 24 hours after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/62-64\">",
"     62-64",
"    </a>",
"    ], particularly within six hours of the initial hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/63\">",
"     63",
"    </a>",
"    ]. The risk of rebleeding in the first 24 hours ranges from 2.6 to 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/62,64\">",
"     62,64",
"    </a>",
"    ]. Most rebleeding (73 percent) occurs within the first 72 hours of ictus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/64\">",
"     64",
"    </a>",
"    ]. Factors that may be independent predictors of rebleeding include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      the Hunt-Hess grade on admission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      maximal aneurysm diameter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      a higher initial blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      a sentinel headache preceding SAH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      a longer interval from ictus to admission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      early ventriculostomy (prior to aneurysm treatment) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/41\">",
"       41",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The overall incidence of rebleeding after initial SAH in the modern era is uncertain. A prospective studies have documented incidence rates of 6.9 and 8.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rebleeding is usually diagnosed on the basis of an acute deterioration of neurologic status accompanied by appearance of new hemorrhage on head CT scan. Lumbar puncture is harder to evaluate because xanthochromia can persist for two weeks or more. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Lumbar puncture'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Only aneurysm treatment is effective for the prevention of rebleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Treatment of aneurysms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rebleeding is associated with a higher rate of other complications and worse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/65\">",
"     65",
"    </a>",
"    ]. The prognosis of rebleeding after SAH is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link&amp;anchor=H24#H24\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Management of complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vasospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasospasm causes symptomatic ischemia and infarction in approximately 20 to 30 percent of patients with aneurysmal SAH; it is the leading cause of death and disability after aneurysm rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Vasospasm typically begins no earlier than day three after hemorrhage, reaching a peak at days seven to eight. The onset of clinical vasospasm is characterized by a decline in neurologic status, including the onset of focal neurologic abnormalities. The severity of symptoms depends upon the artery affected and the degree of collateral circulation.",
"   </p>",
"   <p>",
"    Transcranial Doppler (TCD) sonography is useful for detecting and monitoring vasospasm in spontaneous SAH, and it is probably useful for detecting vasospasm after traumatic SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Velocity changes detected by TCD typically precede the clinical sequelae of vasospasm. Daily recordings offer a window of opportunity to treat patients prior to clinical decline. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary but accumulating data suggest that brain perfusion asymmetry demonstrated on CT perfusion (CTP) scanning in the acute stage of SAH may be a useful and highly sensitive method for predicting delayed cerebral ischemia, which is most cases, is presumably due to vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. A finding of perfusion-diffusion mismatch on MRI may be another method of detecting brain areas at risk of infarction in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/74\">",
"     74",
"    </a>",
"    ]. However, the clinical utility of either of these methods remains to be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of delayed cerebral vasospasm involves an interaction between the metabolites of blood and the vasculature. Spasmogenic substances generated during the lysis of subarachnoid blood clots can cause endothelial damage and smooth muscle contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/75\">",
"     75",
"    </a>",
"    ]. The vascular endothelium produces nitric oxide, which tonically dilates the cerebral vasculature; endothelial damage may interfere with nitric oxide production, leading to vasoconstriction and an impaired response to vasodilators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/76\">",
"     76",
"    </a>",
"    ]. In addition, increased release of the potent vasoconstrictor endothelin may play a major role in the induction of cerebral vasospasm after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of blood on computed tomography (CT) scan and its extent can help predict the likelihood of complicating cerebral vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. In one series, severe vasospasm was correctly predicted and localized in 20 of 22 patients using the CT criteria of clots larger than 3 x 5 mm or layers of blood more than 1 mm thick [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/78\">",
"     78",
"    </a>",
"    ]. Radiologic grading scales including those of Fisher (",
"    <a class=\"graphic graphic_table graphicRef81122 \" href=\"mobipreview.htm?8/36/8779\">",
"     table 1",
"    </a>",
"    ) and Claassen (",
"    <a class=\"graphic graphic_table graphicRef57558 \" href=\"mobipreview.htm?12/19/12603\">",
"     table 2",
"    </a>",
"    ) are often used to predict the likelihood of vasospasm and cerebral ischemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/406?source=see_link\">",
"     \"Subarachnoid hemorrhage grading scales\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors that may increase the risk of vasospasm include age less than 50 years and hyperglycemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Most [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/82-84\">",
"     82-84",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/80\">",
"     80",
"    </a>",
"    ] studies have found that poor clinical grade (eg, Hunt-Hess grade 4 or 5, or Glasgow Coma Scale score &lt;14) is associated with an increased risk of vasospasm, and a longer duration of unconsciousness after SAH may also be a predictor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/82\">",
"     82",
"    </a>",
"    ]. In contrast, the type of therapy chosen (surgical versus endovascular) does not appear to influence risk.",
"   </p>",
"   <p>",
"    Evidence from a retrospective cohort study examining vasoactive medication usage at the time of SAH suggests that patients exposed to statins and selective serotonin reuptake inhibitors (SSRIs) have a higher risk for vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/84\">",
"     84",
"    </a>",
"    ]. In addition, SSRI users may have a higher risk for symptomatic vasospasm with focal neurologic worsening.",
"   </p>",
"   <p>",
"    The increased risk of vasospasm with statin use may be related to rebound effects from statin discontinuation at the time of SAH, as there is some evidence that statins may be useful for the prevention of vasospasm after SAH. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Prevention of vasospasm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Early vasospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early vasospasm (EVSP) is arterial narrowing that is present at the time of or shortly after hospital admission; it is also called ultra early vasospasm, acute cerebral vasoconstriction, and acute arterial spasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/85-87\">",
"     85-87",
"    </a>",
"    ]. Although EVSP is rarely reported, a study that examined data from 3552 patients with aneurysmal SAH enrolled in clinical trials testing the drug tirilazad found that EVSP was present within 48 hours of admission in 339 patients (10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/88\">",
"     88",
"    </a>",
"    ]. The following additional observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EVSP was significantly more likely in patients with a poor neurologic grade on admission, intracerebral hematoma, larger aneurysm, thick SAH on CT scan, intraventricular hemorrhage, a history of previous SAH, and a history of hypertension.",
"     </li>",
"     <li>",
"      EVSP was not associated with delayed cerebral vasospasm, suggesting that the etiology of the two types of vasospasm is different.",
"     </li>",
"     <li>",
"      EVSP was associated with cerebral infarction, neurologic worsening, and unfavorable outcome at three months, after adjustment for differences in admission characteristics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Cerebral infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral infarction is a frequent complication of SAH. Hypodense brain lesions on head CT have been noted in 40 to 60 percent of survivors at 3 to 12 months after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/5,89,90\">",
"     5,89,90",
"    </a>",
"    ]. In a case series of 143 patients with acute aneurysmal SAH admitted from 1998 to 2000 at a single center, cerebral infarction defined on CT scan was found in 56 patients (39 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/91\">",
"     91",
"    </a>",
"    ]. The time from SAH onset to the last CT scan during the acute hospital stay ranged from 5 to 32 days (mean 12 days).",
"   </p>",
"   <p>",
"    The two most common patterns of infarction in these 56 patients were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Single cortical infarcts, typically located near the site of the ruptured aneurysm, in 23 (40 percent)",
"     </li>",
"     <li>",
"      Multiple widespread infarcts, often involving bilateral and subcortical regions and frequently located distal to the ruptured aneurysm, in 28 (50 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common cause of infarction after SAH is assumed to be vasospasm (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Vasospasm'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/92\">",
"     92",
"    </a>",
"    ]. However, one study found that a substantial proportion (19 percent) of patients with vasospasm attributed-CT hypodensities had only mild or no vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/93\">",
"     93",
"    </a>",
"    ]. Hypovolemia may add to the risk of cerebral ischemia in the setting of vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/94\">",
"     94",
"    </a>",
"    ]. Other mechanisms of ischemia include occlusion (temporary or permanent) of or damage to cerebral arteries during aneurysm surgery, thromboembolism related to turbulent or stagnant aneurysmal blood flow or clip application, and embolism unrelated to SAH.",
"   </p>",
"   <p>",
"    Hypodense lesions on CT consistent with infarction appear to be more likely with larger volume SAH and poor initial clinical condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/5,89,90,95\">",
"     5,89,90,95",
"    </a>",
"    ]. These observations are supported by the results of a study that analyzed CT scans of 156 patients three months after SAH; additional independent risk factors for hypodense lesions included nocturnal occurrence of SAH (between 12:01 and 8:00 AM), fixed symptoms of delayed ischemia, duration of temporary artery occlusion during surgery, and body mass index [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/96\">",
"     96",
"    </a>",
"    ]. The mechanism of increased ischemia risk with nocturnal SAH is unknown and has not been replicated. In contrast, one study found that there is a very low risk of delayed cerebral infarction in patients 68 years or older, with a low grade SAH (World Federation of Neurologic Surgeons I to III or modified Fisher grade 1 to 2), absent intracranial hematoma and aneurysm in the posterior circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocephalus (acute and chronic) is a common complication of SAH. In one large series, hydrocephalus was documented by CT scan in 15 percent of patients, 40 percent of whom were symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/98\">",
"     98",
"    </a>",
"    ]. Factors associated with an increased risk for hydrocephalus included intraventricular hemorrhage, posterior circulation aneurysms, treatment with antifibrinolytic agents, and a low Glasgow score on presentation. The incidence was also increased in patients with hyponatremia or a history of hypertension. Older age is an additional risk factor.",
"   </p>",
"   <p>",
"    Hydrocephalus after SAH is thought to be caused by obstruction of cerebrospinal fluid (CSF) flow by blood products or adhesions, or by a reduction of CSF absorption at the arachnoid granulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/99\">",
"     99",
"    </a>",
"    ]. The former occurs as an acute complication; the latter tends to occur two weeks or later, and is more likely to be associated with shunt dependence.",
"   </p>",
"   <p>",
"    Spontaneous improvement occurs in one-half of patients with acute hydrocephalus and impaired consciousness, usually within 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/100\">",
"     100",
"    </a>",
"    ]. In the remainder, acute hydrocephalus is associated with increased morbidity and mortality secondary to rebleeding and cerebral infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Increased ICP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SAH may develop increased intracranial pressure (ICP) due to a number of factors, including increased cerebrospinal fluid outflow resistance, acute hydrocephalus, hemorrhage volume, reactive hyperemia after hemorrhage, vasoparalysis, and distal cerebral arteriolar vasodilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/102-105\">",
"     102-105",
"    </a>",
"    ]. In a series of 234 patients with SAH who had ICP monitoring, increased ICP occurred during the hospital stay in 54 percent, including 49 percent of those considered to have a good clinical grade (Hunt and Hess grades I to III) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures at the onset of SAH appear to be an independent risk factor for late seizures and a predictor of poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/107\">",
"     107",
"    </a>",
"    ]. One study of 247 patients with SAH found that 7 percent developed new-onset epilepsy (defined as two or more unprovoked seizures after hospital discharge), and these patients had poor functional recovery and quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/108\">",
"     108",
"    </a>",
"    ]. Associated cerebral infarction and subdural hematoma predicted epilepsy, suggesting that epilepsy in this setting is due to focal rather than diffuse brain injury.",
"   </p>",
"   <p>",
"    The incidence of late epilepsy (more than two weeks after surgery) after surgical management of SAH is unclear. Multiple studies have cited an incidence of up to 25 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/109-111\">",
"     109-111",
"    </a>",
"    ]. However, the true incidence now may be lower, given advances in surgical management that have occurred since these studies took place. Patients with a poor grade SAH appear to have a higher incidence of late epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Antiepileptic drug therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia following subarachnoid hemorrhage is relatively common, and is probably mediated by hypothalamic injury. The water retention that leads to hyponatremia is due to increased secretion of antidiuretic hormone, which may result from either the syndrome of inappropriate ADH secretion or, much less often, volume depletion induced by cerebral salt wasting. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8567?source=see_link\">",
"     \"Cerebral salt-wasting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cardiac abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac abnormalities and electrocardiographic (ECG) changes are commonly seen after SAH and appear to be more common and more severe in those with more severe SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. The most frequent ECG abnormalities are ST segment depression, QT interval prolongation, deep symmetric T wave inversions, and prominent U waves. Life-threatening rhythm disturbances such as torsades de pointes have also been described, as well as atrial fibrillation and flutter. ST-T wave abnormalities along with bradycardia and relative tachycardia were found in one large series to be independently associated with mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/115\">",
"     115",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26952?source=see_link\">",
"     \"Cardiac complications of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ECG changes are predominantly reflective of ischemic changes in the subendocardium of the left ventricle. The development of actual myocardial injury (in as many as 20 percent of patients) can be established by elevations of CK-MB or serum troponin I (&gt;0.1",
"    <span class=\"nowrap\">",
"     &micro;g/L),",
"    </span>",
"    which is a specific and more sensitive marker of myocardial necrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/114,116\">",
"     114,116",
"    </a>",
"    ]. Patients with elevated troponin I concentrations are more likely to have ECG abnormalities and clinical evidence of left ventricular dysfunction. Subendocardial ischemia is an independent predictor of poor outcome in patients with SAH and must be managed aggressively (although without the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=see_link\">",
"     \"Troponins and creatine kinase as biomarkers of cardiac injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A wide spectrum of regional left ventricular wall motion abnormalities, demonstrable by echocardiography, can occur with SAH; these are typically but not always reversible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/114,117,118\">",
"     114,117,118",
"    </a>",
"    ]. Some patients develop a pattern of transient apical left ventricular dysfunction that mimics myocardial infarction (but in the absence of significant coronary artery disease), a condition known as takotsubo cardiomyopathy, or transient left ventricular apical ballooning syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30745?source=see_link\">",
"     \"Stress-induced (takotsubo) cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute troponin elevation after SAH appears to be associated with increased risk of cardiopulmonary and cerebrovascular complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/113,120\">",
"     113,120",
"    </a>",
"    ]. In a series of 253 patients with SAH who had serial troponin measurements for clinical or ECG signs of potential cardiac injury, elevated peak troponin levels were associated with an increased risk of left ventricular dysfunction, pulmonary edema, hypotension requiring pressors, and delayed cerebral ischemia from vasospasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/120\">",
"     120",
"    </a>",
"    ]. These findings were confirmed in a meta-analysis of 25 studies of SAH including 2960 patients; in this analysis, elevated troponin levels were also associated with increased mortality and worse functional outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=see_link&amp;anchor=H12#H12\">",
"     \"Elevated cardiac troponin concentration in the absence of an acute coronary syndrome\", section on 'Acute stroke'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevation of serum brain type natriuretic peptide (BNP) has been noted after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/113,121,122\">",
"     113,121,122",
"    </a>",
"    ], although the source of this elevation is unclear. BNP is present in the brain and in the heart; serum BNP elevation occurs with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .) In a prospective cohort of 57 subjects with SAH, elevated BNP levels were associated with the presence of cardiac regional wall motion abnormalities, diastolic dysfunction, pulmonary edema, elevated cardiac troponin I, and left ventricular ejection fraction &lt;50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/123\">",
"     123",
"    </a>",
"    ]. These findings suggest that BNP is released from patients with cardiac injury after SAH. A meta-analysis that included almost 3000 patients with SAH found that elevated BNP levels were associated with increased mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Mechanisms of myocardial injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial injury is most likely the result of a centrally mediated release of catecholamines within the myocardium due to hypoperfusion of the posterior hypothalamus. In support of this neurocardiogenic hypothesis, a study of 223 patients with SAH found an incremental and independent relationship between the degree of neurologic injury related to SAH and the probability of elevated serum levels of cardiac troponin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/124\">",
"     124",
"    </a>",
"    ]. In contrast to some previous reports, this study found no association between serum levels of catecholamines and troponin levels.",
"   </p>",
"   <p>",
"    While the neurocardiogenic hypothesis seems to be the most plausible mechanism, the causes of myocardial damage associated with SAH are likely to be multifactorial and include not only autonomic dysfunction but also factors affecting myocardial oxygen demand, the effect of medications given during treatment, and gender differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/125\">",
"     125",
"    </a>",
"    ]. As an example, one small case series found that hypomagnesemia was present in 37 percent of patients with SAH and was related to a prolongation of the PR interval and a shorter QTc interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/126\">",
"     126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16085?source=see_link\">",
"     \"Significance of hypomagnesemia in cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden \"thunderclap\" headache, regardless of severity or prior headache history, should raise the clinical suspicion for subarachnoid hemorrhage (SAH) and compel a diagnostic evaluation. Altered consciousness, collapse or vomiting at onset, meningismus, retinal subhyaloid hemorrhages, and a paucity of lateralizing neurologic signs are additional features that are characteristic of SAH. In patients with a suspicious history, the first step is to determine the presence of SAH, followed by an evaluation for the cause of hemorrhage.",
"   </p>",
"   <p>",
"    The combination of vitreous (preretinal) hemorrhages with SAH is known as Terson's syndrome and implies a poorer prognosis. In a systematic review, patients with Terson's syndrome had higher Hunt and Hess grades (",
"    <a class=\"graphic graphic_table graphicRef69179 \" href=\"mobipreview.htm?8/57/9115\">",
"     table 3",
"    </a>",
"    ) and significantly higher mortality than those without [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/127\">",
"     127",
"    </a>",
"    ]. The preretinal hemorrhages of Terson's syndrome may indicate a more abrupt increase in intracranial pressure and must be distinguished from the more benign retinal hemorrhages sometimes associated with SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/128\">",
"     128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Noncontrast head computed tomography (CT), with or without lumbar puncture, is the mainstay of diagnosis of SAH. A negative head CT and lumbar puncture effectively eliminate the diagnosis of SAH as long as both tests are performed within a few days of the event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/129\">",
"     129",
"    </a>",
"    ]. Nevertheless, cerebral angiography should be considered if diagnostic doubt remains.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Head CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cornerstone of SAH diagnosis is the noncontrast head CT scan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/130,131\">",
"     130,131",
"    </a>",
"    ]. Clot is demonstrated in the subarachnoid space in 92 percent of cases if the scan is performed within 24 hours of the bleed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/131,132\">",
"     131,132",
"    </a>",
"    ]. Intracerebral extension is present in 20 to 40 percent of patients and intraventricular and subdural blood may be seen in 15 to 35 and 2 to 5 percent, respectively. The head CT scan should be performed with thin cuts through the base of the brain to increase the sensitivity to small amounts of blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/133\">",
"     133",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of blood on CT (performed within 72 hours after the bleed) is a poor predictor of the site of an aneurysm except in patients with ruptured anterior cerebral artery or anterior communicating artery aneurysms and in patients with a parenchymal hematoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity of head CT for detecting SAH is highest in the first 6 to 12 hours after SAH (nearly 100 percent) and then progressively declines over time to about 58 percent at day five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/131,132,134-136\">",
"     131,132,134-136",
"    </a>",
"    ]. The sensitivity of head CT is also reduced with more minor bleeds. In one study, for example, a minor SAH was not diagnosed by CT scan in 55 percent of patients; lumbar puncture was positive in all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar puncture is mandatory if there is a strong suspicion of SAH despite a normal head CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/130\">",
"     130",
"    </a>",
"    ]. The classic findings are an elevated opening pressure and an elevated red blood cell (RBC) count that does not diminish from CSF tube one to tube four. Immediate centrifugation of the CSF can help differentiate bleeding in SAH from that due to a traumatic spinal tap.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Clearing of blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clearing of blood (a declining RBC count with successive collection tubes) is purported to be a useful way of distinguishing a traumatic LP from SAH. However, this is an unreliable sign of a traumatic tap, since a decrease in the number of RBCs in later tubes can occur in SAH. This method can reliably exclude SAH only if the late or final collection tube is normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=see_link&amp;anchor=H11#H11\">",
"     \"Cerebrospinal fluid: Physiology and utility of an examination in disease states\", section on 'Predicted WBC after traumatic tap'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Xanthochromia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Xanthochromia (pink or yellow tint) represents hemoglobin degradation products. An otherwise unexplained xanthochromic supernatant in CSF is highly suggestive of SAH. Xanthochromia may be visually detected by comparing a vial of CSF with a vial of plain water held side by side against a white background in bright light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of xanthochromia and CSF red cell counts is illustrated by a retrospective study of 117 adults with no known history of aneurysm or previous SAH who presented with thunderclap headache in the absence of trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/139\">",
"     139",
"    </a>",
"    ]. All had a negative noncontrast head CT followed by LP. Xanthochromic CSF was found by visual inspection in 18 patients (15 percent). Those patients then had four-vessel catheter angiography, which detected a ruptured cerebral aneurysm in 13 (72 percent). One patient with no xanthochromia had an elevated red blood cell count",
"    <span class=\"nowrap\">",
"     (&ge;20,000/microL)",
"    </span>",
"    in four successive collection tubes and a ruptured aneurysm by angiography. Xanthochromia for the detection of cerebral aneurysms had a sensitivity and specificity of 93 and 95 percent.",
"   </p>",
"   <p>",
"    The presence of xanthochromia indicates that blood has been in the CSF for at least two hours; lumbar puncture performed before this time may not reveal xanthochromia. Xanthochromia can last for two weeks or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/140,141\">",
"     140,141",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Xanthochromia can also occur with increased CSF concentrations of protein (150",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    systemic hyperbilirubinemia (serum bilirubin &gt;10 to 15",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    and traumatic lumbar puncture with more than 100,000 red blood",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Spectrophotometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spectrophotometry detects blood breakdown products as they progress from oxyhemoglobin to methemoglobin and finally to bilirubin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/52,140,142\">",
"     52,140,142",
"    </a>",
"    ]. Bilirubin concentration peaks about 48 hours after SAH onset, and it may last as long as four weeks after major SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sample of CSF to be tested by spectrophotometry should be the one that contains the least amount of blood staining. It should be protected from light and sent immediately to the laboratory for analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/140,143\">",
"     140,143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spectrophotometry for detection of bilirubin is highly sensitive (&gt;95 percent) when LP is done at least 12 hours after SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/141\">",
"     141",
"    </a>",
"    ]. Although xanthochromia is generally confirmed by visual inspection, laboratory confirmation with CSF spectrophotometry is more sensitive and, if available, is recommended by some experts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/140,143-146\">",
"     140,143-146",
"    </a>",
"    ]. This point is illustrated by a study that involved 11 analysts who compared xanthochromic CSF samples using visual and spectrophotometric analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/145\">",
"     145",
"    </a>",
"    ]. The spectrophotometric detection of bilirubin was significantly higher than visual detection in conditions where CSF samples were contaminated by presence of hemolyzed blood, or when CSF samples contained low levels of bilirubin.",
"   </p>",
"   <p>",
"    Despite a higher sensitivity than visual inspection for the detection of xanthochromia, CSF spectrophotometry has only a low to moderate specificity for the diagnosis of SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that CSF spectrophotometry is not universally recommended. As a practical matter, spectrophotometry is rarely available in North American hospitals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Brain MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that proton density and FLAIR sequences on brain MRI may be as sensitive as head CT for the acute detection of SAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/148\">",
"     148",
"    </a>",
"    ]. In addition, FLAIR and T2* sequences on MRI have a high sensitivity in patients with a subacute presentation of SAH (eg, &gt;4 days from the bleed) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/149\">",
"     149",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Misdiagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Misdiagnosis of SAH is not infrequent, and usually results from three common errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/150\">",
"     150",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to appreciate the spectrum of clinical presentation associated with SAH (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Failure to obtain a head CT scan or to understand its limitations in diagnosing SAH (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Head CT scan'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Failure to perform a lumbar puncture and correctly interpret the results (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Lumbar puncture'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a hospital-based series of 482 patients admitted with SAH, initial misdiagnosis occurred in 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/151\">",
"     151",
"    </a>",
"    ]. Misdiagnosis was independently associated with small SAH volume, normal mental status at presentation, and right-sided aneurysm location. Failure to obtain a head CT scan at initial contact was the most common error, occurring in 73 percent of misdiagnosed patients. Among SAH patients with normal mental status at first contact (45 percent), the misdiagnosis rate rose to 20 percent and was associated with a nearly four-fold increase in mortality at 12 months as well as increased morbidity among survivors.",
"   </p>",
"   <p>",
"    Delays in diagnosis of SAH are also common, even in patients with a characteristic history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/152\">",
"     152",
"    </a>",
"    ], leading to delays in treatment in 25 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/130\">",
"     130",
"    </a>",
"    ] that can worsen outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     IDENTIFYING THE ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a diagnosis of SAH has been made, the etiology of the hemorrhage must be determined with angiographic studies. Of the available tests, digital subtraction angiography (DSA) is believed to have the highest resolution to detect intracranial aneurysms and define their anatomic features and remains the gold standard test for this indication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No angiographic cause of SAH is evident in 14 to 22 percent of cases. It is critical to repeat the angiogram in 4 to 14 days if the initial angiogram is negative, since lesions may be hidden in cisterns packed with fresh hemorrhage. A third angiogram at a period of two to three months is advocated by some, but is probably not necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38696?source=see_link\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Digital subtraction angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most responsible lesions can be readily identified using standard cross-sectional imaging techniques coupled with DSA that includes injections of the external carotid circulation and deep cervical branches, which may supply a cryptic dural arteriovenous fistula. Angiographic demonstration of key branch points, including the proximal posterior circulation, is essential to definitively rule out aneurysm.",
"   </p>",
"   <p>",
"    The morbidity of DSA in patients with SAH is relatively low. In a meta-analysis of three prospective studies, for example, the combined risk of permanent and transient neurologic complications was significantly lower in patients with SAH compared with those with a TIA or stroke (1.8 versus 3.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     CT and MR angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT angiography (CTA) and magnetic resonance angiography (MRA) are noninvasive tests that are useful for screening and presurgical planning. Both CTA and MRA can identify aneurysms 3 to 5 mm or larger with a high degree of sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/154\">",
"     154",
"    </a>",
"    ], but they do not achieve the resolution of conventional angiography.",
"   </p>",
"   <p>",
"    The sensitivity of CTA for the detection of ruptured aneurysms, using conventional angiography or digital subtraction angiography as the gold standard, is 83 to 98 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/155-161\">",
"     155-161",
"    </a>",
"    ]. Small aneurysms, in particular may not be reliably identified.",
"   </p>",
"   <p>",
"    As technology improves, the sensitivity and specificity of noninvasive imaging is also likely to improve. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/55\">",
"     55",
"    </a>",
"    ]. A 2011 meta-analysis of CTA diagnosis of intracranial aneurysms found that, compared with single-detector CTA, use of multidetector CTA was associated with an overall improved sensitivity and specificity for aneurysm detection (both &gt;97 percent) as well as improved detection of smaller aneurysms &le;4 mm in diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/162\">",
"     162",
"    </a>",
"    ]. Another systematic review and meta-analysis restricted to patients with SAH had similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major advantage of CTA over conventional angiography is the speed and ease by which it can be obtained, often immediately after the diagnosis of SAH is made by head CT when the patient is still in the scanner. CTA is increasingly used as an alternative to angiography in many patients with SAH, thereby avoiding the need for conventional angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/164,165\">",
"     164,165",
"    </a>",
"    ], and is particularly useful in the acute setting in a rapidly declining patient who needs emergent craniotomy for hematoma evacuation. Furthermore, CTA offers a more practical approach to acute diagnosis than MRA, given the constraints of acute patient management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Perimesencephalic hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with an initially negative angiogram have blood in the cisterns around the midbrain, which reflects a perimesencephalic (nonaneurysmal) pattern of hemorrhage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72476 \" href=\"mobipreview.htm?13/20/13633\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/166-168\">",
"     166-168",
"    </a>",
"    ]. Perimesencephalic hemorrhage accounts for about 10 percent of all cases of SAH.",
"   </p>",
"   <p>",
"    This pattern is associated with a more favorable prognosis as illustrated in a study of 65 patients with perimesencephalic SAH; no patient rebled, none had delayed cerebral ischemia (compared to 4 of 49 with aneurysmal SAH), and only three (5 percent) developed clinical signs of acute hydrocephalus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/167\">",
"     167",
"    </a>",
"    ]. All had a good outcome after three months with none having died or been disabled.",
"   </p>",
"   <p>",
"    It is believed that this nonaneurysmal pattern of hemorrhage is the result of rupture of a small pial fistula or prepontine vein. In support of a venous origin of bleeding, a study involving 55 patients with perimesencephalic SAH found that these patients were more likely than patients with aneurysmal SAH to have a primitive venous drainage directly into the dural sinuses instead of the vein of Galen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/169\">",
"     169",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat angiography is probably not necessary in patients with perimesencephalic hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/168\">",
"     168",
"    </a>",
"    ]. One study suggested that angiography may be avoided altogether if CT angiography excludes the presence of a vertebrobasilar aneurysm in patients with a perimesencephalic pattern of hemorrhage on unenhanced CT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/170\">",
"     170",
"    </a>",
"    ]. A decision analysis supported omitting invasive angiography in these individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/39/38522/abstract/171\">",
"     171",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perimesencephalic hemorrhage is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6441?source=see_link\">",
"     \"Perimesencephalic nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minority of SAH is nonaneurysmal. The causes of these hemorrhages are diverse. This topic is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38696?source=see_link\">",
"     \"Nonaneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/34/22050?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/17/5394?source=see_link\">",
"       \"Patient information: Brain aneurysm (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/19/30002?source=see_link\">",
"       \"Patient information: Subarachnoid hemorrhage (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/63/8180?source=see_link\">",
"       \"Patient information: Hemorrhagic stroke treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28752055\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most subarachnoid hemorrhages (SAH) are caused by ruptured saccular aneurysms. The causes of nonaneurysmal SAH are diverse. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38696?source=see_link\">",
"       \"Nonaneurysmal subarachnoid hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aneurysmal SAH occurs at an estimated rate of 3 to 25 per 100,000 population. Most aneurysmal SAH occur between 40 and 60 years of age; however young children and elderly adults can be affected. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cigarette smoking appears to be the most important preventable risk factor for SAH. Family history, hypertension and moderate to heavy alcohol consumption, and sympathomimetic drug use are other risk factors Stressful life events have not been convincingly shown to be a risk factor for SAH. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overwhelming majority of patients present with a sudden onset severe headache which may be associated with brief loss of consciousness, seizures, nausea or vomiting or meningismus. While not invariable, symptom onset may occur in the setting of physical exertion. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sudden onset of headache, regardless of severity or prior headache history, should raise the clinical suspicion for SAH and compel a diagnostic evaluation. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Noncontrast head CT reveals the diagnosis in more than 90 percent of cases if performed within 24 hours of bleeding onset. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Head CT scan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbar puncture is mandatory if thre is a strong suspicion of SAH despite a normal head CT. The classic findings are an elevated opening pressure and an elevated red blood cell count that does not diminish from CSF tube one to tube four. Immediate centrifugation of the CSF can help differentiate bleeding in SAH from that due to a traumatic spinal tap. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Lumbar puncture'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once a diagnosis of SAH has been made, the etiology of the hemorrhage must be determined with vascular imaging. Of the available tests, digital subtraction angiography is believed to have the highest resolution to detect intracranial aneurysms and define their anatomic features and remains the gold standard test for this. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'Identifying the etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SAH is associated with a mortality rate as high as 50 percent; many patients die before reaching the hospital. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications of SAH include rebleeding, vasospasm and delayed cerebral ischemia, hydrocephalus, increased intracranial pressure, seizures, hyponatremia, cardiac abnormalities, and hypothalamic dysfunction and pituitary insufficiency. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/1\">",
"      STEHBENS WE. ANEURYSMS AND ANATOMICAL VARIATION OF CEREBRAL ARTERIES. Arch Pathol 1963; 75:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/2\">",
"      Ingall T, Asplund K, M&auml;h&ouml;nen M, Bonita R. A multinational comparison of subarachnoid hemorrhage epidemiology in the WHO MONICA stroke study. Stroke 2000; 31:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/3\">",
"      de Rooij NK, Linn FH, van der Plas JA, et al. Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends. J Neurol Neurosurg Psychiatry 2007; 78:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/4\">",
"      Sandvei MS, Mathiesen EB, Vatten LJ, et al. Incidence and mortality of aneurysmal subarachnoid hemorrhage in two Norwegian cohorts, 1984-2007. Neurology 2011; 77:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/5\">",
"      Mayberg MR, Batjer HH, Dacey R, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994; 25:2315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/6\">",
"      Rinkel GJ, Djibuti M, Algra A, van Gijn J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke 1998; 29:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/7\">",
"      Jordan LC, Johnston SC, Wu YW, et al. The importance of cerebral aneurysms in childhood hemorrhagic stroke: a population-based study. Stroke 2009; 40:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/8\">",
"      Broderick JP, Brott T, Tomsick T, et al. The risk of subarachnoid and intracerebral hemorrhages in blacks as compared with whites. N Engl J Med 1992; 326:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/9\">",
"      Sarti C, Tuomilehto J, Salomaa V, et al. Epidemiology of subarachnoid hemorrhage in Finland from 1983 to 1985. Stroke 1991; 22:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/10\">",
"      Shiue I, Arima H, Anderson CS, ACROSS Group. Life events and risk of subarachnoid hemorrhage: the australasian cooperative research on subarachnoid hemorrhage study (ACROSS). Stroke 2010; 41:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/11\">",
"      Penrose RJ. Life events before subarachnoid haemorrhage. J Psychosom Res 1972; 16:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/12\">",
"      Knekt P, Reunanen A, Aho K, et al. Risk factors for subarachnoid hemorrhage in a longitudinal population study. J Clin Epidemiol 1991; 44:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/13\">",
"      Anderson CS, Feigin V, Bennett D, et al. Active and passive smoking and the risk of subarachnoid hemorrhage: an international population-based case-control study. Stroke 2004; 35:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/14\">",
"      Feigin VL, Rinkel GJ, Lawes CM, et al. Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies. Stroke 2005; 36:2773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/15\">",
"      Feigin V, Parag V, Lawes CM, et al. Smoking and elevated blood pressure are the most important risk factors for subarachnoid hemorrhage in the Asia-Pacific region: an overview of 26 cohorts involving 306,620 participants. Stroke 2005; 36:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/16\">",
"      Sandvei MS, Romundstad PR, M&uuml;ller TB, et al. Risk factors for aneurysmal subarachnoid hemorrhage in a prospective population study: the HUNT study in Norway. Stroke 2009; 40:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/17\">",
"      Woo D, Haverbusch M, Sekar P, et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke 2004; 35:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/18\">",
"      Inagawa T. Risk factors for aneurysmal subarachnoid hemorrhage in patients in Izumo City, Japan. J Neurosurg 2005; 102:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/19\">",
"      Lepp&auml;l&auml; JM, Paunio M, Virtamo J, et al. Alcohol consumption and stroke incidence in male smokers. Circulation 1999; 100:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/20\">",
"      Korja M, Silventoinen K, McCarron P, et al. Genetic epidemiology of spontaneous subarachnoid hemorrhage: Nordic Twin Study. Stroke 2010; 41:2458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/21\">",
"      Okamoto K, Horisawa R, Kawamura T, et al. Family history and risk of subarachnoid hemorrhage: a case-control study in Nagoya, Japan. Stroke 2003; 34:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/22\">",
"      van der Jagt M, Hasan D, Bijvoet HW, et al. Validity of prediction of the site of ruptured intracranial aneurysms with CT. Neurology 1999; 52:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/23\">",
"      Schievink WI, Schaid DJ, Rogers HM, et al. On the inheritance of intracranial aneurysms. Stroke 1994; 25:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/24\">",
"      Bromberg JE, Rinkel GJ, Algra A, et al. Familial subarachnoid hemorrhage: distinctive features and patterns of inheritance. Ann Neurol 1995; 38:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/25\">",
"      Ruigrok YM, Rinkel GJ, Wijmenga C, Van Gijn J. Anticipation and phenotype in familial intracranial aneurysms. J Neurol Neurosurg Psychiatry 2004; 75:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/26\">",
"      Onda H, Kasuya H, Yoneyama T, et al. Genomewide-linkage and haplotype-association studies map intracranial aneurysm to chromosome 7q11. Am J Hum Genet 2001; 69:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/27\">",
"      Farnham JM, Camp NJ, Neuhausen SL, et al. Confirmation of chromosome 7q11 locus for predisposition to intracranial aneurysm. Hum Genet 2004; 114:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/28\">",
"      Ruigrok YM, Seitz U, Wolterink S, et al. Association of polymorphisms and haplotypes in the elastin gene in Dutch patients with sporadic aneurysmal subarachnoid hemorrhage. Stroke 2004; 35:2064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/29\">",
"      Nahed BV, Seker A, Guclu B, et al. Mapping a Mendelian form of intracranial aneurysm to 1p34.3-p36.13. Am J Hum Genet 2005; 76:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/30\">",
"      Roos YB, Pals G, Struycken PM, et al. Genome-wide linkage in a large Dutch consanguineous family maps a locus for intracranial aneurysms to chromosome 2p13. Stroke 2004; 35:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/31\">",
"      Olsson S, Csajbok LZ, Jood K, et al. Association between genetic variation on chromosome 9p21 and aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2011; 82:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/32\">",
"      Ozturk AK, Nahed BV, Bydon M, et al. Molecular genetic analysis of two large kindreds with intracranial aneurysms demonstrates linkage to 11q24-25 and 14q23-31. Stroke 2006; 37:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/33\">",
"      Olson JM, Vongpunsawad S, Kuivaniemi H, et al. Search for intracranial aneurysm susceptibility gene(s) using Finnish families. BMC Med Genet 2002; 3:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/34\">",
"      van der Voet M, Olson JM, Kuivaniemi H, et al. Intracranial aneurysms in Finnish families: confirmation of linkage and refinement of the interval to chromosome 19q13.3. Am J Hum Genet 2004; 74:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/35\">",
"      Yamada S, Utsunomiya M, Inoue K, et al. Genome-wide scan for Japanese familial intracranial aneurysms: linkage to several chromosomal regions. Circulation 2004; 110:3727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/36\">",
"      Iniesta JA, Gonz&aacute;lez-Conejero R, Piqueras C, et al. Platelet GP IIIa polymorphism HPA-1 (PlA) protects against subarachnoid hemorrhage. Stroke 2004; 35:2282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/37\">",
"      Kernan WN, Viscoli CM, Brass LM, et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/38\">",
"      Yoon BW, Bae HJ, Hong KS, et al. Phenylpropanolamine contained in cold remedies and risk of hemorrhagic stroke. Neurology 2007; 68:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/39\">",
"      Levine SR, Brust JC, Futrell N, et al. A comparative study of the cerebrovascular complications of cocaine: alkaloidal versus hydrochloride--a review. Neurology 1991; 41:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/40\">",
"      Nolte KB, Brass LM, Fletterick CF. Intracranial hemorrhage associated with cocaine abuse: a prospective autopsy study. Neurology 1996; 46:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/41\">",
"      Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 2009; 40:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/42\">",
"      Longstreth WT, Nelson LM, Koepsell TD, van Belle G. Subarachnoid hemorrhage and hormonal factors in women. A population-based case-control study. Ann Intern Med 1994; 121:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/43\">",
"      Mhurchu CN, Anderson C, Jamrozik K, et al. Hormonal factors and risk of aneurysmal subarachnoid hemorrhage: an international population-based, case-control study. Stroke 2001; 32:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/44\">",
"      Jung SY, Bae HJ, Park BJ, et al. Parity and risk of hemorrhagic strokes. Neurology 2010; 74:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/45\">",
"      Schmidt M, Johansen MB, Lash TL, et al. Antiplatelet drugs and risk of subarachnoid hemorrhage: a population-based case-control study. J Thromb Haemost 2010; 8:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/46\">",
"      Risselada R, Straatman H, van Kooten F, et al. Withdrawal of statins and risk of subarachnoid hemorrhage. Stroke 2009; 40:2887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/47\">",
"      Gorelick PB, Hier DB, Caplan LR, Langenberg P. Headache in acute cerebrovascular disease. Neurology 1986; 36:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/48\">",
"      Fontanarosa PB. Recognition of subarachnoid hemorrhage. Ann Emerg Med 1989; 18:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/49\">",
"      Schievink WI. Intracranial aneurysms. N Engl J Med 1997; 336:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/50\">",
"      Polmear A. Sentinel headaches in aneurysmal subarachnoid haemorrhage: what is the true incidence? A systematic review. Cephalalgia 2003; 23:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/51\">",
"      Linn FH, Wijdicks EF, van der Graaf Y, et al. Prospective study of sentinel headache in aneurysmal subarachnoid haemorrhage. Lancet 1994; 344:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/52\">",
"      Morgenstern LB, Luna-Gonzales H, Huber JC Jr, et al. Worst headache and subarachnoid hemorrhage: prospective, modern computed tomography and spinal fluid analysis. Ann Emerg Med 1998; 32:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/53\">",
"      Anderson C, Ni Mhurchu C, Scott D, et al. Triggers of subarachnoid hemorrhage: role of physical exertion, smoking, and alcohol in the Australasian Cooperative Research on Subarachnoid Hemorrhage Study (ACROSS). Stroke 2003; 34:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/54\">",
"      Vlak MH, Rinkel GJ, Greebe P, et al. Trigger factors and their attributable risk for rupture of intracranial aneurysms: a case-crossover study. Stroke 2011; 42:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/55\">",
"      van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet 2007; 369:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/56\">",
"      Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke 1997; 28:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/57\">",
"      Broderick JP, Brott TG, Duldner JE, et al. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke 1994; 25:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/58\">",
"      Ingall TJ, Whisnant JP, Wiebers DO, O'Fallon WM. Has there been a decline in subarachnoid hemorrhage mortality? Stroke 1989; 20:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/59\">",
"      Truelsen T, Bonita R, Duncan J, et al. Changes in subarachnoid hemorrhage mortality, incidence, and case fatality in New Zealand between 1981-1983 and 1991-1993. Stroke 1998; 29:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/60\">",
"      Stegmayr B, Eriksson M, Asplund K. Declining mortality from subarachnoid hemorrhage: changes in incidence and case fatality from 1985 through 2000. Stroke 2004; 35:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/61\">",
"      Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, et al. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA 2007; 298:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/62\">",
"      Winn HR, Richardson AE, Jane JA. The long-term prognosis in untreated cerebral aneurysms: I. The incidence of late hemorrhage in cerebral aneurysm: a 10-year evaluation of 364 patients. Ann Neurol 1977; 1:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/63\">",
"      Inagawa T, Kamiya K, Ogasawara H, Yano T. Rebleeding of ruptured intracranial aneurysms in the acute stage. Surg Neurol 1987; 28:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/64\">",
"      Naidech AM, Janjua N, Kreiter KT, et al. Predictors and impact of aneurysm rebleeding after subarachnoid hemorrhage. Arch Neurol 2005; 62:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/65\">",
"      Lord AS, Fernandez L, Schmidt JM, et al. Effect of rebleeding on the course and incidence of vasospasm after subarachnoid hemorrhage. Neurology 2012; 78:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/66\">",
"      Beck J, Raabe A, Szelenyi A, et al. Sentinel headache and the risk of rebleeding after aneurysmal subarachnoid hemorrhage. Stroke 2006; 37:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/67\">",
"      Kassell NF, Sasaki T, Colohan AR, Nazar G. Cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Stroke 1985; 16:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/68\">",
"      Kreiter KT, Mayer SA, Howard G, et al. Sample size estimates for clinical trials of vasospasm in subarachnoid hemorrhage. Stroke 2009; 40:2362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/69\">",
"      Sloan MA, Alexandrov AV, Tegeler CH, et al. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2004; 62:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/70\">",
"      Krejza J, Kochanowicz J, Mariak Z, et al. Middle cerebral artery spasm after subarachnoid hemorrhage: detection with transcranial color-coded duplex US. Radiology 2005; 236:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/71\">",
"      van der Schaaf I, Wermer MJ, van der Graaf Y, et al. Prognostic value of cerebral perfusion-computed tomography in the acute stage after subarachnoid hemorrhage for the development of delayed cerebral ischemia. Stroke 2006; 37:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/72\">",
"      van der Schaaf I, Wermer MJ, van der Graaf Y, et al. CT after subarachnoid hemorrhage: relation of cerebral perfusion to delayed cerebral ischemia. Neurology 2006; 66:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/73\">",
"      Pham M, Johnson A, Bartsch AJ, et al. CT perfusion predicts secondary cerebral infarction after aneurysmal subarachnoid hemorrhage. Neurology 2007; 69:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/74\">",
"      Vatter H, G&uuml;resir E, Berkefeld J, et al. Perfusion-diffusion mismatch in MRI to indicate endovascular treatment of cerebral vasospasm after subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2011; 82:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/75\">",
"      Zimmermann M, Seifert V. Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery 1998; 43:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/76\">",
"      Sobey CG, Faraci FM. Subarachnoid haemorrhage: what happens to the cerebral arteries? Clin Exp Pharmacol Physiol 1998; 25:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/77\">",
"      Weisberg LA. Computed tomography in aneurysmal subarachnoid hemorrhage. Neurology 1979; 29:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/78\">",
"      Kistler JP, Crowell RM, Davis KR, et al. The relation of cerebral vasospasm to the extent and location of subarachnoid blood visualized by CT scan: a prospective study. Neurology 1983; 33:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/79\">",
"      Ko SB, Choi HA, Carpenter AM, et al. Quantitative analysis of hemorrhage volume for predicting delayed cerebral ischemia after subarachnoid hemorrhage. Stroke 2011; 42:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/80\">",
"      Charpentier C, Audibert G, Guillemin F, et al. Multivariate analysis of predictors of cerebral vasospasm occurrence after aneurysmal subarachnoid hemorrhage. Stroke 1999; 30:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/81\">",
"      Badjatia N, Topcuoglu MA, Buonanno FS, et al. Relationship between hyperglycemia and symptomatic vasospasm after subarachnoid hemorrhage. Crit Care Med 2005; 33:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/82\">",
"      Hop JW, Rinkel GJ, Algra A, van Gijn J. Initial loss of consciousness and risk of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke 1999; 30:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/83\">",
"      Qureshi AI, Sung GY, Razumovsky AY, et al. Early identification of patients at risk for symptomatic vasospasm after aneurysmal subarachnoid hemorrhage. Crit Care Med 2000; 28:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/84\">",
"      Singhal AB, Topcuoglu MA, Dorer DJ, et al. SSRI and statin use increases the risk for vasospasm after subarachnoid hemorrhage. Neurology 2005; 64:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/85\">",
"      Wilkins RH. Aneurysm rupture during angiography: does acute vasospasm occur? Surg Neurol 1976; 5:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/86\">",
"      Bederson JB, Levy AL, Ding WH, et al. Acute vasoconstriction after subarachnoid hemorrhage. Neurosurgery 1998; 42:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/87\">",
"      Qureshi AI, Sung GY, Suri MA, et al. Prognostic value and determinants of ultraearly angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery 1999; 44:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/88\">",
"      Baldwin ME, Macdonald RL, Huo D, et al. Early vasospasm on admission angiography in patients with aneurysmal subarachnoid hemorrhage is a predictor for in-hospital complications and poor outcome. Stroke 2004; 35:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/89\">",
"      Haley EC Jr, Kassell NF, Torner JC. A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1993; 78:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/90\">",
"      Haley EC Jr, Kassell NF, Torner JC, et al. A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 1994; 80:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/91\">",
"      Rabinstein AA, Weigand S, Atkinson JL, Wijdicks EF. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2005; 36:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/92\">",
"      Rabinstein AA, Friedman JA, Weigand SD, et al. Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke 2004; 35:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/93\">",
"      Ibrahim GM, Weidauer S, Vatter H, et al. Attributing hypodensities on CT to angiographic vasospasm is not sensitive and unreliable. Stroke 2012; 43:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/94\">",
"      Hoff R, Rinkel G, Verweij B, et al. Blood volume measurement to guide fluid therapy after aneurysmal subarachnoid hemorrhage: a prospective controlled study. Stroke 2009; 40:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/95\">",
"      Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/96\">",
"      Juvela S, Siironen J, Varis J, et al. Risk factors for ischemic lesions following aneurysmal subarachnoid hemorrhage. J Neurosurg 2005; 102:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/97\">",
"      Crobeddu E, Mittal MK, Dupont S, et al. Predicting the lack of development of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke 2012; 43:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/98\">",
"      Graff-Radford NR, Torner J, Adams HP Jr, Kassell NF. Factors associated with hydrocephalus after subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. Arch Neurol 1989; 46:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/99\">",
"      Douglas MR, Daniel M, Lagord C, et al. High CSF transforming growth factor beta levels after subarachnoid haemorrhage: association with chronic communicating hydrocephalus. J Neurol Neurosurg Psychiatry 2009; 80:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/100\">",
"      Hasan D, Vermeulen M, Wijdicks EF, et al. Management problems in acute hydrocephalus after subarachnoid hemorrhage. Stroke 1989; 20:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/101\">",
"      Suarez-Rivera O. Acute hydrocephalus after subarachnoid hemorrhage. Surg Neurol 1998; 49:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/102\">",
"      Nornes H, Magnaes B. Intracranial pressure in patients with ruptured saccular aneurysm. J Neurosurg 1972; 36:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/103\">",
"      Par&eacute; L, Delfino R, Leblanc R. The relationship of ventricular drainage to aneurysmal rebleeding. J Neurosurg 1992; 76:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/104\">",
"      Brinker T, Seifert V, Stolke D. Acute changes in the dynamics of the cerebrospinal fluid system during experimental subarachnoid hemorrhage. Neurosurgery 1990; 27:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/105\">",
"      Heinsoo M, Eelm&auml;e J, Kuklane M, et al. The possible role of CSF hydrodynamic parameters following in management of SAH patients. Acta Neurochir Suppl 1998; 71:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/106\">",
"      Heuer GG, Smith MJ, Elliott JP, et al. Relationship between intracranial pressure and other clinical variables in patients with aneurysmal subarachnoid hemorrhage. J Neurosurg 2004; 101:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/107\">",
"      Butzkueven H, Evans AH, Pitman A, et al. Onset seizures independently predict poor outcome after subarachnoid hemorrhage. Neurology 2000; 55:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/108\">",
"      Claassen J, Peery S, Kreiter KT, et al. Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. Neurology 2003; 60:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/109\">",
"      Ker&auml;nen T, Tapaninaho A, Hernesniemi J, Vapalahti M. Late epilepsy after aneurysm operations. Neurosurgery 1985; 17:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/110\">",
"      Kotila M, Waltimo O. Epilepsy after stroke. Epilepsia 1992; 33:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/111\">",
"      Olafsson E, Gudmundsson G, Hauser WA. Risk of epilepsy in long-term survivors of surgery for aneurysmal subarachnoid hemorrhage: a population-based study in Iceland. Epilepsia 2000; 41:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/112\">",
"      Buczacki SJ, Kirkpatrick PJ, Seeley HM, Hutchinson PJ. Late epilepsy following open surgery for aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2004; 75:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/113\">",
"      van der Bilt IA, Hasan D, Vandertop WP, et al. Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis. Neurology 2009; 72:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/114\">",
"      Hravnak M, Frangiskakis JM, Crago EA, et al. Elevated cardiac troponin I and relationship to persistence of electrocardiographic and echocardiographic abnormalities after aneurysmal subarachnoid hemorrhage. Stroke 2009; 40:3478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/115\">",
"      Coghlan LA, Hindman BJ, Bayman EO, et al. Independent associations between electrocardiographic abnormalities and outcomes in patients with aneurysmal subarachnoid hemorrhage: findings from the intraoperative hypothermia aneurysm surgery trial. Stroke 2009; 40:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/116\">",
"      Parekh N, Venkatesh B, Cross D, et al. Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage. J Am Coll Cardiol 2000; 36:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/117\">",
"      Mayer SA, Lin J, Homma S, et al. Myocardial injury and left ventricular performance after subarachnoid hemorrhage. Stroke 1999; 30:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/118\">",
"      Lee VH, Connolly HM, Fulgham JR, et al. Tako-tsubo cardiomyopathy in aneurysmal subarachnoid hemorrhage: an underappreciated ventricular dysfunction. J Neurosurg 2006; 105:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/119\">",
"      Hakeem A, Marks AD, Bhatti S, Chang SM. When the worst headache becomes the worst heartache! Stroke 2007; 38:3292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/120\">",
"      Naidech AM, Kreiter KT, Janjua N, et al. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation 2005; 112:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/121\">",
"      Masuda T, Sato K, Yamamoto S, et al. Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model. Stroke 2002; 33:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/122\">",
"      Crago EA, Kerr ME, Kong Y, et al. The impact of cardiac complications on outcome in the SAH population. Acta Neurol Scand 2004; 110:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/123\">",
"      Tung PP, Olmsted E, Kopelnik A, et al. Plasma B-type natriuretic peptide levels are associated with early cardiac dysfunction after subarachnoid hemorrhage. Stroke 2005; 36:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/124\">",
"      Tung P, Kopelnik A, Banki N, et al. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. Stroke 2004; 35:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/125\">",
"      Homma S, Grahame-Clarke C. Editorial comment--myocardial damage in patients with subarachnoid hemorrhage. Stroke 2004; 35:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/126\">",
"      van den Bergh WM, Algra A, Rinkel GJ. Electrocardiographic abnormalities and serum magnesium in patients with subarachnoid hemorrhage. Stroke 2004; 35:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/127\">",
"      McCarron MO, Alberts MJ, McCarron P. A systematic review of Terson's syndrome: frequency and prognosis after subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2004; 75:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/128\">",
"      Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med 2006; 354:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/129\">",
"      Perry JJ, Spacek A, Forbes M, et al. Is the combination of negative computed tomography result and negative lumbar puncture result sufficient to rule out subarachnoid hemorrhage? Ann Emerg Med 2008; 51:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/130\">",
"      Vermeulen M, van Gijn J. The diagnosis of subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 1990; 53:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/131\">",
"      Kassell NF, Torner JC, Haley EC Jr, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J Neurosurg 1990; 73:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/132\">",
"      Perry JJ, Stiell IG, Sivilotti ML, et al. Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage: prospective cohort study. BMJ 2011; 343:d4277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/133\">",
"      Latchaw RE, Silva P, Falcone SF. The role of CT following aneurysmal rupture. Neuroimaging Clin N Am 1997; 7:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/134\">",
"      van der Wee N, Rinkel GJ, Hasan D, van Gijn J. Detection of subarachnoid haemorrhage on early CT: is lumbar puncture still needed after a negative scan? J Neurol Neurosurg Psychiatry 1995; 58:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/135\">",
"      Sidman R, Connolly E, Lemke T. Subarachnoid hemorrhage diagnosis: lumbar puncture is still needed when the computed tomography scan is normal. Acad Emerg Med 1996; 3:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/136\">",
"      Sames TA, Storrow AB, Finkelstein JA, Magoon MR. Sensitivity of new-generation computed tomography in subarachnoid hemorrhage. Acad Emerg Med 1996; 3:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/137\">",
"      Leblanc R. The minor leak preceding subarachnoid hemorrhage. J Neurosurg 1987; 66:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/138\">",
"      Wijdicks EF, Kallmes DF, Manno EM, et al. Subarachnoid hemorrhage: neurointensive care and aneurysm repair. Mayo Clin Proc 2005; 80:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/139\">",
"      Dupont SA, Wijdicks EF, Manno EM, Rabinstein AA. Thunderclap headache and normal computed tomographic results: value of cerebrospinal fluid analysis. Mayo Clin Proc 2008; 83:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/140\">",
"      UK National External Quality Assessment Scheme for Immunochemistry Working Group. National guidelines for analysis of cerebrospinal fluid for bilirubin in suspected subarachnoid haemorrhage. Ann Clin Biochem 2003; 40:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/141\">",
"      Vermeulen M, Hasan D, Blijenberg BG, et al. Xanthochromia after subarachnoid haemorrhage needs no revisitation. J Neurol Neurosurg Psychiatry 1989; 52:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/142\">",
"      Vermeulen M, van Gijn J, Blijenberg BG. Spectrophotometric analysis of CSF after subarachnoid hemorrhage: limitations in the diagnosis of rebleeding. Neurology 1983; 33:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/143\">",
"      Cruickshank A, Beetham R, Holbrook I, et al. Spectrophotometry of cerebrospinal fluid in suspected subarachnoid haemorrhage. BMJ 2005; 330:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/144\">",
"      Beetham R, UK NEQAS for Immunochermistry Working group. Recommendations for CSF analysis in subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry 2004; 75:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/145\">",
"      Petzold A, Keir G, Sharpe TL. Why human color vision cannot reliably detect cerebrospinal fluid xanthochromia. Stroke 2005; 36:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/146\">",
"      Sidman R, Spitalnic S, Demelis M, et al. Xanthrochromia? By what method? A comparison of visual and spectrophotometric xanthrochromia. Ann Emerg Med 2005; 46:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/147\">",
"      Perry JJ, Sivilotti ML, Stiell IG, et al. Should spectrophotometry be used to identify xanthochromia in the cerebrospinal fluid of alert patients suspected of having subarachnoid hemorrhage? Stroke 2006; 37:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/148\">",
"      Wiesmann M, Mayer TE, Yousry I, et al. Detection of hyperacute subarachnoid hemorrhage of the brain by using magnetic resonance imaging. J Neurosurg 2002; 96:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/149\">",
"      Mitchell P, Wilkinson ID, Hoggard N, et al. Detection of subarachnoid haemorrhage with magnetic resonance imaging. J Neurol Neurosurg Psychiatry 2001; 70:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/150\">",
"      Edlow JA, Caplan LR. Avoiding pitfalls in the diagnosis of subarachnoid hemorrhage. N Engl J Med 2000; 342:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/151\">",
"      Kowalski RG, Claassen J, Kreiter KT, et al. Initial misdiagnosis and outcome after subarachnoid hemorrhage. JAMA 2004; 291:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/152\">",
"      Kassell NF, Kongable GL, Torner JC, et al. Delay in referral of patients with ruptured aneurysms to neurosurgical attention. Stroke 1985; 16:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/153\">",
"      Cloft HJ, Joseph GJ, Dion JE. Risk of cerebral angiography in patients with subarachnoid hemorrhage, cerebral aneurysm, and arteriovenous malformation: a meta-analysis. Stroke 1999; 30:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/154\">",
"      Li MH, Cheng YS, Li YD, et al. Large-cohort comparison between three-dimensional time-of-flight magnetic resonance and rotational digital subtraction angiographies in intracranial aneurysm detection. Stroke 2009; 40:3127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/155\">",
"      Villablanca JP, Hooshi P, Martin N, et al. Three-dimensional helical computerized tomography angiography in the diagnosis, characterization, and management of middle cerebral artery aneurysms: comparison with conventional angiography and intraoperative findings. J Neurosurg 2002; 97:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/156\">",
"      Chappell ET, Moure FC, Good MC. Comparison of computed tomographic angiography with digital subtraction angiography in the diagnosis of cerebral aneurysms: a meta-analysis. Neurosurgery 2003; 52:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/157\">",
"      Wintermark M, Uske A, Chalaron M, et al. Multislice computerized tomography angiography in the evaluation of intracranial aneurysms: a comparison with intraarterial digital subtraction angiography. J Neurosurg 2003; 98:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/158\">",
"      Colen, TW, Wang, LC, Basavaraj, BV, et al. Effectiveness of MDCT angiography for the detection of intracranial aneurysms in patients with nontraumatic subarachnoid hemorrhage. AJR Am J Roentgenol 2007; 189:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/159\">",
"      Papke K, Kuhl CK, Fruth M, et al. Intracranial aneurysms: role of multidetector CT angiography in diagnosis and endovascular therapy planning. Radiology 2007; 244:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/160\">",
"      Li Q, Lv F, Li Y, et al. Evaluation of 64-section CT angiography for detection and treatment planning of intracranial aneurysms by using DSA and surgical findings. Radiology 2009; 252:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/161\">",
"      Lu L, Zhang LJ, Poon CS, et al. Digital subtraction CT angiography for detection of intracranial aneurysms: comparison with three-dimensional digital subtraction angiography. Radiology 2012; 262:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/162\">",
"      Menke J, Larsen J, Kallenberg K. Diagnosing cerebral aneurysms by computed tomographic angiography: meta-analysis. Ann Neurol 2011; 69:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/163\">",
"      Westerlaan HE, van Dijk JM, van Dijk MJ, et al. Intracranial aneurysms in patients with subarachnoid hemorrhage: CT angiography as a primary examination tool for diagnosis--systematic review and meta-analysis. Radiology 2011; 258:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/164\">",
"      Velthuis BK, Van Leeuwen MS, Witkamp TD, et al. Computerized tomography angiography in patients with subarachnoid hemorrhage: from aneurysm detection to treatment without conventional angiography. J Neurosurg 1999; 91:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/165\">",
"      Villablanca JP, Martin N, Jahan R, et al. Volume-rendered helical computerized tomography angiography in the detection and characterization of intracranial aneurysms. J Neurosurg 2000; 93:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/166\">",
"      van Gijn J, van Dongen KJ, Vermeulen M, Hijdra A. Perimesencephalic hemorrhage: a nonaneurysmal and benign form of subarachnoid hemorrhage. Neurology 1985; 35:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/167\">",
"      Rinkel GJ, Wijdicks EF, Vermeulen M, et al. The clinical course of perimesencephalic nonaneurysmal subarachnoid hemorrhage. Ann Neurol 1991; 29:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/168\">",
"      Rinkel GJ, Wijdicks EF, Hasan D, et al. Outcome in patients with subarachnoid haemorrhage and negative angiography according to pattern of haemorrhage on computed tomography. Lancet 1991; 338:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/169\">",
"      van der Schaaf IC, Velthuis BK, Gouw A, Rinkel GJ. Venous drainage in perimesencephalic hemorrhage. Stroke 2004; 35:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/170\">",
"      Velthuis BK, Rinkel GJ, Ramos LM, et al. Perimesencephalic hemorrhage. Exclusion of vertebrobasilar aneurysms with CT angiography. Stroke 1999; 30:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/39/38522/abstract/171\">",
"      Ruigrok YM, Rinkel GJ, Buskens E, et al. Perimesencephalic hemorrhage and CT angiography: A decision analysis. Stroke 2000; 31:2976.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1130 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38522=[""].join("\n");
var outline_f37_39_38522=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28752055\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Alcohol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sympathomimetic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Estrogen deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antithrombotic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rebleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vasospasm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Early vasospasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Cerebral infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Increased ICP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cardiac abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Mechanisms of myocardial injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Head CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Clearing of blood",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Xanthochromia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Spectrophotometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Brain MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Misdiagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      IDENTIFYING THE ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Digital subtraction angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      CT and MR angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Perimesencephalic hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28752055\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1130\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1130|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?13/20/13633\" title=\"diagnostic image 1\">",
"      CT perimesencephalic nonaneurysmal SAH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1130|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/41/41630\" title=\"figure 1\">",
"      Alcohol intake stroke risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/5/88\" title=\"figure 2\">",
"      Headache and vomiting in stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1130|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/36/8779\" title=\"table 1\">",
"      Fisher SAH CT grading scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/19/12603\" title=\"table 2\">",
"      Claassen SAH CT grading scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/57/9115\" title=\"table 3\">",
"      Hunt and Hess grading system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33348?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an unruptured intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/20/26952?source=related_link\">",
"      Cardiac complications of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/23/8567?source=related_link\">",
"      Cerebral salt-wasting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/10/17576?source=related_link\">",
"      Cerebrospinal fluid: Physiology and utility of an examination in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/30/2537?source=related_link\">",
"      Elevated cardiac troponin concentration in the absence of an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38696?source=related_link\">",
"      Nonaneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35098?source=related_link\">",
"      Overview of infected (mycotic) arterial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/17/5394?source=related_link\">",
"      Patient information: Brain aneurysm (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?21/34/22050?source=related_link\">",
"      Patient information: Hemorrhagic stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/63/8180?source=related_link\">",
"      Patient information: Hemorrhagic stroke treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/19/30002?source=related_link\">",
"      Patient information: Subarachnoid hemorrhage (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/18/6441?source=related_link\">",
"      Perimesencephalic nonaneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/43/3767?source=related_link\">",
"      Screening for intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/61/30682?source=related_link\">",
"      Secondary prevention of stroke: Risk factor reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/45/16085?source=related_link\">",
"      Significance of hypomagnesemia in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/1/30745?source=related_link\">",
"      Stress-induced (takotsubo) cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/25/406?source=related_link\">",
"      Subarachnoid hemorrhage grading scales",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/38/39530?source=related_link\">",
"      Troponins and creatine kinase as biomarkers of cardiac injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_39_38523="DSM-IV-TR diagnostic criteria for alcohol withdrawal";
var content_f37_39_38523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F61595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F61595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for alcohol withdrawal",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         A.",
"        </strong>",
"        Cessation of (or reduction in) alcohol use that has been heavy and prolonged.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         B.",
"        </strong>",
"        Two (or more) of the following, developing within several hours to a few days after Criterion A:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Autonomic hyperactivity (eg, sweating or pulse rate greater than 100)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Increased hand tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Insomnia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Nausea or vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Transient visual, tactile, or auditory hallucinations or illusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Psychomotor agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Grand mal seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         C.",
"        </strong>",
"        The symptoms in Criterion B cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         D.",
"        </strong>",
"        The symptoms are not due to a general medical condition and are not better accounted for by another mental disorder.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition. Copyright &copy; 2000 American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38523=[""].join("\n");
var outline_f37_39_38523=null;
var title_f37_39_38524="Differential dx Sjogrens synd";
var content_f37_39_38524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of the manifestations of Sj&ouml;gren's syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Dry eyes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aqueous tear deficiency",
"       </td>",
"       <td>",
"        Keratoconjunctivitis sicca (Sj&ouml;gren's syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mucin deficiency",
"       </td>",
"       <td>",
"        <p>",
"         Hypovitaminosis A",
"        </p>",
"        <p>",
"         Ocular pemphigoid",
"        </p>",
"        <p>",
"         Chemical burns",
"        </p>",
"        <p>",
"         Stevens-Johnson syndrome",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ocular lipid abnormalities",
"       </td>",
"       <td>",
"        Blepharitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corneal epitheliopathy",
"       </td>",
"       <td>",
"        <p>",
"         Cranial nerve V dysfunction",
"        </p>",
"        <p>",
"         Contact lens use",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Impaired lid function",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Dry mouth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Drugs",
"       </td>",
"       <td>",
"        <p>",
"         Antidepressants",
"        </p>",
"        <p>",
"         Antihistamines",
"        </p>",
"        <p>",
"         Anticholinergics",
"        </p>",
"        <p>",
"         Diuretics",
"        </p>",
"        <p>",
"         Neuroleptics",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psychogenic",
"       </td>",
"       <td>",
"        Anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Systemic diseases",
"       </td>",
"       <td>",
"        <p>",
"         Sj&ouml;gren's syndrome",
"        </p>",
"        <p>",
"         Amyloidosis",
"        </p>",
"        <p>",
"         Sarcoidosis",
"        </p>",
"        <p>",
"         HIV infection",
"        </p>",
"        <p>",
"         Uncontrolled diabetes mellitus",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dehydration",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Salivary gland enlargement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uusually unilateral",
"       </td>",
"       <td>",
"        <p>",
"         Bacterial infection",
"        </p>",
"        <p>",
"         Chronic sialadenitis",
"        </p>",
"        <p>",
"         Obstruction",
"        </p>",
"        <p>",
"         Primary neoplasm (adenoma, adenocarcinoma, lymphoma, mixed salivary gland tumors)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Usually bilateral",
"       </td>",
"       <td>",
"        <p>",
"         Viral infection (EBV, mumps, CMV, coxsackie A)",
"        </p>",
"        <p>",
"         Sj&ouml;gren's syndrome",
"        </p>",
"        <p>",
"         Amyloidosis",
"        </p>",
"        <p>",
"         Granulomatous diseases (sarcoidosis, TB)",
"        </p>",
"        <p>",
"         HIV infection",
"        </p>",
"        <p>",
"         Hyperlipidemia",
"        </p>",
"        <p>",
"         Cirrhosis and alcoholism",
"        </p>",
"        <p>",
"         Acromegaly",
"        </p>",
"        <p>",
"         Anorexia",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38524=[""].join("\n");
var outline_f37_39_38524=null;
var title_f37_39_38525="Contents: Primary care calculators";
var content_f37_39_38525=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Primary care calculators",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Primary care calculators",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Clinical Criteria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/20/19776\">",
"           Calculator: Alcohol consumption screening AUDIT questionnaire (Patient information)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?33/0/33796\">",
"           Calculator: CIWA-Ar Clinical Institute Withdrawal Assessment for Alcohol scale",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/3/41023\">",
"           Calculator: International Prostatism Symptom Score (IPSS)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Medical Equations",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/26/29089\">",
"           Calculator: Lean body weight (adult female)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?28/21/29009\">",
"           Calculator: Lean body weight (adult male)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?35/55/36722\">",
"           Calculator: Post Test Probability from Pre Test Probability, Sensitivity and Specificity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?10/3/10291\">",
"           Calculator: Post-test probability from likelihood ratios and multiple test results",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?19/24/19841\">",
"           Calculator: SI unit conversions for immunology lab values",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-7D0E73368A-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f37_39_38525=[""].join("\n");
var outline_f37_39_38525=null;
var title_f37_39_38526="Karl Storz rigid bronchoscopes";
var content_f37_39_38526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61399&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Karl Storz rigid bronchoscopes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Set of Karl Storz rigid bronchoscopes, with internal channel for rigid telescopes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henri G Colt, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38526=[""].join("\n");
var outline_f37_39_38526=null;
var title_f37_39_38527="Hormonal response hypocalcemia";
var content_f37_39_38527=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Hormonal response to hypocalcemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Physiologic sequence of events following the development of hypocalcemia. The interaction of parathyroid hormone (PTH) with calcitriol results in an appropriate elevation in the plasma calcium concentration with little or no change in the plasma phosphate concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from DeLuca, H, Am J Med 1975; 58:39.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_39_38527=[""].join("\n");
var outline_f37_39_38527=null;
